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ABSTRACT
Although there is evidence for a protective role of long-chain polyunsaturated 
fatty acids (PUFAs) in cardiovascular disease, their mechanism of action as 
well as their participation in intracellular signalling processes remain to be 
elucidated. Therefore the aims of this study were twofold: (i) to characterize 
the roles of the mitogen-activated protein kinases (MAPKs) and protein kinase 
B (PKB/Akt) in ischaemia/reperfusion-induced apoptosis of neonatal 
cardiomyocytes and (ii) to establish whether long-chain PUFAs protect the 
heart via manipulation of these kinases.
Rat neonatal ventricular myocytes exposed to simulated ischaemia and 
reperfusion (Sl/R) were used to characterize the role(s) of extracellular signal- 
regulated kinase (ERK), p38 and c-Jun NH2-terminal protein kinase (JNK), as 
well as PKB/Akt in apoptosis. The effects of an omega-3 fatty acid 
(eicosapentaenoic acid -  EPA) and an omega-6 fatty acid (arachidonic acid -  
ARA) on the response of neonatal rat cardiomyocytes to Sl/R with regard to 
the above parameters were determined.
Exposure of the myocytes to SI (energy depletion induced by KCN and 2- 
deoxy-D-glucose) reduced cell viability, as measured by the 3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, and 
stimulated apoptosis (increased caspase-3 activation and poly(ADP-ribose) 
polymerase (PARP) cleavage). However, morphological evidence of 
increased apoptosis (Hoechst 33342 staining) occurred only after reperfusion. 
A rapid activation of p38 and PKB/Akt Ser473 occurred during SI, while 
significant activation of ERK and JNK was observed during reperfusion only. 
Myocytes pre-treated with SB203580, a p38-inhibitor, displayed a significant 
increase in cell viability and attenuation of apoptosis during Sl/R, while 
SP600125, a specific JNK inhibitor, significantly increased both caspase-3 
activation and the apoptotic index. However, PD98059, an ERK inhibitor, was 
without effect. Wortmannin, a PI3-kinase inhibitor, reduced PKB/Akt Thr308 but 
not Ser473 phosphorylation during Sl/R and caused a significant increase in
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PARP cleavage during reperfusion, but had no effect on caspase-3 activation 
or the apoptotic index.
EPA and ARA (20 jiM, present before and after SI) significantly reduced 
caspase-3 activation, PARP-cleavage and the apoptotic index during 
reperfusion. This was associated with increased ERK- and decreased p38 
phosphorylation. Vanadate (a tyrosine phosphatase inhibitor), but not okadaic 
acid (a serine-threonine phosphatase inhibitor), significantly reduced ARA- 
induced inhibition of p38 phosphorylation, suggesting involvement of tyrosine 
phosphatases during Sl/R. MKP-1, a dual-specificity phosphatase, was 
targeted and a significant induction of MKP-1 by ARA and EPA was observed. 
An in vitro dephosphorylation assay confirmed that this phosphatase might be 
responsible for the inhibition of p38 activation. It was also demonstrated that 
the protective actions of ARA are PI3-K dependent.
The results suggest that p38 has a pro-apoptotic role while JNK 
phosphorylation is protective and that these kinases act via caspase-3 to 
prevent or promote cell survival in response to SI/R-induced injury. It was 
demonstrated for the first time that EPA and ARA protect neonatal cardiac 
myocytes from ischaemia/reperfusion-induced apoptosis through induction of 
a dual-specific phosphatase, MKP-1, causing dephosphorylation of the pro- 
apoptotic kinase, p38. These beneficial effects of ARA and EPA were also 
reflected by improvement in functional recovery during ischaemia/reperfusion 
of the isolated perfused rat heart model.
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OPSOMMING
Dit word algemeen aanvaar dat lang-ketting poli-onversadigde vetsure teen 
kardiovaskulere siektes beskerm, maar hul meganisme van aksie sowel as 
hul invloed op intrasellulere seinoordragpaaie is egter onbekend. Die 
doelwitte van hierdie studie is dus tweevoudig: (i) om die belang van 
mitogeen-geaktiveerde proteien kinases (MAPKs) en protein kinase B 
(PKB/Akt) in isgemie/herperfusie-geinduseerde apoptose vas te stel en (ii) om 
te bepaal of lang-ketting poli-onversadigde vetsure die hart, deur manipulering 
van hierdie kinases, beskerm.
Rot neonatale ventrikulere miosiete, blootgestel aan gesimuleerde isgemie en 
herperfusie (Sl/H), is gebruik om die aktivering van ekstrasellulere sein- 
gereguleerde kinase (ERK), p38, c-Jun NH2-terminale protein kinase (JNK) 
asook PKB/Akt tydens apoptose, te karakteriseer. Die effek van ‘n omega-3 
vetsuur (eikosapentaenoSsuur -  EPA) en ‘n omega-6 vetsuur (aragidoonsuur 
-  ARA) op die respons van bogenoemde kinases in neonatale kardiomiosiete 
tydens Sl/H, is ondersoek.
Blootstelling van miosiete aan SI (energie-uitputting gemduseer deur 
kaliumsianied en 2-deoksi-D-glukose) het ‘n afname in die vermoe van die sel 
om te oorleef, soos gemeet deur die MTT (3-[4,5-dimetieltiazol-2-yl]-2,5- 
difeniel tetrazolium bromied) bepaling, tot gevolg gehad. ‘n Toename in 
apoptose (kaspase-3 aktivering en poli(ADP-ribose) polimerase (PARP) 
kliewing) is ook waargeneem. Morfologiese bewyse van apoptose (Hoechst 
33342 kleuring) was egter eers tydens herperfusie sigbaar. SI is gekenmerk 
deur vinnige aktivering van p38 en PKB/Akt Ser473, terwyl ERK en JNK 
fosforilering slegs tydens herperfusie waargeneem is. Vooraf-behandeling met 
SB203580, ‘n p38 inhibitor, het ‘n beduidende toename in 
sellewensvatbaarheid asook ‘n afname in die apoptotiese indeks tydens Sl/H 
teweeggebring, terwyl SP600125, ‘n spesifieke JNK inhibitor, apoptose 
bevorder het. PD98059, ‘n ERK inhibitor, het geen invloed op apoptose 
tydens Sl/H gehad nie. Wortmannin, ‘n PI3-kinase inhibitor, het Thr308 (nie 
Ser473) fosforilering onderdruk, gepaargaande met ‘n toename in PARP
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kliewing, maar dit het geen invloed op kaspase-3 aktivering of die apoptotiese 
indeks gehad nie.
EPA en ARA (20 (iM, teenwoordig voor en na SI) het kaspase-3 aktivering en 
PARP kliewing asook die apoptotiese indeks tydens herperfusie beduidend 
verminder. Beide vetsure het ook ‘n beduidende toename in ERK en afname 
in p38 fosforilering veroorsaak. Vanadaat (‘n serien-threonien fosfatase 
inhibitor), maar nie “okadaic” suur (‘n tirosien fosfatase inhibitor), kon die 
ARA-gemduseerde inhibisie van p38 ophef nie. Induksie van MKP-1, ‘n 
tweeledige-spesifieke fosfatase, is beduidend deur ARA en EPA tydens 
herperfusie verhoog. 'n In vitro defosforileringbepaling het bevestig dat hierdie 
fosfatase wel betrokke by die inhibisie van p38 kan wees. Daarbenewens is 
gevind dat die beskermende aksie van ARA PI3-K afhanklik is.
Hierdie resultate wys dat fosforilering van p38 pro-apoptoties is, terwyl JNK 
beskermend is en dat hierdie kinases via kaspase-3 seldood of oorlewing 
tydens SI/H-geinduseerde beskadiging bemiddel. In hierdie model is daar vir 
die eerste keer getoon dat EPA en ARA neonatale kardiale miosiete teen 
isgemie/herperfusie-geinduseerde apoptose beskerm deur induksie van MKP- 
1, wat defosforilering van die pro-apoptotiese kinase, p38 teweegbring. 
Hierdie voordelige effekte van EPA en ARA is ook sigbaar in die funksionele 
herstel tydens isgemie/herperfusie van die geisoleerde rothart model.
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1CHAPTER 1 INTRODUCTION
1.1 MOTIVATION FOR STUDY
There is increasing evidence that fatty acids are important role players in 
cardiovascular disease. Fatty acids, released from membrane phospholipids 
by cellular phospholipases or taken up by the cell from the extracellular 
environment, play an important role in many steps in cytosolic signalling 
pathways, initiated by triggers at the level of the cell membrane (Speizer et 
al., 1991). In this regard, fatty acids can either act as second messengers, 
i.e. molecules involved in the transduction of external signals to the cytosol in 
a rapid and transient fashion, or they can act as modulators, i.e. molecules 
acting in a reversible manner at a precise intracellular location for a very short 
time to amplify, attenuate or deviate a signal. It has indeed been shown that 
fatty acids can substitute for classical second messengers of the inositide 
phospholipid and cAMP signal transduction pathways. Since fatty acids can 
modulate the composition of the membrane phospholipids, the structural unit 
of biological membranes, they can modify the activities of phospholipases, 
protein kinases, G-proteins, adenylate and guanylate cyclases, as well as ion 
channels (Graber et al., 1994) and thus also affect the response of the heart 
to ischaemia/reperfusion.
During the past ten years it has become clear that, in addition to necrosis, 
apoptosis plays an important role in ischaemia/reperfusion injury. Apoptosis or 
programmed cell death is a physiological process critical for organ 
development, tissue homeostasis and elimination of defective or potentially 
dangerous cells in complex organisms -  it permits cell death without a 
concomitant inflammatory response in the surrounding tissues. The process 
of apoptosis depends on the reception of multiple extracellular and 
intracellular signals, integration and amplification of these signals by second 
messengers and finally, activation of the death effector proteases. Defects in 
control of the apoptotic pathways may contribute to a variety of diseases, 
including coronary heart disease.
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2Myocardial ischaemia/reperfusion activate several protein kinase pathways, 
which potentially regulates the onset of cellular injury and apoptosis. The 
primary protein kinases that are activated under these circumstances include 
the mitogen-activated protein kinases (MAPKs) and protein kinase B 
(PKB/Akt).
MAPKs are proline-directed Ser/Thr protein kinases activated by dual 
phosphorylation on both a tyrosine and a threonine residue (Waskiewicz & 
Cooper, 1995). These enzymes are critical components of a complex 
intracellular signalling network that ultimately regulates gene expression in 
response to a variety of extracellular stimuli. The three well-known 
mammalian MAPK families are: the extracellular signal-regulated kinases 
(ERKs), the c-Jun N-terminal kinases/stress-activated protein kinases 
(JNKs/SAPKs), and the p38 MAP kinases (p38 MAPKs). Each of these 
enzymes is a target for discrete but closely related phosphorylation cascades 
in which the sequential activation of three kinases constitutes a common 
signaling module. The best characterized MAPK pathway is the Ras/Raf/MEK 
cascade leading to the activation of ERK1/2 in response to growth factors 
(Davis, 1993). JNK and p38 MAPK are key mediators of stress signals and 
inflammatory responses evoked by a variety of agents such as UV- and y- 
irradiation, heat shock, osmotic stress, and inflammatory cytokines (Hibi et al., 
1993; Han et al., 1994). Many studies have suggested an important role for 
the MAPKs in apoptosis in ischaemia/reperfusion, but the reports on their 
specific roles are conflicting (reviewed by Steenbergen, 2002).
Studies conducted over the last few years also showed that PKB/Akt (a 
serine/threonine protein kinase) is critical for cell survival. For example, 
dominant negative alleles of PKB/Akt reduce the ability of growth factors and 
other stimuli to maintain cell survival whereas over-expression of wild type or 
activated PKB/Akt can rescue cells from apoptosis induced by various stress 
signals (Kauffmann-Zeh et al., 1997; Kennedy et al., 1997). Although there
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3can be little doubt that PKB/Akt promotes cell survival, the mechanisms 
involved have only recently begun to emerge.
In addition, although there is ample evidence for the role of polyunsaturated 
fatty acids (PUFAs) as second messengers in signal transduction cascades, 
there is no evidence for their participation in or effect on the MAPK or PKB/Akt 
signal transduction pathways during stressful conditions such as myocardial 
ischaemia and reperfusion.
Using cultured neonatal cardiomyocytes as model, the aims of this study are:
• To characterize the effects of simulated ischaemia and reperfusion on 
the phosphorylation status of the MAPKs and PKB/Akt as well as their 
role in apoptosis.
• To determine the effect of long-chain PUFAs on cell viability and 
apoptosis during simulated ischaemia and reperfusion.
• To determine the importance of the MAPK family and PKB/Akt in fatty 
acid-induced protection during simulated ischaemia and reperfusion.
• To unravel some of the signalling mechanisms in the above-mentioned 
cascades.
• To determine the effects of long-chain PUFAs on mechanical recovery 
of the isolated rat heart subjected to ischaemia/reperfusion.
Before a study of this nature can be attempted, a thorough knowledge and 
insight into the processes of necrosis, apoptosis and the MAPK- as well as 
PKB/Akt signalling pathways are required. In addition, fatty acid metabolism 
and p-oxidation as well as the participation of these processes in apoptosis 
and signal transduction need to be outlined for the purpose of this study. The 
current understanding and knowledge of these aspects will now be addressed 
in the literature discussion.
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4CHAPTER 2 LITERATURE DISCUSSION
2.1 Apoptosis in cardiovascular disease
2.1.1 Introduction
Cardiovascular disease remains one of the major killers in modern society. It is 
believed to account for ~12 million deaths annually (Gill et al., 2002). To enable 
the development of viable treatment strategies, the complex pathogenesis of the 
disease must first be understood.
In the human heart, cardiac failure is characterized by the progressive death of 
myocytes (Olivetti et al., 1997). Until recently, it was believed that all adult 
cardiomyocyte death is caused by necrosis (unprogrammed cell death as a result 
of massive injury). However, Narula et al. (1996) and Olivetti et al. (1997) 
provided the first evidence that apoptosis (programmed cell death) occurs in the 
myocardium of patients with end-stage dilated cardiomyopathy. Similarly, 
Saraste et al. (1997) demonstrated the presence of apoptotic cells in the infarct 
and peri-infarct regions of myocardium obtained from patients dying from a 
recent myocardial infarction. Probably the best information about apoptosis in the 
heart has been derived from studies of experimental ischaemia/reperfusion. For 
example, Kajstura and co-workers have shown that apoptosis is the predominant 
mode of cell death in ischaemia-reperfused tissue (1996).
The significance of cell death by apoptosis in cardiac pathology recently gained 
great interest as, unlike necrosis, which is thought to be an essentially 
irreversible process, the step-by-step nature of apoptosis suggests it may be 
amenable to therapeutic intervention.
Stellenbosch University http://scholar.sun.ac.za/
52.1.2 A morphologic description of the apoptotic and necrotic cell
Apoptosis was first reported by Kerr and co-workers (1972), a group of 
pathologists studying cell population regulation. In this paper, the authors 
described a form of cell death marked by its singularity, unique morphology and 
resolution without apparent traces of inflammation in the tissue of origin. 
Apoptosis may be considered a mechanism that counterbalances the effects of 
cell proliferation by mitotic division. In fact, deregulated apoptosis has been 
implicated as a fundamental pathogenic mechanism in a variety of human 
diseases. Excessive apoptotic cell death may cause organ atrophy and organ 
failure, as suggested for neurodegenerative diseases and viral hepatitis. On the 
other hand, inefficient elimination of malignant, autoreactive, infected, or 
redundant cells may lead to the development of neoplasia, autoimmunity, viral 
persistence, and congenital malformations (Haunstetter & Izumo; 1998).
Apoptosis is an energy-dependent process, which is characterized by 
preservation of mitochondria and sarcolemmal integrity, nuclear chromatin 
condensation and removal by macrophages and neighbouring cells. On the other 
hand, prominent features of oncosis (accidental cell death), induced by depletion 
of intracellular ATP stores, include swelling, disruption of the sarcolemma and 
the mitochondria, chromatin clumping, blebbing and removal by inflammation (fig 
2.1). The term “necrosis” often used to describe cell death other than apoptotic 
cell death, is imprecise, because it should be reserved for changes that occur 
after cell death irrespective of whether cell death is apoptotic or oncotic (Levin et 
al., 1999). However, the term oncosis as proposed by Manjo and Joris (1995) 
has not been widely accepted even though the nomenclature would be more 
distinct. The term necrosis to indicate acute ischaemic cell death will, therefore, 
be used throughout this thesis.
Apoptosis is an active and physiological mode of cell death, in which the cell 
itself designs and executes the program of its own demise and subsequent
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Figure 2.1 Schematic representation of typical characteristics of 
oncosis and apoptosis (Manjo and Joris, 1995)
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6disposal. A multistep complex mechanism regulates the cell’s propensity to 
respond to various stimuli by apoptosis. The complexity of this mechanism has 
become apparent over the last decade (Oltvai & Korsmeyer SJ, 1994). The 
regulation system involves the presence of at least two distinct checkpoints, one 
controlled by the bcl-2/bax family of proteins (Hockenberry; 1995; Reed, 1994), 
another by cysteine-proteases (caspases) (Fernandes-Alnemri et al., 1995; 
Lazebnik et al., 1994; Nicholson et al., 1995) and possibly by serine-proteases 
(Bruno et al., 1992; Hara et al., 1996; Weaver eta!., 1993).
A cell undergoing apoptosis activates a series of molecular and biochemical 
events which lead to its total physical disintegration. Because many of these 
changes are very characteristic and appear to be unique to apoptosis, they have 
become markers used to identify this mode of cell death biochemically, by 
microscopy or cytometry. One of the early events is cell dehydration. Loss of 
intracellular water leads to condensation of the cytoplasm resulting in a change in 
cell shape and size. Another change, perhaps the most characteristic feature of 
apoptosis, is condensation of nuclear chromatin. The condensation starts at the 
nuclear periphery and the condensed chromatin often takes on a concave shape 
resembling a half-moon, horseshoe or sickle (Manjo & Joris; 1995). The 
condensed chromatin has a uniform, smooth appearance, with no evidence of 
any texture normally seen in the nucleus. DNA in condensed (pycnotic) 
chromatin exhibits hyperchromasia, staining strongly with fluorescent or light 
absorbing dyes. The nuclear envelope disintegrates, lamin proteins undergo 
proteolytic degradation, followed by nuclear fragmentation (karyorrhexis). Many 
nuclear fragments, which stain uniformly with DNA dyes and thereby resemble 
DNA droplets of different sizes, are scattered throughout the cytoplasm. The 
nuclear fragments, together with constituents of the cytoplasm (including intact 
organelles), are then packaged and enveloped by fragments of plasma 
membrane. These structures, called “apoptotic bodies” , are then shed from the 
dying cell (Liu et al., 1995a; Elsasser et al., 1997). When apoptosis occurs in 
vivo, apoptotic bodies are phagocytosed by neighbouring cells, including those of
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7epithelial (Bennett et al., 1995) or fibroblast origin (i.e. not necessarily by 
machrophages), without triggering an inflammatory reaction in the tissue (Cohen, 
1993; Compton, 1992; Wyllie eta!., 1992a).
Activation of endonuclease(s) preferentially cleaving DNA between the 
nucleosomes is another characteristic event of apoptosis (Arends et al., 1990; 
Compton, 1992; Wyllie et al., 1992b). The products of DNA degradation are 
nucleosomal and oligonucleosomal DNA fragments (180 bp and multiples of 180 
bp) which generate a characteristic “ladder” pattern during agarose gel 
electrophoresis.
Another characteristic feature of apoptosis is the preservation, at least during the 
initial phase of cell death, of the structural integrity and most of the plasma 
membrane transport function. Also, cellular organelles, including mitochondria 
and lysosomes remain preserved during apoptosis. The mitochondrial 
transmembrane potential, however, is markedly decreased (Petit et al., 1995; 
Zamzami et al., 1995a). Release of cytochrome c from mitochondria appears to 
be an earlier important event in apoptosis, triggering activation of caspases and 
other downstream apoptotic effectors (Chinnaiyan et al., 1997; Wu et al., 1997; 
Yang et al., 1997, Kluck et al., 1997a). Other features of apoptosis include 
mobilization of intracellular ionized calcium (McConkey et al., 1989), activation of 
transglutaminase which crosslinks cytoplasmic proteins (Piacentini et al., 1995), 
loss of microtubules (Endersen et al., 1995), and loss of asymmetry of the 
phospholipids on the plasmamembrane. In most cell membranes, an asymmetry 
of phospholipids is maintained, with phosphatidylserine and 
phosphatidylethanolamine being confined to the inner leaflet and 
phosphatidylcholine and sphingomyelin are exposed on the external surface of 
the lipid bilayer. This asymmetry of membrane composition is lost during 
apoptosis, leading to exposure of phosphatidylserine on the cell surface, which 
can be recognized by specific receptors (Zwaal & Schroit, 1997).
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8While apoptosis is characterized by an active participation of the affected cell in 
its own demise, even to the point of triggering (in some cell systems), the de 
novo synthesis of the effectors, necrosis, on the other hand, is a passive, 
catabolic and degenerative process. Necrosis generally represents a cell’s 
response to gross injury and can be induced, for example by an overdose of 
cytotoxic agents or exposure to ischaemia. The early events of necrosis are 
mitochondrial swelling followed by rupture of the plasma membrane and release 
of cytoplasmic constituents, which include proteolytic enzymes (Manjo & Joris, 
1995; Wyllie, 1992a). Nuclear chromatin shows patchy areas of condensation 
and the nucleus undergoes slow dissolution (karyolysis). Necrosis triggers an 
inflammatory reaction in the tissue and often results in scar formation. DNA 
degradation is not so extensive during necrosis as in the case of apoptosis, and 
the products of degradation are heterogenous in size, failing to form discrete 
bands on elecrophoretic gels.
The pattern of cell death may not always have the classical features of either 
apoptosis or necrosis. Numerous examples of cell death have been described 
where the morphological and/or biochemical changes resembled neither typical 
apoptosis nor necrosis, but often had features of both (Ueda et al., 1995; 
Schwartz et al., 1993). In some cases, the integrity of the plasma membrane was 
preserved but DNA degradation was random, without evidence of 
internucleosomal cleavage. In other situations, DNA degradation was typical of 
apoptosis but nuclear fragmentation and other features of apoptosis were not 
apparent.
2.1.3 The molecular pathways through which apoptosis is induced
2.1.3.1 Introduction
One of the most widely recognized biochemical features of apoptosis is the 
activation of a class of cysteine proteases known as caspases (Thornberry &
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9Lazebnik, 1998). Caspases are present in the cell as inactive procaspases that 
are cleaved and activated in response to apoptotic stimuli. Initial activation of 
caspases may involve transduction of a signal from membrane death receptors 
belonging to the tumor necrosis factor (TNF) receptor family, such as Fas and 
TNF receptor 1 (TNFR1) (Ashkenazi & Dixit, 1998), or may be mediated by a 
mitochondrial pathway (Green & Reed, 1998).
Stimulation of death receptors results in the activation of caspase-8, which goes 
on to activate caspase-3, a key effector protein of the apoptotic machinery. 
Release of cytochrome c from the mitochondria, on the other hand, leads to 
activation of caspase-9 through formation of a cytosolic complex and subsequent 
activation of caspase-3.
Unlike necrosis, which is a passive, unregulated process, apoptosis is both 
energy dependent and highly regulated. Apoptosis is controlled by the complex 
interaction of numerous prosurvival and prodeath signals. These include the Bcl-
2 family of proteins, which may be antiapoptotic (Bcl-2, Bcl-XL) or pro-apoptotic 
(Bad, Bid), and exerts its effects primarily at the level of mitochondria (Adams & 
Cory, 1998). Other important regulators of apoptosis act at the level of caspases. 
Such proteins include cellular FADD-like inhibitory protein (cFLIP) and the 
inhibitor of apoptosis (IAP) family (Rasper et al., 1998; Uren et al., 1998). 
There are also proteins that counteract the effect of the caspase inhibitors 
themselves such as the recently characterized Smac/DIABLO, a mitochondrial 
protein that, when released, binds and neutralizes lAPs, thus promoting caspase 
activity (Srinivasula et al., 2000). Several other factors are also believed to be 
involved in the regulation of apoptosis including, growth factors, mitogen 
activated protein kinases (MAPKs), PKB/Akt, calcium, and oxidants. The 
complex interaction of all these molecules determines the ultimate fate of the cell: 
life or death.
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2.1.3.2 Caspases, the proteases of the apoptotic pathway
As stated before, a key phenomenon of apoptotic cell death is the activation of a 
unique class of aspartate-specific proteases known as caspases. Until now, at 
least 14 members have been identified in this subclass of proteases (Nicholson & 
Thornberry, 1997). In order to simplify the confusing terminology of the known 
aspartate-specific proteases, a new nomenclature has been adopted, classifying 
all aspartate-specific proteases as caspases (Alnemri et al., 1996). Crystal 
structure analysis of the prototypical caspase ICE (caspase-1) revealed that the 
serine residue common to many proteases is replaced by a cysteine residue 
within a highly conserved pentameric sequence in the catalytic center (Walker et 
al., 1994; Wilson et al., 1994). All caspases are composed of a prodomain and 
an enzymatic region. Heterogeneity among the proteases exists regarding the 
structure of the prodomain, suggesting that this region may define important 
functional differences between caspases. Caspase-1, -2, -4, -5, -8, -9, and -10 
contain a long prodomain of «15 to 25 kDA compared with <5 kDA in caspases- 
3, -6, and -7 . For activation, the caspase proform has to be cleaved into a large 
subunit and a small subunit within the enzymatic domain that finally reassociate 
to form a complex comprising two small and two large subunits. The prodomain 
is not necessary for the proteolytic activity once the caspase is activated. 
Interestingly, all activating cleavages occur behind an aspartate residue (fig 2.2). 
Because this cleavage site is a unique characteristic of caspases (with the serine 
protease, granzyme B, being the only exception), activation can occur only 
through auto activation or cleavage by another caspase or granzyme B.
Cells possess multiple caspases, which may work in a cascade fashion. The 
redundancy may serve to amplify and accelerate the response, as well as to 
provide multiple mechanisms to complete the process. Indeed, the redundancy is 
apparent in the phenotypes of knockout mice in which the deletion of a single 
caspase is associated with a relatively unimpressive phenotype. Deletion of
Stellenbosch University http://scholar.sun.ac.za/
Figure 2.2 Structural characteristics of
caspases (Tran and Milller, 1999)
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caspase-1 or caspase-11 does not result in dramatic phenotypic changes; thus 
the roles for these caspases are less clear (Li et al., 1997; Wang et al., 1998). 
However, deletion of caspase-3 results in a failure of neuronal apoptosis, and the 
mice are born with overlarge brains and die soon after birth (Kuida et al., 1996).
Substrates for caspases comprise many different proteins, including nuclear 
proteins, proteins involved in signal transduction, and cytoskeletal targets 
(Cardone et al., 1997; Kothakota et al., 1997; Sakahira et al., 1998). Most of 
these protein substrates appear to be cleaved by caspases-3 and -7 . However, 
lamin is selectively cleaved by caspase-6 (Orth et al., 1996; Takahashi et al.,
1996). Although many of the target proteins defined to date have a nuclear 
localization, apoptotic cell death does not depend on the presence of a cell 
nucleus, as the characteristic cytoplasmic features of apoptosis can be observed 
in anucleate cytoplasts (Jacobson et al., 1994). Therefore, proteolytic cleavage of 
nuclear proteins may be important in eliciting the nuclear features of apoptosis, 
like chromatin margination induced by lamin B cleavage, but does not constitute 
a critical event for the apoptotic death of the entire cell (Liu et al., 1997; Lazebnik 
et al., 1995). Interestingly, internucleosomal DNA fragmentation requires the prior 
cleavage of a cytoplamic inhibitor of the apoptosis-specific endonuclease (Enari 
et al., 1998; Sakahira et al., 1998; Liu et al., 1997). Only after cleavage of the 
inhibitor can the endonuclease translocate to the nucleus and degrade genomic 
DNA (Enari et al., 1998; Sakahira et al., 1998). For most of the downstream 
targets, the overall contribution to the final cell fate remains to be determined.
In summary, caspases can be grouped into an upstream (caspases -1, -2, -4, -5, 
-8, -9, -10) and a downstream (caspases -3, -6, -7) subgroup. Upstream 
caspases are characterized by long prodomains that appear to contain essential 
regulatory proteins. Most of the activity that finally leads to the lethal proteolytic 
breakdown of cellular target proteins is exerted by downstream caspases 
sensitive to DEVD (aspartate-glutamine-valine-aspartate) oligopeptides 
(caspase-3 and caspase-7).
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2.1.3.3 Mechanisms of caspase activation
Once downstream caspases, that execute the lethal cuts to vital cellular 
components, are activated, cell death appears to be inevitable. Therefore, 
understanding the mechanisms that initiate proteolytic activation of caspases is a 
crucial step in defining targets that allow for the modulation of apoptotic cell 
death. Recent data suggest that activation of caspases may take place either 
within death receptor complexes of the cytoplamic membrane or by a 
mitochondrion-dependent mechanism within the cytosol.
2.1.3.3 (a) Death- and decoy receptor pathway (fig 2.3)
The best characterized pathways for the initiation of apoptosis involve the binding 
of extracellular death signal ligands (FasL and TNF) to receptors that belong to 
the TNFR gene superfamily (Smith et al., 1994). The cytoplasmic sequence 
divides the TNFR superfamily into two main subgroups of receptors that either 
possess or lack a ‘death domain’ (DD) (Tartaglia et al., 1993; Itoh & Nagata, 
1993). The death-domain-containing receptors, or ‘death receptors’ (DR) include 
TNFR1, Fas (Apo1/CD95), DR3 (Apo3), DR4 (TRAIL-R1), DR5 (TRAIL-R2) and 
DR6. The death receptors interact via their DD with intracellular DD-containing 
adaptors, such as FADD (Fas-associating protein with DD) and TRADD (TNF 
receptor-associated death domain), and recruit these adaptors to the cell 
membrane. Thus, binding of Fas ligand to the Fas receptor leads to clustering of 
the Fas receptor’s DD. The adapter, FADD, then binds through its own DD to the 
cluster receptor DD. FADD also contains a ‘death effector domain’ (DED) that 
binds to an analogous domain within the pro-caspase-8 protein. Upon 
recruitment by FADD, pro-caspase-8 oligomerization drives its own activation (to 
caspase-8) through self-cleavage. Caspase-8 then activates downstream effector 
caspases, such as caspase-3, thereby initiating apoptosis. Signaling induced by
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Figure 2.3 Death receptor complexes
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activation of TNFR1 or DR3 diverges at the level of TRADD (Hsu et al., 1995). 
On the one hand, nuclear translocation of the transcription factor nuclear factor 
kB (NFkB) and activation of c-Jun N-terminal kinase (JNK) are initiated 
(Chinnaiyan et al., 1996; Hsu et al., 1996b; Yeh et al., 1997). On the other hand, 
TNF -a signaling is linked to Fas signaling pathways through interaction of 
TRADD with FADD. Surprisingly, FADD knockout mice exhibit a phenotype of 
ventricular thinning and poorly developed trabeculation of the heart (Yeh et al., 
1998). An additional death domain-containing protein, receptor-interaction protein 
(RIP), was also shown to interact with the cytoplasmic domain of TNFR1 
(Stanger et al., 1995; Hsu et al., 1996a). Caspase-2 can be recruited to RIP 
through an adaptor protein called RIP-associated ICH/Ced-3-homologous death 
domain protein (RAIDD) (Duan et al., 1997).
Another subgroup of TNFR-homologues consists of decoy receptors, which 
function as inhibitors, rather than transducers of signalling. This subgroup 
includes decoy receptor (DcR)1 and DcR2 (both of which are cell-surface 
molecules) as well as osteoprotegerin (OPG) and DcR3 (both of which are 
secreted, soluble proteins) (reviewed by Ashkenazi & Dixit, 1999).
2.1.3.3 (b) Mitochondrial pathway (fig 2.4)
The other well-characterized pathway to caspase activation involves participation 
of the mitochondria. In 1997, Zou and co-workers showed that cytochrome c 
participates in caspase activation, in concert with other proteins that were 
subsequently identified as caspase-9 and Apaf-1. Apaf-1 contains a region 
shared with other caspases and may be required for protein-protein interaction. 
In addition, it has a binding site for ATP (or dATP), and a series of 12 WD-40 
repeats, which may be involved in binding cytochrome c (Zou et al., 1997). In 
addition, Apaf-1 has a region of homology to the Caenorhabditis elegans death 
gene 4 (Ced-4), one of the three genes controlling developmental programmed 
cell death in the nematode. It is now thought that Apaf-1 represents the
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Figure 2.4. The mitochondrial pathway of apoptosis 
(modified from Kang et al., 2002)
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mammalian homolog of Ced-4 and interacts with cytochrome c and dATP to 
activate caspase-9 (Li et al., 1997a). The activated and processed caspase-9 
then cleaves caspase-3 to generate the active enzyme, which is the effector 
protease that proceeds to degrade most of the cellular targets.
One problem with this model is that it depends upon cytochrome c being 
released from the mitochondria, where it is normally sequestered in the 
intermembrane space. Thus, agents affecting mitochondrial integrity may lead to 
cytochrome c release and activation of caspases. Little information is available 
explaining how cytochrome c release is controlled, or even if this is a nonspecific 
event accompanying general loss of mitochondrial integrity or a regulated release 
of a single protein. It appears to occur before loss of mitochondrial membrane 
potential (Kluck et al., 1997b), but may represent generalized leakage of 
intermembrane space constituents. Adachi and co-workers (1998) have shown 
that loss of outer membrane integrity is a rather late event, but far earlier, 
cytochrome c has become unavailable for electron transport, although still 
present in the intermembrane space. This suggests its interaction with other 
protein(s) that eventually may all be released from the mitochondria when the 
outer membrane ruptures. One postulated mechanism for the rupture of the outer 
mitochondrial membrane to occur is swelling of the matrix (Vander Heiden et al.,
1997). Since the inner membrane is heavily folded, it can tolerate swelling in 
response to ion fluxes without rupture, however, as it swells, it will stretch and 
eventually rupture the outer membrane. Disruption of mitochondrial calcium 
homeostasis, leading to the formation of the permeability transition pore, may 
also result in mitochondrial matrix swelling and rupture (Crompton, 1999).
A widely recognized target of caspases is the enzyme poly-(ADP-ribose) 
polymerase (PARP). PARP was the first cellular protein to be identified as being 
specifically cleaved in apoptosis (Kaufmann, 1989), and its cleavage 
subsequently was shown to be a universal phenomenon occurring in apoptosis 
induced by a variety of stimuli (Kaufmann et al., 1993). Specific proteolysis of
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PARP occurs in the DNA binding domain and as a result, two polypeptides of 24 
and 89 kDa are formed, thereby abolishing PARP’s catalytic activity (Nicholson et 
al., 1995; Tewari et al., 1995). An apparent active role for PARP in apoptosis 
came from studies using human osteosarcoma cells that undergo spontaneous 
apoptosis. Smulson and co-workers (1997) observed transient PARP activation 
in the early phase of apoptosis, prior to caspase-mediated cleavage and 
inactivation of PARP protein. This transient burst of poly-(ADP-ribosyl)ation of 
nuclear proteins was subsequently detected at an early stage of induced 
apoptosis in other cell types (Simbulan-Rosenthal, 1998). These findings suggest 
that PARP and poly-(ADP-ribosyl)ation may trigger an important step of early 
apoptosis. However, treatment of PARP'/_ fibroblasts with TNF-a, anti-Fas and IL- 
3 withdrawal (Menissier-de Murcia et al., 1997; Wang et al, 1997), and of 
thymocytes with y-irradiation, dexamethasone, ceramide and etoposide induces 
normal apoptotic responses (Leist et al., 1997; Wang et al., 1997). Moreover, 
PARP'/_ primary neurons and hepatocytes undergo apoptosis normally in 
response to a variety of stimuli, including potassium withdrawal, staurosporine, 
and colchicine (Leist et al., 1997). These results indicate that at least in certain 
cell types, PARP does not actively participate in the apoptotic cascade. Despite 
the above-mentioned discrepancies, most studies point out that PARP is 
specifically cleaved during apoptosis, and that massive DNA damage activates 
PARP, before or in parallel to caspase activation, leading to necrosis. Therefore, 
it remains to be elucidated whether the activation and/or cleavage of PARP has a 
specific role in the “decision-making” phase or activating phase of programmed 
cell death.
An important question, which is often raised, is why must PARP be cleaved in 
cells destined to die? It has been postulated that PARP cleavage occurs in order 
to prevent depletion of energy pools required for later stages of apoptosis 
(Earnshaw, 1995). Transient transfection of cells with non-cleavable PARP 
delays apoptosis induced by anti-Fas, as judged by morphological criteria such 
as cell shrinkage and nuclear condensation. The authors claimed that PARP
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A cell can respond to physiological or genotoxic stimuli by activating apoptosis that 
involves activation of caspases and cleavage of chromatin DNA and PARP. Cleavage 
and inactivation of PARP prevents energy depletion and induction of necrosis. Acute and 
massive DNA damage induces hyper-activation of PARP leading to NAD+/ATP depletion, 
which eventually causes necrosis (modified figure from Herceg & Wang, 2001).
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cleavage facilitates cellular disassembly ensuring cell death completion (Olivier,
1998). However, in two other studies, cell lines stably expressing non-cleavable 
PARP exhibit an increased apoptosis in response to TNF-a and staurosporine, 
as determined by extensive morphological analyses (Herceg & Wang, 1999; 
Boulares et al., 1999). It was hypothesized that mutant PARP accelerates 
apotosis through compromised energy metabolism and the mitochondrial 
permeability transition (PT) (Nicholson & Thornberry, 1997), or by shifting 
caspase-3 activation to an earlier time point (Boulares et al., 1999). Alternatively, 
poly(ADP-ribosyl)ation of histones and other nuclear proteins by non-cleavable 
PARP could also substantially contribute to unwinding of chromatin structures 
thereby facilitating access to apoptotic DNAase(s). The apparent discrepancy of 
the results between the above-mentioned studies using non-cleavable PARP can 
be attributed to the technical means by which the mutant PARP was introduced 
into the target cells, i.e. transient versus stable transfection. More importantly, the 
observed induction of massive necrosis coupled with NAD+ and ATP depletion in 
mutant PARP expressing cells (Herceg & Wang, 1999), strongly argues that 
PARP cleavage plays an important role in ensuring the normal speed and order 
of apoptotic events, and prevention from necrosis in cells undergoing apoptosis. 
Since massive activation of PARP leads to necrotic cell death, cells that die via 
apoptosis must block PARP-mediated necrosis by cleaving PARP (fig 2.5). 
Together, these findings fit well with the proposal that PARP cleavage has a 
function in the prevention of necrotic death that would otherwise lead to 
pathological inflammatory responses (Earnshaw, 1998). This theory is also 
supported by several other studies demonstrating that PARP activation is 
involved in inflammatory responses (Szabo et al., 1997, 1998; Cuzzocrea et al., 
1999; Olivier et al., 1999). Moreover, streptozotocin-induced disruption of 
pancreatic p-cells underlines PARP activation and energy depletion as a cause 
of necrotic cell death in this cell type (Burkart et al., 1999).
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Figure 2.6 Regulation of cardiomyocyte apoptosis (Gill etal., 
2002)
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Apoptotic pathways include those initiated by death receptor ligation, mitochondrial stress 
or ER stress. These pathways may be downregulated at several levels by anti-apoptotic 
bcl-2 family members, heat shock proteins and inhibitors of apoptosis such as cFLIP, IAP 
and ARC. In contrast, they may be up-regulated by pro-apoptotic bcl-2 family members 
such as Bax, Bad and Bid. The balance between these molecules determines the 
ultimate fate of the cell: life or death.
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2.1.3.4 Regulatory proteins
In apoptosis, protein-protein interactions are the underlying theme in both 
mitochondria and death receptor pathways (fig 2.6). A sophisticated and tightly 
controlled network of protein-protein interactions exists to ensure the accuracy of 
the cell-death machinery.
The Bcl-2 family is a large key group of apoptosis regulators which, through the 
diverse interactions among themselves and with other proteins, control the 
release of apoptogenic factors needed for caspase activation (Adams & Cory, 
1998; Chao & Korsmeyer, 1998). The IAP (Inhibitor of apoptosis protein) 
family is another family of proteins that inhibits apoptosis through physically 
interacting with caspases and thereby directly inhibiting their function.
2.1.3.4(a) Bcl-2 Protein Family
Members of the Bcl-2 family include both anti-apoptotic proteins, exemplified by 
Bcl-2, B c I-X l, Mcl-1, Bcl-w and A-1, and pro-apoptotic proteins exemplified by 
Bax, Bak, Bik, Bad and Bid. In terms of sequence, Bcl-2 family proteins share at 
least one of four homologous regions termed Bel homology (BH1 to BH4) (fig 
2.7). Based on sequence homology, a subclass of pro-apoptotic proteins termed 
“BH3-only” can be classified that share sequence homology only in the BH3 
domain. While all of the pro-apoptotic members use the BH3 domain to interact 
with anti-apoptotic proteins, BH3-only proteins, including Bad and Bid, appear to 
act mainly as antagonists of anti-apoptotic members such as Bcl-2 and Bcl-XL. In 
contrast to the opposing biological functions and wide differences in amino-acid 
sequences, experimentally determined crystal structures of Bcl-2 (Petros et al., 
2001) and Bcl-XL (Muchmore et al., 1996; Aritomi et al., 1997), vs Bax (Suzuki et 
al., 2000) and Bid (McDonnel et al., 1999; Chou et al., 1999) are surprisingly 
similar.
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Figure 2.7 Structural features of anti-apoptotic and pro- 
apoptotic members of the bcl-2 protein family
(Haunstetter and Izumo, 1998)
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The mechanism by which Bcl-2 family proteins regulate apoptosis has been a 
subject of intensive research. Currently it remains controversial and several 
models have been proposed. An attractive hypothesis for the mode of action is 
the heterotrimerization between anti-apoptotic and pro-apoptotic Bcl-2 family 
members (Reed et al., 1996; Yang et al., 1995; Oltvai et al., 1993). Some 
information about the structural basis of these interactions is provided by the 
three-dimensional structure of Bcl-XL in complex with a peptide derived from the 
BH3 domain of Bak (Sattler et al., 1997). The structure reveals a hydrophobic 
surface pocket on BcI-X l formed by the BH1-3 domains bound by the Bak BH3 
domain peptide in helical conformation. Since the BH3 domain is buried in the 
structure of pro-apoptotic proteins Bid (McDonnel et al., 1999; Chow et al., 1999) 
and Bax (Suzuki et al., 2000), this raises the speculation that conformational 
changes are necessary for the exposure of the BH3 domain of a pro-apoptotic 
protein and its inhibition of the functional pocket on the anti-apoptotic partner. In 
the cell environment, pro-apoptotic Bcl-2 family members are suggested to 
undergo such conformational changes (Desagher et al., 1999) triggered by 
dephosphorylation (Zha et al., 1996) or proteolytic cleavage by caspases (such 
as the cleavage of Bid to generate tBid) (Slee et al., 2000; Li et al., 1998; Luo et 
al., 1998).
2.1.3.4 (b) IAP (Inhibitor of apoptosis protein) family
The Bcl-2 and IAP families are regulators of caspases at two different levels: the 
Bcl-2 family controls signaling events upstream of caspases, while the IAP family 
directly binds and inhibits caspases. The human IAP family contains eight distinct 
cellular members that were just discovered in the past 5-6 years, including X-IAP 
(X-linked IAP), C-IAP1, C-IAP2, and survivin (Devereaux et al., 1999). In humans, 
lAPs such as X-IAP, C-IAP1, and C-IAP2 selectively inhibit caspase-3, -7 and -9  
through direct molecular interactions but not caspase-1, -6, -8, -10. In addition, 
lAPs can interact with Smac/DIABLO, which is released from the mitochondria
Stellenbosch University http://scholar.sun.ac.za/
Figure 2.8 Inhibitor of apoptosis (IAP) proteins
Cellular stress
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together with cytochrome c upon death stimuli. The binding of Smac/DIABLO 
removes lAPs from their association with caspases and thus relieves their 
caspase-inhibiting function (Devereaux et al., 1997; Roy et al., 1997) (fig 2.8).
2.1.4 Regulators of apoptosis with therapeutic potential
Apoptosis is a sequential, multistep process and there are many different points 
at which it can be regulated (fig 2.6). This is of particular importance in fully 
differentiated cardiomyocytes in order to avoid unnecessary death of salvageable 
cells and to promote apoptosis in response to irreversible cellular damage, as 
opposed to necrosis, which could further harm the myocardium. Although most of 
our knowledge of regulation of apoptosis is of that occurring in non-myocytes, 
emerging evidence suggests that similar controls are present in the heart.
2.1.4.1 Caspase inhibitors
Apoptosis may be initiated by a variety of different signals, but the ultimate result 
is the same in most cells. Thus, it appears that the final steps of apoptotic death 
are highly conserved and likely to be mediated by a similar set of caspases. As 
described earlier, various regulatory mechanisms exists within cells that target 
caspases. These include cFLIP and the IAP family, inhibitors present in a variety 
of cell types that may also play an important role in the heart. An inhibitor of 
apoptosis that is expressed almost exclusively in skeletal muscle and heart has 
been characterized. ARC (apoptosis repressor with caspase recruitment domain) 
was first shown to interact with caspase-8 and -2  and to attenuate apoptosis 
induced by stimulation of death receptors (Koseki et al., 1998). More recently it 
was demonstrated that ARC inhibits cytochrome c release from mitochondria and 
protects against hypoxia-induced apoptosis (Ekhterase et al., 1999), suggesting 
that ARC can exert its effect at different levels in the apoptotic pathway and may
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be a key regulator of apoptosis in the heart (fig 2.6). As over-expression of ARC 
had a protective effect compared with cells expressing only endogenous levels of 
ARC, up-regulation of this protein in vivo could provide a means of attenuating 
cell death in certain conditions.
The use of synthetic inhibitors of apoptosis presents another potential therapeutic 
avenue. The broad range caspase inhibitor zVAD-fmk was effective in reducing 
myocardial reperfusion injury in rats, which was attributed in part to the 
attenuation of cardiomyocyte apoptosis (Yaoita et al., 1998). The same inhibitor 
is reported to attenuate apoptosis in rabbit cardiomyocytes (Gottlieb et al., 1996). 
Unfortunately, any potential beneficial effect this inhibitor may have in vivo could 
far be outweighed by its side effects, since caspase inhibition may increase ROS 
production resulting in secondary toxicity as observed in other cell types (Yaoita 
et al., 2000).
Others have investigated the effect of specific inhibitors of caspases. One group 
found that cardiomyocyte DNA fragmentation and caspase activation were 
prevented by inhibitors of caspase-1 and -3  without reduction of infarct size in 
ischemia/reperfused rat hearts (Okamura et al., 2000). This is in contrast with 
another study where it was found that, in addition to zVAD-fmk, inhibitors of 
caspase-8, -9, and -3  all limited infarct size as a result of reperfusion injury 
(Mocanu et al., 2000). The different outcomes of these studies may be due to the 
time of administration. In the former study, inhibitors were administered before 
ischemia; in the latter, they were administered during early reperfusion. This 
underscores the importance of establishing the optimum time for therapeutic 
intervention. Like zVAD-fmk, specific caspase inhibitors might not be of major 
therapeutic value. They do, however, provide a starting point for the development 
of more sophisticated inhibitors for use in treating cardiac disease.
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2.1.5 Signaling pathways and apoptosis
2.1.5.1 Introduction
Only recently have efforts been made to disentangle the intricate relationships 
between signal transduction and apoptosis. Analysis is complicated by the fact 
that receptor agonists may activate several signal transduction mechanisms with 
opposing effects on apoptosis regulation. In the recent past it has become 
evident that the MAPK- as well as the PKB/Akt signalling pathways play major 
roles in the regulation of apoptosis in the heart.
2.1.5.2 Mitogen-activated protein kinase (MAPK) pathways
2.1.5.2.1 The major MAPK subfamilies
Regulatory mechanisms controlling proliferation, differentiation, or apoptosis of 
cells involve intracellular protein kinases that can transduce signals detected on 
the cell’s surface into changes in gene expression. Most prominent amongst the 
known signal transduction pathways that control these events are the MAPK 
cascades. MAPKs represent a family of serine-threonine kinases with the 
potential to phosphorylate other cytoplasmic proteins and to translocate from the 
cytoplasm to the nucleus, where they can directly regulate the activity of 
transcription factors controlling gene expression. Their components are 
evolutionary highly conserved in structure and organization, each consisting of a 
module of three cytoplasmic kinases: a mitogen-activated protein (MAP) kinase 
kinase kinase (MAPKKK), and MAP kinase kinase (MAPKK), and the MAP 
kinase (MAPK) itself (fig 2.9). The MAPKKK (Fanger et al., 1997) is a serine- 
threonine kinase that receives activating signals from a membrane-spanning 
receptor and then phosphorylates and activates its substrate, a MAPKK (Siow et 
al., 1997). This enzyme is a dual-specificity kinase with the potential to 
phosphorylate critical threonine and tyrosine residues in its substrate protein, the 
MAPK (Gartner et al., 1992). As illustrated in Figure 2.10, the mammalian
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Figure 2.9 Basic assembly of mitogen-activated protein kinase (MAPK) pathways is 
a three-component cascade conserved from yeast to humans. Divergent 
stimuli (activators) feed into core MAPK kinase kinase (MKKK), MAPK 
kinase (MKK) and MAPK pathways that are sequentially activated by 
phosphorylation (Marais, PhD dissertation, 2001)
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Figure 2.10 MAPK activation in stress-induced signaling 
(modified from Wernig and Xu, 2002)
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MAPKs fall into three main families, the ERKs (extracellular regulated kinases), 
JNK (c-Jun N-terminal protein kinase) and p38-MAPKs. Each family contains 
multiple isoforms encoded by different genes and splice variants, and differs from 
other family members in the amino acid X in the threonine-X-tyrosine activation 
motif and the size of the loop that contains it.
2.1.5.2.1 (a1) Extracellular signal-regulated kinases (ERKs)
Extracellular signal-regulated kinase-1 (ERK1) and ERK2 also known as p44 and 
p42 MAPKs, represent the prototypical MAPKs in mammalian cells. A wide 
variety of growth promoting or hypertrophic agents activate these kinases in 
cardiac myocytes, fibroblasts, smooth muscle cells and endothelial cells 
(Bogoyevitch, 2000). Activation of ERK may also follow exposure to a variety of 
extracellular stresses. Such activation of a potent growth factor-stimulated 
pathway by stress may seem contradictory, but if stress-activated ERK is 
chemically inhibited, cell death is accelerated (Wang et al., 1998). Therefore 
activation of the ERKs may contribute to cardiovascular cell survival.
Although ERK1 and ERK2 were the first MAPK described, a closely related 
member BMK1 (ERK5) has also been identified (Zhou et al., 1995; Lee et al., 
1995). BMK1/ERK5 is activated in vascular smooth muscle cells and aortic 
endothelial cells exposed to oxidative stress, osmotic shock, and serum but not 
by angiotensin II, PDGF or TNF (Abe et al., 1996; Yan et al., 1999). BMK1/ERK5 
shows similarities to the ERKs with a Thr-Glu-Tyr motif within its activation loop. 
The significant differences within this activation loop sequence confirm that 
BMK1/ERK5 is activated by a distinct upstream kinase MEK5 (Zhou et al., 1995). 
BMK1/ERK5 has also been proposed to be anti-apoptotic based on results of 
MEK5 inhibition. (Kato et al., 1998). MEK5-dependent BMK1 activation results in 
the phosphorylation of MEF2A and MEF2C, pro-survival transcription factors that 
belong to the myocyte enhancer factor-2 (MEF2) family (Kato et al., 1997), which 
are important regulators of cardiac gene expression. Although the expression of
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BMK1/ERK5 in the heart is high (Zhou et al., 1995), its activation in cardiac 
myocytes remains uncharacterized. It is however important to note that 
BMK1/ERK5 can be activated in the ischaemic myocardium (Takeishi et al.,
1999).
2.1.5.2.1 (a2) Structure and basic regulation of the Ras-Raf-MEK-ERK 
pathway
Proliferation signals like growth factors cause activation and autophosphorylation 
of their cognate receptor protein tyrosine kinases (RPTK). The phosphorylated 
tyrosine receptor allows the binding of adaptor proteins like She to the receptor. 
This association of She permits phosphorylation thereof by the receptor itself or 
by intracellular tyrosine kinases such as Src. This phosphorylation allows the 
binding of another adaptor protein Grb2, which also results in the recruitment of 
SOS. The latter stimulates the exchange of GDP bound to Ras for GTP 
(Downward, 1996) and functions as an adaptor that binds to Raf kinases with 
high affinity and causes their translocation to the cell membrane, where Raf 
activation takes place (Moodie & Wolfman, 1994). Raf genes encode 
serine/threonine-specific kinases that integrate the upstream input signals, and 
hence feature a complex regulation. Mammals possess 3 Raf proteins: Raf-1, A- 
Raf and B-Raf (Morrison & Cutler, 1997; Hagemann & Rapp, 1999). Although all
3 Raf isoforms interact with Ras, there are important differences. Activation of B- 
Raf is obtained after binding to Ras alone, whereas for activation of A-Raf and 
Raf-1, additional signals are required (Hagemann & Rapp, 1999).
Phosphatases such as protein phosphatase 2A (PP2A) remove inhibitory 
phosphorylation that keeps Raf-1 in the inactive state (Morrison & Cutler, 1997; 
Hagemann & Rapp, 1999). Several kinases, including PKC (Kolch et al., 1993; 
Morrison et al., 1997), PAK and the Src-family tyrosine kinases phosphorylate 
and activate Raf-1 (Morrison & Cutler, 1997). All three Raf isoforms share Ras as 
a common upstream activator and MEK as the only common accepted
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downstream substrate (Schaeffer & Weber, 1999; Morrison & Cutler, 1997). MEK 
is activated by phosphorylation of two serine residues. Although other kinases 
such as MEKK1 can phosphorylate the same serines, the predominant MEK 
activators in most cell types are Raf kinases (Schaeffer & Weber, 1999). Raf can 
activate both MEK1 and MEK2 (also called MKK1 and MKK2) with similar 
efficacy in vitro. Experimental data suggest a preferential coupling between 
certain Raf and MEK isoforms, but the biological significance is still unclear 
(Schaeffer & Weber, 1999). MEK activates ERK1 and ERK2 via phosphorylation 
of a Thr-Glu-Tyr-motif in the activation loop.
Although more than 50 substrates for ERK have been identified (Lewis et al.,
1998), special attention should be given to p90 ribosomal S6 kinase (p90RSK) in 
the heart, which is a ubiquitous and versatile mediator of ERK signal transduction 
(Frodin et al, 1999). Functions of p90RSK include: (1) regulation of gene 
expression via phosphorylation of transcription factors including c-Fos and cAMP 
response element-binding (CREB) protein; (2) regulation of protein synthesis by 
phosphorylation of polyribosomal proteins and glycogen synthase kinase-3; and 
(3) stimulation of Na+-H+ exchanger by phosphorylating serine 703 of NHE-1 
(Takahashi et al., 1999).
2.1.5.2.1 (a3) The role of ERK in apoptosis
The ERK family of MAPKs have been implicated in survival signaling in response 
to ischaemia/reperfusion, oxidative stress, p-adrenergic stimulation, and 
anthracycline exposure. Several studies have shown that the MEK-ERK pathway 
may be protective or neutral against apoptosis. Insulin-like growth factor-1 (IGF- 
1), cardiotrophin-1 (CT-1), and catecholamines were each shown to exert their 
antiapoptotic effects, in part, by inducing ERK signalling (Sheng et al., 1997; 
Parrizas et al., 1997; De Windt et al., 2000). Ischaemia/reperfusion and oxidative 
stress induced by anthracyclines activate ERK. Inhibition of ERK signalling was 
demonstrated to increase daunomycin-induced apoptosis in cultured
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cardiomyocytes (Zhu et al., 1999), whereas in a model of ischaemia/reperfusion 
in the intact heart, ERK1/2 activation was shown to attenuate the extent of 
apoptosis subsequent to reperfusion injury (Yue et al., 2000). MEK1 transgenic 
mice were also shown to be partially resistant to ischaemia/reperfusion-induced 
DNA laddering, suggesting a cardioprotective function for ERK1/2 signalling 
(Bueno et al., 2000).
Although these various reports discussed have shown that stress- or agonist- 
induced ERK1/2 activation is associated with protection from apoptosis, little is 
known as to how ERK signalling results in cellular protection. Cyclooxygenase-2 
(COX-2) has been identified as a possible downstream mediator of protection in 
association with ERK1/2 signalling in cardiomyocytes (Adderley et al., 1999). In T 
cells, ERK1/2 activation has been associated with induction of expression of 
FLICE (FADD-like interleukin 1 (3-converting enzyme) inhibitory protein, a known 
inhibitor of the caspase cascade (Yeh et al., 1998). It is unknown whether 
protection induced by ERK signalling is mediated by increasing FLICE-inhibitory 
protein expression in the heart.
The cardioprotective effects of estrogen have been extensively investigated. In 
addition to the classical genomic effects, estrogens have also been shown to 
have rapid nongenomic effects, which include NO release and ERK1/2 activation 
(Chen et al., 1999; de Jager et al., 2001). In the heart, ERK signalling induced by 
estrogens results in the rapid expression of early growth response gene-1 (Erg-1) 
and ANF, which have been shown to have cardioprotective effects (de Jager et 
al., 2001; Jankowski e ta i,  2001).
Another mechanism whereby ERK1/2 may function in a cardioprotective manner 
is through the association with protein kinase Cs (PKCs), which is a well- 
characterized mediator of cardiomyocyte protection (Dawn & Bolli, 2002). Indeed, 
Baines and co-workers (2002) recently demonstrated that the ERKs form a 
complex with PKCs in the mitochondria resulting in the phosphorylation and
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inactivation of BAD (Baines et al., 2002). As a final mechanism, it was also 
shown that the ERK substrate, p90RSK, phosphorylated the pro-apoptotic 
protein BAD at serine 112, which specifically suppressed BAD-mediated 
apoptosis (Bonni et al., 1999; Tan etal., 1999).
These findings suggest that p90RSK and ERK promote cell survival by both 
inhibiting components of the cell death machinery (e.g. BAD) and increasing 
transcription of pro-survival genes (e.g. CREB). Future studies using MEK1, 
MEK2, ERK1 or ERK2 gene-targeted mice (or dominant-negative-expressing 
transgenic mice) subjected to cardiac ischaemia/reperfusion injury will ultimately 
establish the overall importance of MEK-ERK signaling as an anti-apoptotic 
effector pathway in vivo.
2.1.5.2.1 (b1) JNK and p38 MAPK (Stress activated protein kinases -  
SAPKs)
Two other MAPK subfamilies that are activated by a diverse range of 
extracellular stresses such as irradiation, ultraviolet light, mechanical stress, 
hyperosmotic shock, heat shock, hypoxia/reoxygenation, reactive oxygen 
species (ROS), pro-inflammatory cytokines (such as interleukin-1 and TNF-a) 
and to a lesser degree by growth factors (Sugden & Clark, 1998; Bogoyevitch,
2000) were identified as c-Jun NH2-terminal kinases (JNK) and p38 MAPK. 
Molecular cloning revealed three genes that encode the 46- and 54-kDa isoforms 
of JNK: JNK1 (SAPKy), JNK2 (SAPKa) and JNK3 (SAPKp) (Kyriakis et al.,
1994). These kinases selectively phosphorylate the NH2-terminal transactivation 
domain of the transcription factor c-Jun (Hibi et al., 1993), which results in gene 
expression of c-jun (Karin, 1994). JNKs are important for cytokine biosynthesis 
and are involved in cell transformation, stress responses and apoptosis (Kyriakis
& Avruch, 1996; Dong etal., 1998; Kuan etal., 1999).
To date, six members of the p38 MAPK group have been cloned and 
characterized: p38 a1/a2 (Han et al., 1994; Lee et al., 1994), p38 p i/p2  (Jiang et
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al., 1996), p38y (Lechner et al., 1996; Li et al., 1996; Cuenda et al., 1997) and 
p388 (Jiang et al., 1997; Kumar et al., 1997). Like the JNKs, they are strongly 
activated by environmental stress and inflammatory cytokines and therefore also 
referred to as stress-activated protein kinases. In almost all instances, the same 
stimuli that recruit the JNKs also recruit p38-MAPKs (Kyriakis & Avruch, 1996). 
One exception is myocardial ischaemia/reperfusion. JNKs are not activated 
during ischaemia, but rather during reperfusion, whereas p38-MAPKs are 
activated during ischaemia and remain active during reperfusion (Pombo et al., 
1994; Bogoyevitch et al., 1996; Kyriakis & Avruch, 1996). Activation of p38 
MAPKs has been implicated in transcription, protein synthesis, cell surface 
receptor expression and cytoskeletal integrity, ultimately affecting cell survival or 
leading to apoptosis (Obata et al., 2000).
2.1.5.2.1 (b2) Stucture and basic regulation of the JNK and p38 MAPK 
pathway
Members of the MAPKKK superfamily responsible for activating JNK and p38 
MAPK pathways that have been identified, include MEKK-1, MEKK-2, MEKK-3, 
MEKK-4 (MTK), MUK (MAPK upstream kinase), MLK (mixed lineage kinase), 
Tpl-2 (tumor progression locus-2), TAK-1 (TGF-p activated kinase 1), ASK-1 
(apoptosis signal-regulation kinase) and TAO (thousand and one amino acid 
protein kinase) (reviewed in Obata et al., 2000; Gutkind, 2000; Widmann et al.,
1999). These MKKK are regulated by Rac and Cdc42, two small guanosine 5'- 
phosphate (GTP)-binding proteins of the Rho family, in a manner similar to that 
of Ras acting on Raf (Minden et al., 1995). At least a portion of this JNK/p38 
MAPK activation by small GTP-binding proteins involves activation of a 
serine/threonine kinase called PAK (p21-activated kinase) (Bagrodia et al.,
1995). The relative contribution of each MKK to either JNK or p38 MAPK 
pathways has not yet been clearly defined. MEKK-1, MEKK-2, MEKK-3, MUK, 
MLK and Tpl-2 seemed to preferentially activate JNK, rather than p38 MAPK 
(Fanger et al., 1997; Obata et al., 2000; Gutkind 2000), through two MAPKK,
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namely MKK4 (Sanchez et al., 1994) and MKK7 (Tournier et al., 1997). On the 
other hand, MEKK-4, TAK-1, ASK-1 and TAO appear to be more effective 
activators of p38 MAPK (Obata et al., 2000), through MKK6 and MKK3 
(Moriguchi et al., 1996). MKK6 appears to phosphorylate all p38 MAPK isoforms, 
whereas MKK3 phoshorylate only p38a, y and 5 (Enslen et al., 1998). Crosstalk 
between the JNK and p38 MAPK pathways has also been observed, since 
MEKK-1 can activate p38-MAPK through MKK-4 in NIH 3T3 cells (Guan et al., 
1998), and similarly, MEKK-2 or MEKK-3 can couple to the p38 MAPK pathway 
via MKK6 (Deacon & Blank, 1999).
2.1.5.2.1 (b3) The role of JNK in apoptosis
JNK has been shown to be activated before or after apoptotic stimulation, and is 
a potential candidate for apoptotic signalling in the heart (Davis, 2000). 
Reoxygenation and reperfusion are known to activate JNK in the heart 
(Bogoyevitch et al., 1996; Laderoute & Webster, 1997; Yue et al., 1998) and 
inhibition of this pathway has been shown to abrogate apoptosis induced by 
these stressors (Laderoute & Webster, 1997; Yue et al., 2000). Furthermore, it 
has been demonstrated in the rat heart that JNK is translocated to the nucleus 
during ischaemia where it is phosphorylated during the reperfusion period (Yue 
et al., 1998). Hreniuk and co-workers (2001) also demonstrated that treatment of 
rat cardiac myocytes with antisense oligonucleotides that specifically targeted 
either JNK1 or JNK2 and significantly reduced both mRNA and protein 
expression of the target isoforms, resulted in almost complete attenuation of 
reperfusion-induced apoptosis.
Several mechanisms have been proposed for JNK-mediated apoptosis, one of 
which is the activation of c-Jun transcriptional activity by phosphorylation. In that 
case, the Fas ligand is upregulated in a MEKK-1 and c-Jun-dependent manner 
(Faris et al., 1998; Behrens et al., 1999). Also, JNK phosphorylation of Bcl-2 and 
BcI-Xl has been implicated (Yamamota et al., 1999; Kharbanda et al., 2000).
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Figure 2.11 A: While caspase activation initiates and executes apoptosis, 
prolonged JNK activation promotes apoptosis by inactivating 
suppressors of the mitochondrial dependent death pathway. 
Activation of NF-kB by TNF-a blocks caspase activation and 
prevents prolonged JNK activation, thereby inhibiting TNF-a-induced 
apoptosis. B: Inactivation of NF-kB removes inhibition on both 
caspases and JNK, allowing TNF-a to induce apoptosis (Lin, 2003).
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However, this has been challenged by the demonstration of an anti-apoptotic 
effect of Bcl-2 phosphorylation by JNK (Deng et al., 2001). Recently, the critical 
role of JNK in ultraviolet (UV)-induced apoptosis was shown using JNK1'/‘JNK2'/‘ 
deficient double null embryonic fibroblasts (Tournier et al., 2000). In this study, 
the JNK pathway was found to be dispensable for Fas-induced receptor- 
mediated apoptosis, but a prerequisite for UV-induced Bid translocation, 
cytochrome c release, mitochondrial dysfunction and apoptosis. However, no 
phosphorylation of Bcl-2 family proteins was detected (Tournier et al., 2000). 
These findings and those of Aoki and co-workers (2001) in cardiac myocytes are 
consistent in that the JNK pathway activates mitochondrial apoptotic signaling 
which does not require phosphorylation of Bcl-2 family, suggesting the presence 
of as yet unidentified JNK target in the mitochondrial pathway.
It has also been proposed by Lin (2002) that JNK might be a modulator rather 
than an intrinsic component of the apoptotic machinery. Thus, JNK facilitates but 
does not induce apoptosis. They hypothesized that activated JNK inactivates 
suppressors of the apoptotic machinery. According to their model, JNK activation 
contributes to apoptosis only if the apoptotic process has already been activated. 
This can explain how prolonged JNK activation alone does not induce apoptosis, 
but is able to promote TNF-a-induced apoptosis in the absence of NF-kB 
activation (fig 2.11). TNF-a is not typically a killer, since activation of NF-kB 
inhibits caspases and prevents prolonged JNK activation (Tang et al., 2001; 
Karin & Lin, 2002). In the absence of NF-KB-mediated inhibition, such as in RelA'
7 fibroblasts, TNF-a induces apoptosis through activation of caspases and 
release of apoptotic pathway inhibtion by prolonged JNK activation (fig 2.11). 
This model may also explain how activation of JNK alone does not induce 
apoptosis, but inhibition of JNK activation blocks UV-induced cell death. UV 
induces apoptosis by activating the mitochondrial-dependent death pathway and 
it also induces prolonged JNK activation by an unknown mechanism (Tournier et 
al., 2000). Nevertheless, prolonged JNK activation may function to inactivate 
inhibitors of the mitochondrial-dependent death pathway, there contributing to
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activation of the death pathway. Since TNF-a activates both receptor- and 
mitochondrial-dependent death pathways, while UV activates only the 
mitochondrial-dependent death pathway, it is likely that prolonged JNK activation 
inactivates inhibitors involved in blocking the mitochondrial-dependent death 
pathway.
In summary, the role of the JNK pathway in apoptosis is complex, as it is able to 
both promote and suppress the process. Although activation of the JNK pathway 
can contribute to apoptosis, JNK may not be an intrinsic component of the 
apoptotic machinery. Instead, activation of JNK may modulate the apoptotic 
process in a cell-type and stimulus-dependent manner.
2.1.5.2.1 (b4) The role of p38-MAPK in apoptosis
The role of p38-MAPK in myocyte apoptosis is intriguing because p38 MAPK can 
also mediate cardiac hypertrophy. One of the ways that p38 MAPK can induce 
apoptosis is through its effect on cyclin D1 expression during the cell cycle. It has 
been demonstrated that the coexpression of MKK3 along with p38 MAPK inhibits 
mitogen-induced cyclin D1 expression (Lavoie etal., 1996).
Studies using chemical inhibitors have led to the conclusion that activation of p38 
MAPK promote cardiac myocyte death during extended periods of ischaemia 
(Mackay & Mochly-Rosen, 1999; Saurin et al., 2000; Barancik et al., 2000). In a 
cultured neonatal rat cardiac myocyte model, inhibition of p38 MAPK protects 
against ischaemic injury as evidenced by a reduction in LDH release (Mackay & 
Mochly-Rosen, 1999; Saurin et al., 2000). In addition, Barancik and co-workers 
(2000) reported that a specific inhibitor of p38 MAPK, SB203580, reduced infarct 
size in ischaemic pig hearts in vivo. Several studies indicated that p38 MAPK 
activation also plays a pivotal role in promoting myocardial apoptosis (Ma et al., 
1999; Mackay & Mochly-Rosen, 1999; Yue et al., 2000). Ma and co-workers
(1999) demonstrated that in isolated perfused rabbit hearts, ischaemia alone
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caused a moderate but transient increase in p38-MAPK activity. Reperfusion 
further activated p38-MAPK, which remained elevated throughout 20 minutes of 
reperfusion. Administration of SB203580 before ischaemia and during 
reperfusion completely inhibited p38 MAPK activation and exerted significant 
cardioprotective effects, characterized by decreased myocardial apoptosis and 
necrosis as well as improved post-ischaemic function. In contrast, administering 
SB203580 10 minutes after reperfusion (a time point when maximal MAPK 
activation had already been achieved), failed to convey significant 
cardioprotection. Mackay and Mochly-Rosen (1999) observed two distinct 
phases of p38 MAPK activation in ischaemic neonatal rat cardiomyocytes: the 
first phase began within 10 minutes and lasted less than 1 hour, and the second 
began after 2 hours and lasted throughout the ischaemic period. They 
demonstrated that SB203580 also protected cardiac myocytes against ischaemia 
by reducing activation of caspase-3, a key event in apoptosis. However, the 
protective effect was seen even when the inhibitor was present during only the 
second, sustained phase of p38 MAPK activation. Subsequent studies by Yue 
and co-workers (2000), exposing rat neonatal cardiomyocytes to ischaemia 
showed a rapid and transient activation of p38-MAPK and JNK. On 
reoxygenation, further activation of the SAPKs was noted. With pretreatment of 
the cells with SB203580 apoptotic cells were reduced, suggesting p38 MAPK 
activation mediates apoptosis in rat cardiac myocytes subjected to 
ischaemia/reoxygenation. In addition, Yue and co-workers (2000) also showed 
that SB203580 improved cardiac contractile function in isolated ischaemic rat 
hearts. Thus, in a large number of studies, inhibition of p38 MAPK activation, is 
associated with cardioprotection against ischaemia/reperfusion injury in 
myocytes as well as in isolated hearts.
On the other hand, a number of authors also showed that p38 MAPK activation is 
protective in the heart. Weinbrenner and co-workers (1997) demonstrated that 
phosphorylation of tyrosine 182 of p38 MAPK correlates with protection of 
preconditioning in the rabbit heart and Nakano and co-workers correlated the
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protective effect of ischaemic preconditioning with the activation of MAPKAPK2 
(a substrate of p38 MAPK) in the isolated rabbit heart. Zechner and co-workers 
(1998) reported that overexpression of MKK6 , an upstream activator of p38 
MAPK, resulted in protection of cardiac myocytes from apoptosis. In addition, 
expression of MKK6 elicited a hyperthrophic response, which was enhanced by 
co-infection with p38(3 (Wang et al., 1998). It appears that a distinct isoform of 
p38 MAPK, p38p, participates in mediating cell survival. In contrast, over­
expression of MKK3 in mouse cardiomyocytes led to apoptosis, which was 
increased by co-infection with p38a (Wang et al., 1998). Therefore, differential 
activation of p38 MAPK isoforms may exert opposing effects: p38a is implicated 
in cell death, while p38p may mediate myocardial survival.
These suggestions were subsequently confirmed by Saurin and co-workers
(2000): rat neonatal cardiomyocytes were infected with adenovirus encoding 
either wild-type p38a or p38p, which was differentially activated during sustained 
ischaemia, with p38a remaining activated but p38p deactivated. Furthermore, 
cells expressing a dominant negative p38a, which prevented ischaemia-induced 
p38 MAPK activation, were resistant to sustained ischaemic injury. It was 
concluded from these observations that activation of p38a MAPK isoform is 
detrimental during ischaemia.
2.1.5.2.2 MAPK inactivation by phosphatases
Dephosphorylation of either the threonine or tyrosine residue within the MAPK 
activation loop TxY motif alone can result in their inactivation. In intact cells, 
dephosphorylation and inactivation of MAPK occur, within minutes to several 
hours depending on the cell type and activating stimulus. In endothelial cells, 
exposure to serum leads to ERK activation that is sustained at high levels for 
over 2 h. In contrast, different patterns can be observed in the a PC12 cell line 
where EGF-(epidermal growth factor) stimulated ERK activation is transient, with 
inactivation initiated within 5 min and nearly completed within 15-30 min,
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whereas this MAPK displays prolonged activation for several hours on 
stimulation with NGF (nerve growth factor) (Alessi et al., 1995). It is believed that 
different patterns of ERK activation elicited by EGF and NGF underlie their 
differential effects to drive either cellular proliferation of differentiation, 
respectively (Marshall, 1995). Using PC12 cells as a model system to identify key 
phosphatases suppressing ERK activation, biochemical studies revealed that 
early rapid inactivation of these MAPKs reflects, in part, threonine 
dephosphorylation by the serine/threonine protein phosphatase PP2A (Alessi et 
al., 1995).
In addition to threonine dephosphorylation, these studies also indicated that the 
tyrosine-specific protein phosphatases (PTPs) also contribute to ERK inactivation 
(Alessi et al., 1995). Currently, 50 or more PTPs have been characterized (Neel 
& Tonks, 1997; Hooft van Huisduijnen; 1998; Denu & Dixon, 1998), and although 
the PTPs in PC12 cells have not been identified molecularly (Alessi et al., 1995), 
recent studies in other cell types have identified a possible role for three related 
PTP gene family members (Wurgler-Murphy et al., 1997; Shiozaki & Russel, 
1995, Millar et al., 1995; Zhan et al., 1997). Notwithstanding the importance of 
these early reports on PP2A and tyrosine-specific protein phosphatases 
inactivating ERKs, little is known about their general importance in terminating 
MAPK signaling and the molecular mechanisms that may control phosphatase 
catalytic activity, or of their specificity for inactivating different MAPK isoforms.
In contrast to these protein phosphatase classes, there has been significant and 
rapid progress in our understanding of the role played by a subclass of PTP 
which can dephosphorylate both phosphotyrosine and phosphothreonine 
residues, known as the dual specificity phosphatases (DSPs). The first 
mammalian DSP was identified as the mouse immediate early gene 3CH134 or 
its human orthologue CL100, which is induced rapidly after exposure to growth 
factors, heat shock, or oxidative stress (Keyse & Emslie, 1992; Charles et al., 
1992; Noguchi et al., 1993). Recombinant CL100/3CH134 was shown to
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dephosphorylate threonine and tyrosine residues of ERK, leading to its 
inactivation. These studies showed that CL100/3CH134 was specific for 
dephosphorylation of ERK when compared to a number of other unrelated 
phosphoproteins (Alessi et al., 1993). A correlation between 3CH134 levels and 
ERK inactivation was also found in mammalian cells, leading to its renaming to 
MAPK phosphatase-1 (MKP-1) (Sun et al., 1993). Despite this important early 
work, the relevance of MKP-1 in ERK inactivation remains to be elucidated. 
Firstly, ERK activity is apparently normal after deletion of the MKP-1 gene in 
mice (Dorfman et al., 1996). Secondly, it has also become evident that MKP-1 is 
at least as effective in inactivating JNK and p38 when compared to the ERKs 
(Chu et al., 1996; Franklin & Kraft, 1997). Thirdly, newly identified members of 
the DSP gene family appear highly selective for ERK and may represent the true 
physiological regulators of this MAPK isoform. Since the initial cloning of MKP-1, 
eight additional mammalian DSP gene family members have been identified and 
characterized, which include MKP-2, MKP-3, MKP-4, MKP-5, MKP-X, PAC1, 
M3/6 and B59. These DSPs all appear to be effective in mediating inactivation of 
MAPKs.
The following model for MAPK inactivation by DSP is suggested (fig 2.12). 
Stimulation by growth factors, cytokines, cellular stresses or some active 
oncogenes leads to rapid transcription of one or a subset of DSP genes. 
Increased DSP transcription may reflect activation of specific MAPK, although 
alternative pathways are not excluded. After translation of the DSP mRNA into 
protein, the catalytically inactive DSP translocates to a specific subcellular 
compartment within either the nucleus or the cytosol. Upon encountering its 
target MAPK, the DSP binds tightly to its amino terminus, which in turn triggers 
activation of the phosphatase catalytic domain. If the bound MAPK is already 
activated, this will result in its rapid inactivation. Conversely, if the MAPK is not 
active, then its tight interaction with an active DSP is expected to block any 
possibility of kinase activation by a subsequent stimulus. MAPKs that fail to bind 
the DSP within its amino terminus remain active or susceptible to activation after
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Figure 2.12 Model for MAPK inactivation by DSPs 
(Camps et al., 1999)
Cell exposure to growth factors, cytokines and cell stresses leads to induction of a subset 
of DSP genes. Increased expression is likely to reflect activation of transcription factors 
(black circles) via both MAPK-dependent and independent pathways. Newly synthesized 
DSPs translocate to specific subcellular compartments as dictated by anchorage and/or 
localization motifs not yet identified. Specific binding to target MAPKs through regions 
within the DSP amino terminus then triggers activation of the phosphatase catalytic 
domain. Bound MAPKs are in turn inactivated by dephosphorylation on threonine and 
tyrosine residues localized within the “activation loop” motif of TxY. Inactive MAPKs then 
dissociate, leaving the DSP free to bind and inactivate another MAPK molecule. In the 
absence of continued DSP gene transcription and protein synthesis, rapid degradation 
may limit their duration of activity in cells.
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extracellular stimulation. Depending on their cellular localization, these regulatory 
effects allow for selected inhibition of MAPK activities in specific subcellular 
compartments. Some DSPs have been shown to possess short half-lives (Alessi 
et al., 1993; Noguchi et al., 1993), suggesting that in the absence of continued 
gene transcription and protein synthesis, their rapid turnover limits their duration 
of action in cells. Overall, tight control of DSP gene induction, combined with their 
differential binding and catalytic activation by a specific repertoire of MAPKs, 
provides a sophisticated mechanism for rapid targeted inactivation of selected 
MAPK activities.
2.1.5.2.3 Protein kinase B (PKB)/Akt pathway
The serine/threonine protein kinase, protein kinase B or Akt (PKB/Akt), has 
emerged as a crucial regulator of widely divergent cellular processes including 
apoptosis, proliferation and differentiation. The PKB/Akt story began with the 
isolation of two genes, named Akt1 and Akt2, which were identified as human 
homologues of the viral oncogene v-akt, previously known to cause a form of 
leukaemia in mice (Staal, 1987). Subsequently, three independent studies 
revealed that v-akt and its mammalian homologue, encoded a protein kinase with 
some similarities to protein kinase C (PKC) and protein kinase A (PKA) 
(Bellacosa et al., 1991; Coffer & Woodget, 1992; Jones et al., 1991). Its relation 
to PKA and PKC led to it being named PKB by the authors of one of these 
studies. To date, three members of the family have been isolated and these are 
now referred to as PKBa (Akt 1), PKB|3 (Akt 2), and PKBy (Akt 3). They are 
products of distinct genes but are highly related, exhibiting greater than 80% 
homology at amino acid level. The three genes are expressed differentially, with 
PKBa/Akt 1 and PKBp/Akt 2 displaying fairly broad and PKBy/Akt3 more 
restricted tissue distribution.
Although originally suggested to be involved in the regulation of cell growth, its 
central role in signaling only became apparent when PKB/Akt was shown to be a
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downstream target for PI-3K (Burgering & Coffer, 1995; Franke et al., 1995). The 
cellular activation of PKB/Akt is dependent upon the generation of inositol- 
containing membrane lipids phosphorylated by PI-3K at the D3-OH group on the 
inositol ring. A number of studies have also documented PI-3K-independent 
activation of PKB/Akt in various cell systems (Vanhaesebroeck & Alessi, 2000), 
but the physiological significance of these findings remains uncertain. PKB/Akt is 
activated downstream of Class 1A and Class 1b PI-3K, which are activated by 
tyrosine kinases and G-protein coupled receptors, respectively. Following its 
recruitment to these receptors in the plasma membrane, PI-3K is activated and 
phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) on the 3-OH group 
generating the second messenger phosphatidylinositol-3,4,5-trisphosphate 
(PIP3). PIP3 levels are tightly regulated by the action of phosphatases such as 
PTEN, which removes phosphate from the 3-OH position, and SHIP, which 
dephosphorylates at the 5-OH position. PIP3 does not activate PKB/Akt directly 
but instead appears to recruit PKB/Akt to the plasma membrane and to alter its 
conformation to allow subsequent phosphorylation by the phosphoinositide- 
dependent kinase-1 (PDK-1) (fig 2.13). PDK-1 is a 63-kDa serine/threonine 
kinase containing a C-terminal PH domain that binds with high affinity to 3- 
phosphoinositides. PDK-1 phosphorylates PKB/Akt in the activation loop, which 
regulates access to the catalytic site of PKB/Akt. Phosphorylation of this site 
(Thr308 in PKBa/Akt 1) in vitro is enhanced by 3-phosphoinositides and it has 
been suggested that the lipids induce both a favourable conformation of PKB/Akt 
(and possibly PDK-1) allowing access to the acceptor phosphorylation site and 
also co-localization of the two proteins in the lipid micro-environment (Alessi et 
al., 1997; Stokoe et al., 1997).
Although phosphorylation at Thr308 partially activates PKB/Akt (Alessi et al.,
1996), full activation of PKB/Akt requires phosphorylation on a second site 
(Ser473 in PKBa/Akt 1) located in the regulatory tail. The mechanism mediating 
Ser473 phosphorylation remains controversial. Balendran and co-workers (1999) 
showed that, following phosphorylation of PKB/Akt at Thr308, PDK-1 converts to a
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Figure 2.13 Mechanism of activation of PKB/Akt
(Nicholson and Anderson, 2002)
In unstimulated cells PKB/Akt is not phosphorylated on Thr308 or Ser473 
and resides mainly in the cytosol. Following growth factor (GF) 
activation of receptor tyrosine kinases (RTKs, or other cell surface 
receptors, not shown), PI-3K is recruited to the receptor and activated, 
resulting in the production of PIP3. This recruits PKB/Akt to the 
membrane where it is phosphorylated on Thr308 within the catalytic 
domain by PDK-1 and on Ser473 within the regulatory domain by an ill- 
defined mechanism, possibly involving (a) autophosphorylation, (b) 
PDK-1, (c) ILK, or (d) an unidentified PDK-2. PKB/Akt is then released 
from the membrane and translocates to other subcellular 
compartments.
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Ser473 kinase as a result of its interaction with the singly phosporylated PKB/Akt 
and a fragment of a protein known as PRK-2. Modification of Ser473 has also 
been shown to occur through autophosphorylation (Toker & Newton, 2000).
Other findings suggest that Ser473 is modified by a distinct kinase or PDK-2. 
Although in most situations, phosphorylation of PKB/Akt at Ser473 in intact cells, 
occurs in tandem with that at Thr308, a number of studies have shown that 
phosphorylation at the two sites can occur independently (Alessi et al., 1996; 
Kroner et al., 2000). Furthermore, PDK-1 null embryonic stem cells maintain the 
ability to undergo Ser473 phosphorylation (Williams et al., 2000) and a recent 
study showed that Ser473 phosphorylation could be stimulated by insulin in the 
absence of Thr308 phosphorylation and PKB/Akt activation, indicating the 
existence of a ligand-activatable PDK-2 (Hill et al., 2001). The integrin-linked 
kinase (ILK) was shown to phosphorylate Ser473 (Delcommenne et al., 1998) but 
a subsequent report suggested that ILK acts only as a facilitator and does not 
phosphorylate PKB/Akt directly (Lynch et al., 1999). A more recent study showed 
that ILK could phosphorylate PKB/Akt on Ser473 and that the kinase activity of ILK 
was essential for Ser473 phosphorylation in cells. A novel ILK-specific inhibitor 
also blocked Ser473 phosphorylation of PKB/Akt (Persad et al., 2001). These 
studies strongly suggest that ILK plays some role in the activation process but 
whether it phosphorylates PKB/Akt directly remains an open question. Clearly, 
the regulation of PKB/Akt is complex, and not fully understood. Although there is 
evidence for independent regulation of Ser473, phosphorylation at this site alone 
has not been shown to increase PKB/Akt activity, therefore the physiological 
significance of these findings is unclear. A recent report documented evidence 
that PKB/Akt activation requires the phosphorylation of two tyrosine residues in 
the activation loop, Y315 and Y326 in PKBa/Akt 1 (Chen et al., 2001). These 
modifications were shown to be dependent on src family tyrosine kinases. If 
confirmed then these findings add further to the complexity of PKB/Akt 
regulation.
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2.1.5.2.3(a) Involvement of PKB/Akt in anti-apoptotic mechanisms (fig 
2.14)
The intrinsic capacity of all cells to undergo apoptosis is suppressed by survival 
signals induced by factors within their immediate microenvironment. Studies 
conducted over the last few years showed that PKB/Akt is critical for cell survival. 
For example, dominant negative alleles of PKB/Akt reduce the ability of growth 
factors and other stimuli to maintain cell survival whereas over-expression of wild 
type or activated Akt can rescue cells from apoptosis induced by various stress 
signals (Kauffmann-Zeh et al., 1997; Kennedy et al., 1997; Khwaja et al., 1997; 
Kulik et al., 1997). Although there can be little doubt that PKB/Akt promotes cell 
survival, the mechanisms involved have only recently begun to emerge. Progress 
in this regard has come mainly through the identification of PKB/Akt substrates 
that either participate directly in the apoptotic cascade, or regulate the 
transcription of pro- and anti-apoptotic genes. Prosurvival substrates of PKB/Akt 
signaling include ASK1, Bad, CREB, Forkhead family (FKHR, FKHRL1, AFX), I k -  
B kinase and procaspase-9.
One means by which PKB/Akt may promote cell survival is through direct 
phosphorylation of transcription factors that control the expression of pro- and 
anti-apoptotic genes. PKB/Akt appears to both negatively regulate factors that 
promote the expression of death genes and positively regulate factors that 
induce survival genes. An example of the former is the forkhead family of 
transcription factors. The three identified mammalian members of the forkhead 
family, FKHR, FKHRL1, and AFX, all contain consensus PKB/Akt 
phosphorylation sequences, which can be effectively phosphorylated by PKB/Akt 
in vitro (Biggs et al., 1999; Brunet et al., 1999; Rena et al., 1999). 
Phosphorylation of forkhead proteins by PKB/Akt appears to alter their 
subcellular location. Stimulation of cells with factors that increase PKB/Akt 
activity leads to the export of FKHRL1 from the nucleus (Biggs et al., 1999) and 
its accumulation and sequestration by 14-3-3 proteins in the cytoplasm (Brunet et
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Figure 2.14 Regulation of cell survival by PKB/Akt (Nicholson and
Anderson, 2002)
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PKB/Akt promotes cell survival by multiple mechanisms: (1) decreasing the 
transcription of death genes by phosphorylating forkhead family transcription factors 
such as FKHR, which promotes their sequestration by 14-3-3 proteins in the 
cytoplasm, (2) increasing the transcription of survival genes by activating NF-kB and 
CREB transcription factors, (3) phosphorylating and inactivating the pro-apoptotic 
protein BAD, and (4) maintaining mitochondrial integrity by activating hexokinase (the 
direct PKB/Akt substrates that mediate these events are represented in black boxes).
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al., 1999). In addition to negatively regulating forkhead activity, PKB/Akt appears 
to positively regulate at least two other transcription factors, viz NF-kB and 
CREB. NF-kB is involved in the regulation of cell proliferation, apoptosis, and 
survival by a wide range of cytokines and growth factors. Its survival-promoting 
activity is mediated through its ability to induce prosurvival genes such as c-IAP-
1 and c-IAP-2. NF-kB is regulated through its association with an inhibitory 
cofactor I-kB, which sequester NF-kB in the cytoplasm. Phosphorylation of I-kB 
by upstream kinases, known as IKKs, promotes its degradation, allowing NF-kB 
to translocate to the nucleus and induce target genes (fig 2.14). PKB/Akt has 
been shown to interact with and activate IKKa (Romashkova & Makarov, 1999). 
Data suggest that PKB/Akt phosphorylates IKKa directly, but more importantly, 
PKB/Akt is believed to be essential for IKK-mediated destruction of I-kB and 
activation of NF-kB (Romashkova & Makarov, 1999; Ozes et al., 1999). These 
findings indicate that PKB/Akt is a critical regulator of NF-KB-dependent gene 
transcription and may play a critical role in promoting cell survival.
The PKB/Akt pathway has been shown in some cell types to increase expression 
of the anti-apoptotic gene bcl-2 (Skorski et al., 1997; Pugazhenthi et al., 2000). 
Induction of bcl-2 promotor activity by IGF-1 was shown to occur via a PKB/Akt 
pathway involving the cyclic AMP (cAMP)-response element binding protein 
(CREB) transcription factor. CREB is a direct target for phosphorylation by 
PKB/Akt (Du et al., 1998) and this phosphorylation occurs on a site that 
increases binding of CREB to accessory proteins necessary for induction of 
genes containing cAMP response elements (CREs) in their promotor regions.
Panka and co-workers (2001) also indicated a role for PKB/Akt in regulating the 
expression of c-FLIP, a caspase-8 homologue that acts as dominant negative 
inhibitor of TNF receptor family-induced apoptosis. The mechanism by which 
PKB/Akt induces c-FLIP has not been characterized, but work by Micheau and
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co-workers (2001) showed that NF-kB promotes c-FLIP expression and 
suggested that regulation of this transcription factor by PKB/Akt may be critical.
In addition to influencing the transcription of pro- and anti-apoptotic genes, 
numerous studies indicate that PKB/Akt promotes survival by directly 
phosphorylating key regulators of the apoptotic cascade. The most widely 
studied example of this type of regulation involves Bad, a member of the Bcl-2 
family, which promotes apoptosis by binding to and antagonizing the actions of 
prosurvival members of the family such as Bcl-2 and Bcl-XL. PKB/Akt can 
phosphorylate Bad at residue S136 and this modification promotes the 
sequestration of Bad by 14-3-3 proteins in the cytosol, thus preventing Bad from 
interacting with Bcl-2 and Bcl-XL at the mitochondrial membrane (del Peso et al., 
1997; Datta et al., 1997). PKB/Akt-induced phosphorylation of Bad may also 
occur indirectly, through intervening protein kinases such as Raf-1 (Majewski et 
al., 1999) and p65PAK (Schurmann et al., 2000; Tang et al., 2000).
Stress-activated protein kinases (SAPKs) such as JNK are critically involved in 
the induction of apoptosis following exposure of cells to stimuli such as ionizing 
radiation, heat shock, or osmotic stress. A recent report has provided the first 
evidence that PKB/Akt may interfere with SAPK signaling and thereby inhibit 
apoptosis. PKB/Akt was shown to phosphorylate and inactivate ASK1, a kinase 
that transduces stress signals to the JNK and p38 MAP kinase pathways (Kim et 
al., 2001). To this point, all of the PKB/Akt targets mentioned regulating 
apoptosis prior to the release of cytochrome c from the mitochondria and 
activation of the caspase cascade that characterizes the terminal execution 
phase of apoptosis. However, data suggesting that PKB/Akt also influences 
postmitochondrial events have been reported. Procaspase-9, the initiator 
caspase in the caspase cascade, was shown to be a substrate for PKB/Akt 
(Cardone et al., 1998). In these experiments, phosphorylation of human 
procaspase-9 by PKB/Akt blocked its intrinsic protease activity and was shown to 
be critical for overall regulation of the apoptotic process. In a more recent study
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by Zhou and co-workers (2000), exogenous PKB/Akt was shown to inhibit the 
activation of caspase-9 and -3  induced by cytochrome c in a cell-free system. 
However, these authors reported that procaspase-9 was not a direct substrate for 
PKB/Akt, suggesting that PKB/Akt inhibits caspase activation by modifying an 
unknown cytosolic factor.
2.1.5.2.4 Negative regulation of PKB/Akt activity
The activation status of PKB/Akt in cells will depend upon the balance between 
the “on” signals generated by elevated PIP3 levels and the influence of “o ff’ 
signals that lead to PKB/Akt dephosphorylation. Several lines of evidence 
indicated that PKB/Akt phosphatases participate in both the positive and negative 
regulation of PKB/Akt. The facts that key phosphoserine and phosphothreonine 
residues in PKB/Akt have a relatively short half-life and that phosphatase 
inhibitors such as vanadate and okadaic acid were shown to augment PKB/Akt 
kinase activity, indicate that the enzyme is negatively regulated by 
dephosphorylation (Andjelkovic et al., 1996; Meier et al., 1997). Protein 
phosphatase 2A (PP2A) may be the key enzyme associated with 
dephosphorylation of PKB/Akt in vitro and in vivo (Andjelkovic et al., 1996; Meier 
et al., 1997; Meier et al., 1998).
Attenuation of PI-3K activation leads to a rapid dephosphorylation of Ser473 and 
(more slowly) Thr308, accompanied by a loss of PKB/Akt activity, indicating that 
PIP3 constrains phosphatase action as well as promotes PDK-1 activation 
(Anjelkovic et al., 1999). The inactivation of PKB/Akt by ceramide (Schubert et 
al., 2000) and osmotic stress (Meier et al., 1998; Chen et al., 1999) occurs 
predominantly via Ser473 dephosphorylation by an okadaic acid-sensitive 
phosphatase. Dephosphorylation of Thr308 appears to occur independently 
(Schubert et al., 2000) and a recent study suggests, controversially, that PDK-1 
participates in the dephosphorylation of Thr308 by an unknown mechanism 
(Yamada et al., 2001).
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A 3-phosphoinositide-specific phosphatase activity was found to reside in the 
tumor suppressor PTEN (Phosphatase and tensin homologue deleted from 
chromosome 1 0 ), which is mutated or deleted in a wide range of human cancers 
(reviewed in Cantley & Neel, 1999). PTEN shares homology with DSP that can 
dephosphorylate serine, threonine and tyrosine residues. However, attempts to 
confirm PTEN as a protein phosphatase revealed only relatively weak activity (Li 
& Sun, 1997; Myers et al., 1997), suggesting that PTEN is a specialized 
phosphatase for certain proteins and/or possesses a different activity. Indeed, it 
was found that PTEN is a potent lipid phosphatase (Maehama & Dixon, 1998; 
Myers et al., 1998). Overexpression of PTEN significantly reduced PI(3 ,4 ,5 )P3 
production induced by insulin, and PTEN-null cells have higher levels of 
PI(3,4,5)P3 (Haas-Kogan et al., 1998; Maehama & Dixon, 1998; Stambolic et al., 
1998). A recombinant PTEN dephosphorylates 3-phosphoinositides specifically 
at position 3-OH of the inositol ring and has highest specificity for PI(3,4,5)P3 
(Maehama & Dixon, 1998). Since PTEN antagonizes the PI 3-kinase activity, it 
may also affect PKB/Akt. Experiments with inactive PTEN and in PTEN-null 
fibroblasts showed that these cells exhibit high basal activity of PKB/Akt (Myers 
et al., 1998; Li & Sun, 1998; Wu et al., 1998). These results, together with 
genetic studies in C elegans demonstrating that PTEN resides in the same 
pathway as PI 3-kinase/PKB and inhibits PKB/Akt (Ogg & Ruvkun, 1998), 
established PTEN as a negative regulator of PKB/Akt.
Another lipid phosphatase that can negatively regulate PKB/Akt is SHIP -  an 
inositol 5’ phosphatase that hydrolyzes PI(3 ,4 ,5 )P3 to PI(3,4)P2 . Over-expression 
of SHIP was shown to inhibit PKB/Akt activity and SHIP-null cells exhibit 
prolonged activation of PKB/Akt upon stimulation (Liu et al., 1995; Aman et al., 
1998).
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2.1.5 Conclusion
It is clear from the previously discussed pathways that apoptosis is a highly 
regulated and complex process, controlled by numerous checkpoints and 
communication networks. In recent years, however, cell biologists have 
recognized that the regulation of cell death is much more than the fatal result 
from acute cellular injury. Moreover, proliferation and cell death seem to be 
highly connected and considerable overlap exists between the components that 
execute both processes. Apoptosis often represents an immediate response to 
external stimuli. The following adaptive changes leading to a remodelled 
structure are usually beneficial and protective. Overwhelming stress, however, 
may lead to disturbed remodelling processes (fig 2.15).
Although the extent to which apoptosis is involved in cardiac disease remains to 
be established, the evidence that has emerged clearly supports a role for this 
mode of cell death. A better understanding of the underlying pathways may lead 
to the design of a new class of therapeutic agents aimed at preventing myocyte 
death and attenuating the progression of cardiac disease. Indeed, some 
treatments already in use may work in part by inhibition of apoptosis. p-Blockers 
such as carvedilol are known to have anti-apoptotic properties (Yue et al., 1998). 
Similarly, NO donors used in the treatment of myocardial infarction have both 
pro-apoptotic and anti-apoptotic properties, although it has yet to be shown that 
this is part of the therapeutic effect of these agents (Kim et al., 1999). It may turn 
out that other conventionally used pharmaceuticals exert their effect via apoptotic 
pathways. However, there is still controversy whether apoptosis or necrosis is the 
main form of cardiomyocte death involved in the pathogenesis of cardiac disease 
or whether there is a third, as yet uncharacterised, form of cell death that 
combines aspects of both apoptosis and necrosis. Further research should 
provide answers to these questions and determine the therapeutic value of anti- 
apoptotic intervention in the treatment of cardiovascular disease. The challenge
Stellenbosch University http://scholar.sun.ac.za/
Stellenbosch University http://scholar.sun.ac.za/
44
of future therapeutic concepts will be to develop a therapy, which is short acting 
and localized with minimum or no side effects.
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2.2 Fatty acids in cardiovascular disease
2.2.1 Introduction
The concept that dietary polyunsaturated fatty acids (PUFAs) affect the incidence 
of coronary heart disease (CHD) is widely accepted, based on both 
epidemiological and experimental evidence. The effects of dietary PUFAs on 
serum lipoprotein levels and membrane phospholipid composition and its 
(patho)physiological and biochemical consequences have extensively been 
studied in the cardiovascular system, however, the mechanisms underlying the 
beneficial effects of PUFAs, of either n-6 or n-3 family, are largely unclear.
Long-chain PUFAs, taken up by the cell from the extracellular environment or 
released from cellular triglycerides or membrane phospholipids play an important 
role in various biological processes in the heart. Not only can they be (a) 
metabolized to other longer chain fatty acids and eicosanoids, or (b) do they 
serve as fuel through the p-oxidation pathway, but they are also involved in 
(c) apoptosis and (d) cellular signal transduction.
2.2.2 Fatty acid metabolism
Fatty acids are commonly classified according to a shorthand nomenclature 
which designates the chain length, number of double bonds, and position of 
double bond nearest to the methyl group (Willis, 1987). This terminal carbon 
atom is often referred to as the omega (co) carbon atom, as it occurs at the 
opposite end of the molecule to carbon-1, which bears the carboxyl function. The 
term n-x is used instead of omega-x to describe the position of the double bond 
nearest to the methyl group. According to the number of double bonds, fatty 
acids can be classified as saturated-, monounsaturated-, and polyunsaturated 
fatty acids (fig 2.16). Saturated fatty acids are straight chain structures with no 
double bonds and an even number of carbon atoms. In general, human
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monounsaturated fatty acids have an even number of carbon atoms, a chain 
length of 12-22C and a double bond with the cis configuration. Polyunsaturation 
is common, but largely confined to the C18 and C20 acids.
All mammals can synthesise fatty acids de novo from acetyl-coenzyme A. The 
end product of the fatty acid synthesised enzyme is palmitic acid (16:0), which in 
turn can be elongated to stearic acid (18:0). There is little need for the synthesis 
of saturated fatty acids in Western man, since the diet normally supplies 
adequate amounts. However, cell membranes require unsaturated fatty acids to 
maintain their structure, fluidity and function. Therefore a mechanism for the 
introduction of double bonds (i.e. desaturation) exists. The introduction of a 
single double bond between carbon atoms 9 and 10 is catalysed by the enzyme 
A9-desaturase, which is universally present in both plant and animals. This 
enzyme results in the conversion of stearic acid to oleic acid (18:1n-9). Plants, 
unlike animals can insert additional double bonds into oleic acid between the 
existing double bond at the 9-position of the methyl terminus of the carbon chain; 
a A12-desaturase converts oleic acid into linoleic acid (18:2n-6), while a A15- 
desaturase converts linoleic acid into a-linolenic acid (18:3n-3). Since animal 
tissues are unable to synthesise linoleic acid and a-linolenic acid, these fatty 
acids must be consumed in the diet and are termed essential fatty acids. Using 
the pathway outlined in figure 2.17, animal cells can convert dietary a-linolenic 
acid into eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 
22:6n-3), by a similar series of reactions dietary linoleic acid is converted via y- 
linolenic acid (18:3n-6) and dihomo-y-linolenic acid (20:3n-6) to arachidonic acid 
(ARA; 20:4n-6). The n-9, n-6 and n-3 families of polyunsaturated fatty acids 
(PUFAs) are not metabolically interconvertible in mammals. Many marine plants, 
especially the unicellular algae in phytoplankton, also carry out chain elongation 
and further desaturation of a-linolenic acid to yield the long-chain n-3 PUFAs, 
EPA and DHA. It is the formation of these long-chain n-3 PUFAs by marine algae 
and their transfer through the food chain to fish that account for their abundance 
in some marine fish oils.
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Figure 2.16 The basic structures of saturated-, 
monounsaturated- and 
polyunsaturated fatty acids
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Both n-3 and n-6 essential fatty acid families have distinct nutritional and 
metabolic effects, and each has a direct precursor relationship with specific 
classes of eicosanoids. Eicosanoids are a family of oxygenated derivatives of 
dihomo-y-linolenic, arachidonic and eicosapentaenoic acids. Eicosanoids include 
prostaglandins (PGs) and thromboxanes (TXs), which together are termed 
prostanoids, and leukotrienes (LTs), lipoxins, hydroperoxyeicosatetraenoic acids 
(HPETEs) and hydroxyeicosatetraenoic acids (HETEs). In most conditions, the 
principal precursor for these compounds is arachidonic acid and the eicosanoids 
produced from ARA appear to have more potent biological functions than those 
released from dihomo-y-linolenic acid or EPA. PUFAs are released from 
membrane phosphatidylcholine by the action of phospholipase A2 or from 
membrane phosphatidylinositol-4,5-bisphosphate by the actions of 
phospholipase C and a diacylglycerol lipase. The pathways of eicosanoid 
synthesis begin with cyclooxygenase, which yields the PGs and TXs, or with the 
5-, 12-, or 15-lipoxygenases, which yield the LTs, HPETEs, HETEs and lipoxins 
(fig 2.18). A third pathway, which operates through the microsomal cytochrome 
P-450, results in the formation of epoxides, which are converted to HETEs. The 
amounts and types of eicosanoids synthesized are determined by the availability 
of arachidonic acid, by the activities of phospholipases A2 and C and by the 
activities of cyclooxygenase and lipoxygenases. Eicosanoids usually have a 
short half-life and act locally on the cell by which they are produced. Their 
production is initiated by particular stimuli (e.g. cytokines, growth factors, oxygen 
free radicals, bradykinin, thrombin) and, once produced, they themselves are 
able to modify the response to the stimulus.
2.2.3 P-oxidation in the aerobic heart
Within the circulation, fatty acids are tightly bound to albumin and represent an 
important, readily available energy source for certain organs like the heart. Entry 
of fatty acids into the myocardial cell is presently thought to be mediated by
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Figure 2.17 Polyunsaturated fatty acid metabolism
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Figure 2.18 The two major pathways of arachidonic acid 
and eicosapentaenoic acid metabolism to 
eicosanoids
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several proteins including fatty acids binding proteins (FABPs) and a myocardial- 
specific integral membrane transporter (fatty acid translocase or FAT). The non- 
enzymatic FABP also serves as a facilitator of intracellular transport of relatively 
insoluble long-chain fatty acids to sites of metabolic utilization (e.g. 
mitochondria). In mammals, the FABP content in skeletal and cardiac muscle is 
related to the fatty acid oxidation capacity of the tissue (Glatz & Storch, 2001).
Once in the cytoplasm, long-chain fatty acids (LCFAs) may be transported by 
heart-type fatty acid binding protein (H-FABP) (Binas et al., 1999) and are rapidly 
esterified to acyl-CoA by long-chain acyl-CoA synthase (LCAS). Transport of 
LCFAs into the mitochondria occurs via transesterification by carnitine 
palmitoyltransferase I (CPT-I) and subsequent translocation across the inner 
mitochondrial membrane facilitated by carnitine/acyl-carnitine translocase. CPT-I 
catalyzes a key rate-limiting step in mitochondrial fatty acid flux and, as such, is 
highly regulated at gene transcriptional level (Brown et al., 1995; Brandt et al., 
1998; Steffen et al., 1999) as well as through post-translational control via 
reversible binding of the inhibitor, malonyl-CoA, the first committed intermediate 
in the pathway of fatty acid synthesis (McGarry et al., 1989). Upon translocation 
across the inner mitochondrial membrane, long-chain acylcarnitines are re- 
esterified to acyl-CoA derivates by CPT-I I and enter the p-oxidation spiral. The 
initial step in the oxidative spiral is catalysed by: (1) a family of acyl-CoA 
dehydrogenases (AD) specific for very long-chain (VLCAD), long-chain (LCAD), 
medium-chain (MCAD) and short-chain (SCAD) acyl-CoA substrates. 
Subsequent steps involve: (2) hydration by enoyl-CoA hydratase; (3) a second 
oxidation by a 3-hydroxyacyl-CoA dehydrogenase; and then (4) a thiolytic 
cleavage by 3-ketoacyl-CoA thiolase to yield acetyl-CoA and shortened acyl- 
CoAs destined for additional rounds of oxidation. Steps 1 and 3 of the fatty acid 
oxidation (FAO) cycle generate electrons which are ultimately transferred to the 
electron transport chain where ATP is produced in the presence of oxygen (i.e. 
oxidative phosphorylation). The acetyl-CoA end-product is oxidized via the 
tricarboxylic acid (TCA) cycle (fig 2.19).
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Naturally occurring mutations in many of these enzymes, including MCAD and 
VLCAD (Kelly & Strauss, 1994), underlie known inborn errors of metabolism 
which may present early in life with stress-induced hypoglycemia, hepatic 
dysfunction, cardiomyopathy, and sudden death -  a dramatic phenotype 
illustrating the importance of fatty acid oxidation in normal cardiac energy 
production.
The process of fatty acid oxidation is termed p-oxidation, since it occurs through 
the sequential removal of 2 -carbon units by oxidation of the p-carbon position of 
the fatty acyl-CoA molecule. Each round of p-oxidation produces NADH, FADH2 
and acetyl-CoA. The acetyl-CoA, the end product of each round of p-oxidation, 
enters the TCA cycle where it is further oxidized to CO2 with the concomitant 
generation of NADH, FADH2 and ATP. The NADH and FADH2 generated during 
fat oxidation and acetyl-CoA oxidation in the TCA cycle will subsequently enter 
the respiratory pathway for the production of ATP. Consequently, the oxidation of 
fatty acids yields more energy per carbon atom than does the oxidation of 
carbohydrates. However, while fatty acids produce more ATP during complete 
aerobic oxidation than glucose, this occurs at the expense of a higher rate of 
oxygen consumption.
2.2.3.1 Energy metabolism in the aerobic, ischaemic and reperfused 
heart
The high energy demand of the heart is met by utilizing a variety of carbon 
substrates, including free fatty acids (FFAs), carbohydrates, amino acids and 
ketone bodies (Kantor et al., 2001). Free fatty acids and carbohydrates are the 
major substrates from which the heart derives most of its energy (fig 2.20). Under 
normal, aerobic conditions, 50-70% of the total energy is obtained from fatty 
acids, while the majority of the rest is obtained from carbohydrates (mainly 
glucose and lactate). All of the ATP produced from fatty acid oxidation is
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Figure 2.20 Energy metabolism in a normal aerobic heart
(Sambandam & Lopaschuk, 2003)
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The diagram shows some of the major metabolic pathways, which 
contribute, to myocardial energy production. Fatty acids are 
transported into the mitochondria as acyl-CoA which undergoes p- 
oxidation to release acetyl-CoA. Acetyl-CoA then enters the 
tricarboxylic acid cycle (TCA) to produce ATP, CO2 and H20 . 
Glucose on the other hand undergoes glycolysis to produce 
pyruvate. Puruvate is then oxidised via TCA cycle in the 
mitochondria or converted to lactate extra-mitochondrially. 
Glucose can also be stored as glycogen in the myocardium.
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dependent on the presence of oxygen. In contrast, ATP production from glucose 
originates from both glycolysis (oxygen-independent) and glucose oxidation 
(oxygen dependent). During ischaemia, due to restricted oxygen supply to the 
muscle, both fatty acid and carbohydrate oxidation decreases and ATP 
production is impaired (fig 2.21) (Lopaschuk, 1997). Glycolysis, a minor source of 
ATP in the aerobic heart, then becomes a more significant source of energy 
(Olivier & Opie, 1994). However, pyruvate produced from glycolysis is converted 
to lactate rather than being completely metabolized to CO2 and H2O in the 
mitochondria. This not only results in the accumulation of lactate but also H+s, 
since H+ produced from hydrolysis of glycolytically derived ATP are not taken up 
by the mitochondria (with pyruvate) where it eventually is used for H20  
production (fig 2.21). These results in a fall in intracellular pH, the magnitude of 
which depends on the severity of ischaemia (Kloner & Jennings, 2001; Liu et al.,
2001).
During reperfusion of previously ischaemic muscle, there is the possibility of an 
impaired post-ischaemic functional recovery due to a delayed recovery of 
metabolism (Schwaiger et al., 1985). However, in the reversibly injured 
myocardium, fatty acid oxidation rapidly recovers during reperfusion and 
becomes the dominant source of energy replenishing the ATP pool in the heart 
(Belke & Lopaschuk, 1997). Glucose oxidation, on the other hand remains 
suppressed due to the fact that increased fatty acid oxidation inhibits glucose 
oxidation via the well known Randle cycle (increase in fatty acid oxidation inhibits 
glucose oxidation in the muscle via inhibiting the rate limiting pyruvate 
dehydrogenase complex of the glucose oxidation pathway (Kantor et al., 2001). 
Interestingly, glycolysis is unaffected by these high rates of fatty acid oxidation 
and remains elevated during reperfusion resulting in an increase in the 
uncoupling of glycolysis from glucose oxidation and continued H+ accumulation 
(Liu et al., 1996). Activation of AMPK during and following ischaemia is an 
important contributor to these high rates of both glycolysis and fatty acid 
oxidation.
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Figure 2.21 Energy metabolism in the ischaemic myocardium
(Sambandam & Lopaschuk, 2003)
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Due to a lack of oxygen supply, mitochondrial oxidation of fatty acids 
and glucose is restricted. However, anaerobic glycolysis persists to 
meet the energy demand. When pyruvate is not oxidised in the 
mitochondria, the hydrogen ion generated as a result of hydrolysis of 
glycolytic ATP accumulates in the cytosol. Accumulation of protons 
(H+) then leads to Na+ influx via Na+/H+ exchanger which then leads to 
Ca2+ accumulation via the Na+/Ca2+ exchanger.
Stellenbosch University http://scholar.sun.ac.za/
51
Proton accumulation during ischaemia and reperfusion can alter cardiac 
efficiency by a number of potential mechanisms. It can lead to intracellular Na+ 
accumulation via Na+/H+ exchange and a subsequent intracellular Ca2+ 
accumulation via Na+/Ca2+ exchange (Liu et al., 1996). Sudden rises in 
intracellular Ca2+ could potentially cause cell death (Liu et al., 1996). Proton 
accumulation can also result in a decreased efficiency of the contractile proteins, 
impairment of functional recovery during reperfusion and a reduction in cardiac 
efficiency (cardiac work/myocardial 0 2 consumption). Liu and co-workers (1996) 
have also demonstrated that decreasing H+ production (by improving uncoupling) 
and/or inhibiting Na+/H+ exchange, improves functional recovery as well as 
cardiac efficiency during reperfusion. Thus, altered metabolism during 
ischaemia/reperfusion is an important contributor to post-ischaemic functional 
impairment of the heart.
2.2.3.2 AMPK control of fatty acid metabolism during 
ischaemia/reperfusion
AMPK, described as a “cellular fuel gauge”, shuts down the energy consuming 
processes and facilitates energy producing processes during various metabolic 
stresses (Hardie & Hawley, 2001). Ischaemic stress in the heart leads to an 
increase in AMPK activity (Kudo et al., 1995, 1996), which modifies two important 
metabolic pathways during and following ischaemia, namely glycolysis and fatty 
acid oxidation (for the purpose of this study, the role of AMPK in fatty acid 
metabolism only will be discussed). AMPK also inhibits creatine kinase and 
discourages the reverse reaction in which Cr is converted to PCr, and thus 
makes more ATP available for other critical functions of the cell (Ponticos et al., 
1998).
AMPK belongs to a family of serine/threonine kinases which have highly 
conserved kinase domains (Lefebvre et al., 2001). AMPK was originally identified
Stellenbosch University http://scholar.sun.ac.za/
52
as a HMG-CoA reductase kinase and an acetyl CoA carboxylase kinase (Beg et 
al., 1978; Keith et al., 1979). However, when it became clear that this kinase 
phosphorylated a number of proteins and it was activated by 5’AMP, it was 
renamed as AMPK (Ferrer et al., 1985; Carling et al., 1987).
Under normal conditions, fatty acids are the preferred energy source of the 
myocardium contributing to 60-80% of the total ATP production (Belke & 
Lopaschuk, 1997). Although fatty acid oxidation decreases during ischaemia, it 
rapidly recovers during reperfusion contributing to 90-100% of the ATP 
production in the heart (Belke & Lopaschuk, 1997). This increased use of fatty 
acids to support ATP production is due both to an increase in circulating fatty 
acid levels, and intracellular alterations in the control of fatty acid oxidation, 
where AMPK appears to have an important role.
In clinical conditions like myocardial infarction, or during and after cardiac 
surgery, serum fatty acid concentration increases (Opie, 1975; Mueller & Ayres, 
1987; Lopaschuk et al., 1994; Fragaso et al., 2002). As a result, cardiac fatty acid 
supply and oxidation could increase several fold. Indirect evidence suggests that 
heparin administration decreases the ischaemic threshold in coronary artery 
disease patients probably by increasing circulating fatty acid levels and thus fatty 
acid oxidation (Fragaso et al., 2002). Inhibition of fatty acid oxidation protects the 
heart from detrimental effects of heparin (Fragaso et al., 2002), implicating the 
detrimental effects of elevated fatty acid oxidation. Experimental evidence further 
support that over-reliance on fatty acid oxidation is harmful to the functional 
recovery of the heart during reperfusion following severe ischaemia (Lopaschuk 
et al., 1988; 1992). Thus, it is important to understand the mechanisms 
responsible for alterations in fatty acid metabolism during ischaemia/reperfusion.
An important control site of myocardial fatty acid oxidation is at the mitochondrial 
membrane where fatty acids are transported across as acyl carnitine esters (fig 
2.22). This process is facilitated by acyl carnitine translocase and two carnitine
Stellenbosch University http://scholar.sun.ac.za/
Figure 2.22 AMPK regulation of free fatty acid
oxidation in the myocardium
(Sambandam & Lopaschuk, 2003)
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Activation of AMPK during ischaemia results in a decrease of 
malonyl-CoA levels either via decreased synthesis [by inhibition 
of ACC (acetyl-CoA carboxylase)] activity or via increasing 
degradation of malonyl-CoA [by activation of MCD (malonyl-CoA 
decarboxylase)]. Lowering of malonyl-CoA levels then removes 
allosteric inhibition on CPT-I, increase mitochondrial transport of 
fatty acids and therefore increases p-oxidation.
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palmitoyl transferases (CPT-I and CPT-II) (as discussed earlier). Once inside the 
mitochondria, acyl-CoA undergoes p-oxidation in the matrix producing several 
acetyl-CoA molecules, which then enter the TCA cycle for complete oxidation. 
Transport of fatty acids by CPT-I across the mitochondria is the rate- limiting step 
in fatty acid oxidation (Kantor et al., 2001). Activation of AMPK during ischaemia 
results in a decrease of malonyl-CoA levels either via decreased synthesis [by 
inhibition of ACC (acetyl-CoA carboxylase) activity] or via increasing degradation 
of malonyl-CoA [by activation of MCD (malonyl-CoA decarboxylase)]. Lowering 
of malonyl-CoA levels then removes allosteric inhibition on CPT-1, increases 
mitochondrial transport of fatty acids and therefore increases p-oxidation (fig 
2 .22 ).
Thus, AMPK could be a potential target for metabolic modulation during 
ischaemia and reperfusion. It is also proposed that activating AMPK in the heart 
may be beneficial since it reduces lipid accumulation and therefore the 
lipotoxicity (Minokoshi et al., 2002). However, it is important to note that 
activation of AMPK in the heart may also increase fatty acid oxidation and 
glycolysis which may have deleterious effects especially under the conditions 
where plasma fatty acids are already elevated and where the heart utilizes 
exclusively fatty acids as its energy substrate (e.g. in diabetes and myocardial 
ischaemia).
2.2.4 Fatty acids and apoptosis in the heart
The harmful effects of saturated fatty acids have been reported in several cell 
types (Buttke, 1984; Zhang et al., 1992; DeVries et al., 1995) including neonatal 
rat ventricular myocytes (DeVries et al., 1997). The saturated fatty acids 
palmitate (16:0) and stearate (18:0) have been demonstrated to induce 
apoptosis, whereas monounsaturated fatty acids, such as oleate (18:1), did not. 
Both palmitate and stearate are precursors in the de novo synthesis pathway of 
ceramide, a sphingolipid involved in apoptotic signalling.
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The role of sphingolipid metabolites, particularly ceramide, in apoptosis signaling 
pathways is well established (Hannun, 1996; Pena et al., 1997; Obeid & Hannun, 
1997; Ariga et al., 1998). A number of stimuli affect ceramide production, 
including TNF-a, y-interferon, and ionizing radiation (Kim et al., 1991; Dressier et 
al., 1992; Haimovitz-Friedman et al., 1994). In the heart, in vitro induced 
ischaemia, led to a significant increase in endogenous ceramide levels 
(Bielawska et al., 1997). Sphingolipid metabolites have also been implicated in 
the triggering of apoptosis induced by ischaemia and reperfusion. For example in 
an ischaemia/reperfusion model, the addition of a cell-permeable ceramide 
analog, C2-ceramide, induced apoptotic death of neonatal rat cardiomyocytes.
Cellular ceramide is produced by: (i) cleavage of sphingomyelin with 
sphingomyelinase, and (ii) de novo synthesis (Pena et al., 1997; Hannun & 
Obeid, 1995; Kolesnick & Fuks, 1995), which involves palmitoyl-CoA and stearyl- 
CoA, derived from palmitate and stearate, both of which induce apoptosis (de 
Vries et al., 1997; Paumen et al., 1997). It has been proposed that the 
accumulation of ceramide associated with ischaemia/reperfusion is caused by 
sphingomyelin hydrolysis as opposed to de novo synthesis, because cardiac 
ischaemia leads to a rapid loss in ATP from cardiac cells.
Long-chain saturated fatty acids also induce apoptosis in normoxic cells. 
Paumen and co-workers (1997) demonstrated that induction of apoptosis by 
palmitate or stearate was associated with de novo synthesis of the sphingolipid, 
ceramide. The same relationship was also observed by Sparagna and co­
workers (1999) in cultured rat neonatal cardiomyocytes. Using this model 
system, they have shown that incubation of myocytes with extracellular palmitate 
leads to an increase in intracellular ceramide levels. Under the same conditions, 
incubation with physiologic levels of palmitate leads to an overall increase in fatty 
acid metabolites, increased oxidation and increased triglyceride synthesis 
(Sparagna et al., 1999). The temporal sequence of these changes indicates that
Stellenbosch University http://scholar.sun.ac.za/
55
the initiation of apoptosis in cardiac myocytes occur while the cells are actively 
metabolizing palmitate. Thus, one cannot rule out a role for de novo ceramide 
synthesis in cardiac apoptosis.
Inhbition of CPT-1 (the rate-limiting enzyme in the passage of long-chain fatty 
acids from the cytoplasm into the mitochondria for p-oxidation), which would 
prevent palmitoyl-CoA from being oxidised, results in an enhancement of 
palmitate-induced apoptosis and sphingolipid synthesis (Paumen et al., 1997). 
Thus, the accumulation of palmitoyl-CoA, which occurs when palmitate is present 
in the cell media (de Vries et al., 1997) or when CPT-1 is inhibited (Paumen et 
al., 1997), directly influences the production of ceramide and may indeed be the 
rate-limiting step, leading to cardiac apoptosis.
A direct relationship between saturated fatty acids and other indicators of 
apoptosis was also found. Sparanga and co-workers (1999) reported that the 
palmitate-induced elevation of ceramide in neonatal rat cardiac myocytes is 
associated with a concurrent increase in caspase-3 activity. Mitochondria are 
intricately linked to both fatty acid oxidation and apoptosis. Not only are heart 
mitochondria responsible for cardiac fatty acid p-oxidation, which produces most 
of the ATP for the cell’s energy needs, but they also contain CPT-1, which when 
inhibited, may cause palmitoyl-CoA accumulation and apoptosis (Paumen et al.,
1997). Key apoptotic proteins, such as Bcl-2 and cytochrome c are located in the 
mitochondria. Data from the laboratory of Sparanga (1999) indicated that cardiac 
myocyte mitochondria lose their membrane potential several hours after 
exposure to palmitate. During apoptosis, the mitochondria must be able to 
provide ATP for cleavage and activation of apoptotic proteins, but at a relatively 
early stage in the apoptotic process, some of them undergo a membrane 
potential decrease, which is probably associated with the onset of the 
mitochondrial permeability transition (MPT) (Zamzami et al., 1995; Marchetti et 
al., 1996). The mitochondrial permeability transition is an event during which 
large pores open in the mitochondrial inner membrane allowing ions and small
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proteins with molecular masses <1500 Da to follow their concentration gradients 
across the mitochondrial inner membrane (Bernardi, 1996). After undergoing the 
permeability transition, mitochondria become unable to perform any energy 
functions linked to their electrochemical gradient, such as the production of ATP. 
The onset of mitochondrial permeability transition is induced by high levels of 
mitochondrial matrix free Ca2+ in addition to an inducing agent, which in the case 
of apoptosis, has been hypothesized to be reactive oxygen species (ROS) 
(Quillet-Mary et al., 1997; Petit et al., 1997) or ceramide (Decaudin et al., 1997). 
However, Gracia-Ruiz and co-workers (1997) found that ceramide caused the 
production of ROS, but had no effect on the onset of the permeability transition.
Ischaemia affects mitochondria in several ways, for example, in isolated perfused 
rabbit hearts, the cytochrome c content is decreased in sub-sarcolemmal, but not 
interfibrillar mitochondria (Lesnefsky et al., 1997). This could explain how the cell 
can continue to satisfy the energy requirements associated with apoptosis using 
one type of mitochondria after a sub-population of mitochondria has undergone 
permeability transition.
A direct interaction between CPT-I and Bcl-2 has also been suggested (Paumen 
et al., 1997). This interaction may have some significance in the formation of 
ceramide, because the activation of CPT-I by Bcl-2 would cause an increase in 
the rate at which palmitoyl-CoA is oxidized and therefore a decrease in palmitoyl- 
CoA available to form ceramide. This mechanism would indirectly allow Bcl-2 to 
prevent apoptosis via control of ceramide concentrations (fig 2.23).
The relationship between fatty acids and the induction of apoptosis in heart 
tissue deserves further study. The induction of apoptosis by saturated fatty acids 
may partially explain the link between high levels of circulating fatty acids and 
heart disease. If fatty acids indeed play an important role in vivo in the induction 
of heart disease, it is important to elucidate the mechanisms of their effects on 
cells specific to the heart. Mitochondria may play a central role in the relationship
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Figure 2.23 Fatty acid-induced apoptosis
(Sparagna & Hickson-Bick, 1999) 
Myocardial Ischaemia
Observed cell death following 
Heart Failure, Reperfusion
PT - mitochondrial permeability transition; A ^ -  mitochondrial membrane potential
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between fatty acid metabolism and apoptosis in the heart, particularly during 
ischaemia/reperfusion. The presence of cytochrome c and Bcl-2 and the findings 
that these proteins interact with themselves as well as with CPT-I, place the 
mitochondria in the centre of the intricate process of fatty acid induced 
programmed cell death.
2.2.5 The role of fatty acids in signal transduction
Numerous studies on the molecular basis of fatty acid actions have 
demonstrated their effects on many steps in cellular signalling. Particular 
attention has been focused on fatty acid regulation of signals triggered at the 
level of cell membranes. It is now clear that fatty acids have characteristics 
generally attributed to modulators and messengers. Fatty acids are good 
candidates because they can be delivered to cells from extracellular sources and 
act directly on the cell membrane as first messengers or they are incorporated 
into membrane phospholipids from which they can be liberated by cellular 
phospholipases in response to other signals. Once liberated, free fatty acids can 
propagate the primary message by serving as second messengers or they can 
modulate signals coming from other pathways such as the binding of steroid 
hormones to their intracellular receptors.
Many of the enzymes involved in signal transduction are regulated positively or 
negatively by fatty acids as seen in table 2.1. These include enzymes of the 
cAMP signalling pathway and those involving PKC, where regulation has been 
studied in a wide variety of tissues and cells. Fatty acids can also participate in 
feedback control mechanisms since the phospholipases that are involved in the 
liberation of fatty acids from membrane phospholipids are themselves modulated 
by fatty acids. The regulatory action of fatty acids mainly concerns the 
unsaturated fatty acids rather than the saturated fatty acids. The concentrations 
of unsaturated fatty acids used in these studies ranged from as low as 1.4 (iM to 
400 nM. Although it is difficult to determine the local concentration of released
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Table 2.1 Modulatory effects of fatty acids on enzymes and proteins 
involved in membrane signal transduction (modified from 
Sumida etal., 1993)
Tissues or cells Fatty acid References
T Phospholipase A2 human platelets
t  Phospholipase C human platelets
rat brain
rat pancreas
t  Phospholipase D various tissues
t  Adenylate cyclase adipocytes
t  Guanylate cyclase bovine lung
t  G protein frog heart
I  PKA rat brain
t  PKC human neutrophils
rat cardiac myocytes
20:4 Siess ef al., 1983
20:4 Siess et al., 1983
18:1/20:4 Irvine ef al., 1979
20:4 Chaundry et al., 1987
18:1 Shukla et al., 1991
18:1 Malgieri et al., 1975
20:4 Gerzer et al., 1986
20:4 Scherer et al., 1990
PUFAs Speizer et al., 1991
20:4 McPhail et al., 1984
20:4 Mackay & Mochly-
Rosen, 2001
18:1 -  oleic acid
20:4 -  arachidonic acid
PUFAs -  polyunsaturated fatty acids
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fatty acids at a precise moment in time, intracellular concentrations of 50-100 |iM 
of ARA have been reported after pancreatic islet cell stimulation (Wolf et al., 
1986) and in activated platelets (Nishikawa et al., 1988).
In most studies summarised in Table 2.1, fatty acids and not their metabolites, 
have been shown to be the active regulators, for example GTP binding protein 
activation in human neutrophils is stimulated by unsaturated fatty acids per se, 
not by their metabolites, and this activity is correlated with respiratory burst 
(Abramson et al., 1991). However, some studies have been included which 
involve metabolites, for example endoperoxides or thromboxane A2 is probably 
responsible for the activation of phospholipase C in human platelets (Siess et al., 
1983). Metabolites may have opposing activities such as the lipoxygenase 
metabolites, which stimulate and cyclooxygenase metabolites, which inhibit G- 
protein in frog heart (Scherer et al., 1990). However, while ARA itself activates 
guanylate cyclase activity in rat brain, it is inhibited by its hydroperoxide 
derivatives (Louis et al., 1986).
Fatty acids themselves regulate ion fluxes and Ca2+ mobilization directly, much in 
the same way as they regulate the action of many enzymes (table 2.2). ARA 
induces Ca2+ release from intracellular stores in a manner similar to but 
independent of inositol 1,4,5-trisphosphate, which is produced via phospholipase 
C (Chow & Jondal, 1990). When Jurkat cells are exposed to unsaturated fatty 
acids, they block Ca2+ influx through the Ca2+ channels (Chow et al., 1990) but 
activate K+ channels (Ordway et al., 1991). They appear to interact directly, 
either with the channel proteins themselves or with some other component of the 
membrane. These actions of fatty acids have been shown to be due to fatty acids 
per se.
Figure 2.24 summarizes in schematic form various steps in signal transduction 
where fatty acids have been shown to regulate enzyme and protein activities
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Table 2.2 Effects of fatty acids on ion fluxes and mobilization involved 
in membrane signal transduction (modified from Sumida et 
al., 1993)
Tissues or cells Fatty acid References
Ion channels
4 Ca2* channels Jurkat cells UFAs Chow et al., 1990
t  K+ channels muscle 20:4 Ordway et al., 1991
1 Cl‘ channels fetal trachea UFAs Hwang et al., 1990
t  Na+ channels cardiomyocytes EPA/DHA Kang & Leaf, 1994
t  Intracellular Ca2+
mobilization Jurkat cells PUFAs Chow et al., 1990
lymphocytes 20:4 Corado et al., 1990
t  Ca2+ pump red blood cells PUFAs Sarkadi et al., 1982
T Na-K-ATPase rat brain 18:1 Oishi et al., 1990
t  Na+/H+ exchange cardiac sarcolemma EPA/DHA Goel et al., 2002
UFA -  unsaturated fatty acid
20:4 -  arachidonic acid
PUFA -  polyunsaturated fatty acid
18:1 -  oleic acid
EPA -  eicosapentaenoic acid
DHA -  docosahexaenoic acid
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Figure 2.24 Role of fatty acids in signal transduction
Fatty acids stimulate (+) or inhibit (-) the activities of enzymes and ion fluxes.
R- receptor; G -  G-protein; AC -  adenylate cyclase; GC -  guanylate cyclase; PKA -  
protein kinase A; PKC -  protein kinase C; PLC -  phospholipase C; PLA2 -  
phospholipase A2; PLD -  phospholipase D; IP3 -  inositol 1,4,5-trisphosphate; DG -  sn 
1,2-diacylglycerol; Ca2+/CAM kinase -  protein kinase II (Ca2+ /calmodulin-dependent) 
(Sumida et al., 1993)
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either positively or negatively. In most cases, evidence has been presented for 
the modulatory action of fatty acids themselves rather than their metabolites.
The activation of phospholipases is often associated with agonist binding to 
membrane receptors, resulting in the liberation of ARA from the 2-acyl position of 
the membrane phospholipids. The activation of PKC by ARA is a good example 
of the role of fatty acids as second messengers in signal transduction. Since the 
original observation in 1984 by McPhail and co-workers, showing the activation 
of PKC by ARA and other unsaturated fatty acids, an effect which is not inhibited 
by cyclooxygenase or lipoxygenase inhibitors, many studies have shown the 
importance of unsaturated fatty acids in the mechanism of action of PKC 
(Speizer et al., 1991; Lester et al., 1991; Khan et al., 1992; Mackay & Mochly- 
Rosen, 2001).
PKC is an ubiquitous, proteolitically activated protein kinase, which usually 
requires Ca2+ and phosphatidylserine (PS) for its activation (Nishizuka, 1986; 
Kikkawa et al., 1989). Subsequent research has defined a family of at least 10 
PKC isozymes related through the carboxy-terminal catalytic domain. These are 
divided into three subfamilies based on homology in the regulatory domain, 
which determines the activators required. The classical PKC (cPKC) isozymes 
(a, pi, pi I and y) are activated by the second messengers Ca2+ and diacylglycerol 
(DAG) in the presence of PS. The novel PKCs (nPKC), 8, s, r| and 0PKC, also 
require PS and DAG for full activation, but are insensitive to Ca2+. Both the 
cPKCs and the nPKCs are targets for the tumour-promoting phorbol ester PMA, 
which has been used extensively to study PKC function. The third subfamily, the 
atypical (aPKCs), A, and are not activated by PMA, DAG or Ca2+ and their 
regulation is more complex.
The number and levels of PKC isozyme expression vary in different tissues, with 
developmental stage of the animal studied, and possibly with the species used. 
This differential localization and sensitivity of isoforms of PKC create a situation
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where fatty acids can act as second messengers in synergy with or independent 
of DAG and Ca2+. Fatty acids activate preferentially a, p and y isozymes of PKC 
(El Touny et al., 1990; Khan et al., 1991; 1992). Whether this activation requires 
Ca2+, DAG or PS depends on the experimental conditions, the specific cell type 
and the specific isozyme studied. For example, yPKC is a soluble isozyme found 
in the central nervous system, which is activated by very low (10 ^M) 
concentrations of ARA, independent of Ca2+, PS and DAG (Naor et al., 1988). A 
direct effect of unsaturated fatty acids on PKC in the cytosol of human platelets 
under cell-free conditions without DAG or Ca2+ generation has also been shown 
(Khan et al., 1991). Furthermore, interaction of unsaturated fatty acids with 
cytosolic PKC can also induce its translocation to the membrane where it can 
then be activated by DAG (Diaz-Guerra et al., 1991). Fatty acids may act in 
synergy with DAG but do not compete with phorbol esters for the same binding 
site (El Touny et al., 1990). Indirect evidence points to the interation of fatty acids 
at the PS regulatory sites (El Touny et al., 1990; Speizer et al., 1991). ARA 
induces phosphorylation of only a subset of the phosphoproteins which were 
shown to be produced by phorbol ester activation of PKC in the cytosol of human 
platelets (Khan et al., 1991). Therefore, PKC isozymes show specific 
endogenous substrate preferences under physiological conditions in response to 
ARA and DAG.
Activation of PKC by a fatty acid is presented in Figure 2.25. This activation of 
soluble PKC by a free unsaturated fatty acid would increase the range of 
potential protein substrates for PKC phosphorylation. Fatty acid activation might 
lead to a specific, fatty acid-induced protein phosphorylation, mediating a specific 
fatty acid response while the activation of membrane-associated PKC would 
produce other phosphoproteins and responses. Fatty acids and DAG might also 
act in synergy to sustain PKC activity even when DAG and Ca2+ concentrations 
drop, thereby providing a mechanism of compensation to maintain PKC activity.
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Figure 2.25 PKC activation by free fatty acids
Inactive cytosolic PKC
Fatty acids increase the activity of PKC and can also induce its translocation.
R -  receptor; PL -  phospholipases; FFA -  free fatty acid; DG -  diacylglycerol; PS -  
phosphatidylserine; PLC -  phospholipase C; IP3 -  inositol 1,4,5-trisphosphate; PIP2 -  
phosphatidylinositol 4,5-bisphosphate (Sumida et al., 1993)
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More and more evidence is accumulating on the molecular mechanisms of the 
actions of free fatty acids as modulators and/or messengers in signal 
transduction cascades. These studies clearly show the importance of fatty acids 
in regulating the transmission of signals from the extracellular environment, via 
the complex intracellular network of relays, to the nucleus and ultimately 
modulating the biological response.
Stellenbosch University http://scholar.sun.ac.za/
62
2.3 Prevention of coronary heart disease by n-3 long-chain 
polyunsaturated fatty acids: review of the evidence
Current interest in a possible role of the n-3 long-chain polyunsaturated fatty 
acids (PUFAs) dates back almost three decades to the epidemiologic studies of 
Bang and Dyerberg (1976) on the Greenland Inuits. They noted a low mortality 
rate from coronary heart disease among the Eskimos despite a dietary fat intake 
comparable to that of the Danes and the Americans. This benefit has been 
attributed to the relatively high content of two n-3 PUFAs, eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) in the diet of the Inuits.
It was almost ten years after the pioneering work of Bang & Dyerberg (1976), 
before McLennan and co-workers (1985, 1988, 1993) reported that diets high in 
saturated fats or olive oil were associated with a high incidence of ventricular 
fibrillation in rats when their coronary arteries were ligated. A vegetable fat, 
safflower oil, reduced the incidence of ischaemia-induced ventricular arrhythmias 
by about 70%, whereas tuna fish oil (n-3 fatty acids) essentially prevented the 
arrhythmias and death after the experimental infarctions with or without reflow. 
They also confirmed their findings in marmosets (McLennan et al., 1992).
Billman and co-workers (1994) confirmed the antiarrhythmic effects of n-3 fatty 
acids in feeding studies in rats by demonstrating prevention of ischaemia- 
induced ‘sudden death’ in the conscious, unanaesthetized whole animal. They 
studied a dog model susceptible to ischaemia-induced ventricular arrhythmias: 
myocardial infarction was produced by permanent ligature of the left anterior 
descending coronary artery and a hydraulic cuff placed around the left circumflex 
artery. After recovery from the surgery, dogs were trained to run on a treadmill to 
stimulate sympathetic nervous system activity. When a pre-selected exercise 
level or pulse rate was attained, compression of the left circumflex coronary 
artery was invariably followed within 2 min by sustained ventricular tachycardia or 
fibrillation in susceptible animals.
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In order to determine unequivocally that the antiarrhythmic effects were caused 
by the fish oil PUFAs, they administered an intravenous emulsion of a 
concentrated fish oil preparation (2-5g of 70% n-3 PUFAs, of which 34% was 
EPA and 25% was DHA, both as their free acids) for 40-60 min just prior to 
compression of the coronary artery. This infusion prevented the expected fatal 
ventricular fibrillation. The identical protocol was repeated except that an 
emulsion of soybean oil rather than fish oil was infused prior to the ischaemic 
insult: no protection from the ventricular arrhythmias occurred. Eleven out of 
fourteen dogs tested were protected, whereas no protection was obtained in five 
out of five dogs infused with the soybean emulsion (p<0.006). They have also 
found in preliminary studies, that both EPA and DHA administered separately as 
the pure free fatty acids were protective in the canine model of sudden cardiac 
death. These acute pharmacological interventions complemented the feeding 
studies in rats (McLennan e t a i ,  1985; 1988; Hock et al., 1990).
To study the mechanisms of this antiarrhythmic effect, Kang & Leaf (1994) have 
utilized the isolated neonatal rat cardiac myocyte preparation (Thandroyen et al., 
1991), which has proven to be a very useful preparation in this regard. The 
spontaneous, synchronized, rhythmic contractions of syncytia of 10  or more 
electrically coupled myocytes and the amplitude and rate of contractions can be 
recorded and measured (Barry et al., 1985). Kang & Leaf (1994) have studied 
the effects of several agents known to cause fatal ventricular tachyarrhythmias in 
humans; e.g. high concentration of calcium (5 and 7 ^M) or the cardiac glycoside 
ouabain (0.1 mM), added to the fluid perfusing the myocytes. At micromolar 
concentrations, EPA and DHA will slow the spontaneous beating rate of the 
myocytes and prevent the arrhythmogenic effects of calcium or ouabain. If added 
after the arrhythmia is induced, the PUFAs will promptly terminate the 
arrhythmia. When delipidated bovine serum albumin (BSA, 29 ^M, 2mg ml"1) was 
added to the perfusion without the EPA or DHA, but with continued
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arrhythmogenic agents in the medium, the arrhythmia recurred. These simple 
experiments led to the following important conclusions:
• The free fatty acids of EPA and DHA are antiarrhythmic and act promptly.
• The esterified fatty acids (e.g. the ethyl ester of the triglyceride) are ineffective 
in preventing the arrhythmias.
• The fact that the arrhythmias recur upon addition of delipidated bovine serum 
albumin to the perfusion fluid indicates that the active antiarrhythmic form of 
EPA and DHA is their free acid form.
• Incorporation of these fatty acids into membrane phospholipids is not required 
for the antiarrhythmic effects of PUFAs.
Albumin has three high-affinity binding sites for fatty acids, and another three or 
four lower affinity binding sites (Cistola et al., 1987). When delipidated albumin is 
used, its high affinity binding capability will extract the free fatty acids which are 
partitioned into the phospholipids of the myocyte membranes, and thus, remove 
the protective effect of the fatty acids during arrhythmias. Normally, albumin 
molecules in our serum are loaded with bound fatty acids, which they deliver to 
the cells of our body for metabolism. Perfusing with the fatty acid-avid, 
delipidated albumin can reverse the direction of the traffic and extract free fatty 
acids from the myocytes. Furthermore, Kang & Leaf (1994) have also found that 
by addition of antioxidants and oxygenase inhibitors, that it is not active oxidised 
metabolites of EPA or DHA that account for their antiarrhythmic properties. Thus, 
the findings that addition of free fatty acids can abort the arrhythmias and that the 
arrhythmias recur when the fatty acids are extracted from the myocyte make it 
virtually certain that their antiarrhythmic action is a function of the presence of the 
free acid p er  se.
The current hypothesis regarding the mechanism of action of the n-3 PUFAs to 
prevent fatal arrhythmias is based on their actions to inhibit the fast, voltage- 
dependent sodium current (Xiao et al., 1998; 2000) and the L-type calcium 
currents (Xiao et al., 1997). With a myocardial infarction (Ml), a gradient of
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depolarization of cardiomyocytes occurs. In the central core of the ischaemic 
zone, cells rapidly depolarize and die. The depolarization results from the 
reduction of ATP in the ischaemic cells, which causes a dysfunctional Na+/K+- 
ATPase and the rise of interstitial K+ concentrations in the ischaemic zone. 
However, at the periphery of the ischaemic zone, myocytes may be only partially 
depolarized. They become hyperexcitable because their resting membrane has 
become more positive, approaching the threshold for generating action potentials 
(activating fast Na+ channels). Thus, any additional small depolarizing stimulus 
may elicit an action potential, which, if it occurs at a vulnerable moment during 
the cardiac electrical cycle, may initiate an arrhythmia. With nonhomogeneous 
rates of conduction pathways in the ischaemic tissue, re-entry arrhythmias are 
likely. In the presence of the n-3 PUFAs, however, a voltage-dependent shift of 
the steady state inactivation curve to more hyperpolarized potentials occurs. The 
consequence of this hyperpolarizing shift is that sodium channel availability is 
decreased, and the potential necessary to return these Na+ channels in partially 
depolarized myocytes to a closed but activatable state is physiologically 
unobtainable. Also, these partially depolarized cells have Na+ channels, which in 
milliseconds can slip into “resting inactivation” in response to subthreshold 
depolarizations without eliciting an action potential (Lawrence et al., 1991; 
Goldman, 1995) and they do this even faster in the presence of the fish oil fatty 
acids (Xiao et al., 1995; 1998). Myocytes with normal membrane potentials in the 
nonischaemic myocardium will not be so drastically affected by the PUFAs and 
will continue to function normally. Thus, the effect of the n-3 PUFAs on Na+ 
channels, inhibition the L-type Ca2+ channels (Xiao et al., 2000) and their ability 
to prevent triggered arrhythmic afterpotential discharges, caused by excessive 
cytosolic Ca2+ fluctuations are the major mechanisms for the antiarrhythmic 
effects of these PUFAs.
Another mechanism for the antiarrhythmic actions of n-3 PUFAs was proposed 
by Nair and co-workers (2001). They used a model of isolated cardiac myocytes 
from adult pig hearts to investigate the effect of ARA, EPA and DHA on inositol
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phosphate metabolism and PKC activity. Their results showed that both EPA and 
DHA were selectively incorporated into the phosphatidylinositol fraction. To study 
the effect of membrane phospholipid modification on the PLC-mediated inositol 
lipid cycle, cardiac myocytes were labeled with 4|iCi/ml myo-[2-3H]lns for 48 h 
and stimulated with epinephrine and phenylephrine. After stimulation, the levels 
of [3H]lns(1,4,5)P3 and [3H]lns(1,3,4,5)P4 as well as PKC activity in EPA and DHA 
supplemented myocytes were significantly reduced (p<0.05) compared to ARA- 
supplemented myocytes. From these experiments, it is evident that n-3 PUFA 
supplementation modulates intracellular signalling also suggesting a possible 
antiarrhythmic mechanism.
Apart from the antiarrhythmic effects of n-3 PUFAs, Grynberg and co-workers 
(1995) studied the effect of DHA and EPA incorporation in the phospholipids of 
rat heart muscle cells on adrenoceptor responsiveness and mechanism. 
Stimulation of the p-adrenergic receptors (isoproterenol 10-7M) resulted in a 
positive chronotropic effect, which was significantly higher in the DHA-rich cells. 
However, this was associated with a decrease in the affinity of the p-receptors for 
the ligand (dihydroalprenolol) without alteration of the number of p-receptor 
binding sites and provoked a significant decrease in isoproterenol-stimulated 
cAMP production (-19%). To further investigate these controversial data, the 
cardiomyocytes were treated with dibutyryl-cAMP, which elicited a positive 
chronotropic response significantly higher in the DHA-rich cells. The a-adrenergic 
stimulation by phenylephrine (3 x lO^M) increased the spontaneous rate, but in 
a similar manner in the DHA- and EPA-enriched cells. Similarly, neither the ex- 
adrenergic receptor binding characteristics nor the production of 
phosphoinositides was modulated by the membrane DHA content, although the 
phosphatidylinositol PUFAs were significantly altered. They concluded that 
increasing the DHA content in the membrane phospholipids had no affect on the 
a-adrenergic system, but exerted a specific positive influence on the p- 
adrenergic transduction mechanism, in a manner as yet unknown.
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The question now often asked is how do these in vitro and animal studies relate 
to ischaemia-induced lethal ventricular arrhythmias in humans? At present, there 
have been only a few clinical trials which inadvertently seem relevant to this 
question. The first study was published in 1989 (Burr et al.), before the anti­
arrhythmic effects of the n-3 fatty acids were generally appreciated, and thus, no 
record was kept of the incidence of sudden cardiac death. Nevertheless, in this 
multifactorial trial, The Death and Reinfarction Trail (DART), 1015 men who have 
had a recent myocardial infarction were randomly advised to eat fatty fish at least 
twice per week, and if they could not eat fish, they were given a modest 
supplement of fish oil. Another matched 1018 men were simply not given the 
advice to eat fish. At the end of only two years, there was a 29% reduction in 
mortality in the 1015 men who had received advice to eat oily fish, compared with 
the 1018 men who had not received such advice.
In 1994, the results of the Mediterranean a-linolenic acid-rich diet in secondary 
prevention of coronary heart disease were reported (de Logeril et al.). In this 
clinical trial, 302 patients who had just suffered a myocardial infarction were 
prospectively randomised to the experimental group and another 303 were 
randomised to be controls. The experimental group reduced their intake of 
saturated fat, cholesterol and linoleic acid, while increasing that of oleic and a- 
linolenic acid. After one year, higher concentrations of oleic- a-linolenic acid and 
eicospentaenoic acid, and reduced concentrations of stearic- linoleic- and 
arachidonic acid were observed in the plasma lipids of the experimental group. 
This study was planned to have a five-year follow-up, but the results were so 
beneficial that the study was terminated earlier for ethical reasons. With a mean 
follow-up period of 27 months, there was a 70% reduction in all causes of death 
because of a reduction in cardiovascular deaths (76%). Interestingly, in the 
experimental group, receiving the a-linolenic acid (18:3n-3), sudden deaths were 
prevented. It should also be pointed out that these remarkable effects were 
achieved with no differences in the serum cholesterol levels during the study, or 
between the experimental and control cohorts.
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Clinicians also need to know that dietary n-3 PUFAs (and low-dose n-3 PUFA 
supplements) may reduce the risk of sudden cardiac death over a period of 
weeks to months. In a population-based case-control study (Siscovick et al., 
1995), recent dietary intake and cell membrane levels of n-3 PUFAs at the time 
of the event were associated with a lower risk of sudden cardiac death. In the 
GISSI Prevenzione trial, low-dose n-3 PUFA supplements reduced the risk of 
sudden cardiac death among post-myocardial infarction patients within four 
months of initiating treatment (Marchioli et al., 2002).
These n-3 PUFAs have always been an essential component of human diets, 
only having become reduced in our diets in recent times (Leaf & Weber, 1987). It 
seems that an important basic level of control of cardiac function by simple 
dietary choices of the essential PUFAs ingested has been largely overlooked. 
Much further work, especially carefully planned basic research to further explore 
the mechanisms as well as human clinical trials, is needed to test whether these 
natural constituents of a balanced diet will fulfil the need of a safe and effective 
therapeutic agent.
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CHAPTER 3 MATERIALS AND METHODS
3.1 Antibodies and chemicals
Antibodies were purchased from Cell Signalling Technology, collagenase from 
Worthington Biochemical Corporation, DMEM from Gibco Laboratories. PD98059 
(2’-Amino-3’-methoxyflavone), SB203580 [4-(4-Fluorophenyl)-2-(4-
methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole] and Hoechst 33342 from 
Calbiochem; SP600125 (Anthra[1-9-cd]pyrazol-6(2H)-one) from Tocris, UK; All 
other chemicals were obtained from Sigma (St. Louis, MO).
3.2 Experimental Animals
Adult male (250-350 g) or 1-2 day old neonatal Wistar rats were used as 
experimental animals. Rats were allowed free access to food and water. Rats 
were anaesthetized by injecting sodium pentobarbital (30 mg/adult rat and 3 mg 
/neonatal rat) intraperitoneally. The animal procedures in this study conformed 
with the principles outlined in the Guide for the Care and U se  of Laboratory 
Animals, NIH Publication No. 85-23, revised 1996. This investigation was also 
approved by the Ethics committee of the University of Stellenbosch (Faculty of 
Health Sciences).
3.3 Cell culture preparation
Neonatal cardiac myocytes were isolated and cultured by a modification of the 
method described by Pinson (1990). Myocytes were dissociated from the 
ventricles of 1-2 day old Wistar rat hearts using 0.4 mg/ml collagenase and 0.6 
mg/ml pancreatin in a buffer containing (in mM): NaCI 120, HEPES 19, Na2HPC>4 
1, glucose 6 , KCI 5, MgS04 0.3 (pH 7.4). The myocytes were purified by passage 
through a Percoll gradient after digestion. After washing, cells were plated onto
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tissue culture dishes precoated with fibronectin at a density of 0.85x10 
cells/mm2. After 48-72 h, the myocyte cultures were confluent and beating 
spontaneously. Cells were maintained in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal calf serum and antibiotics (100U/ml 
penicillin and 100 ng/ml streptomycin) in a humidified incubator. Confluent, 
spontaneously contracting myocytes were used for experiments at day 3 or 4 
after isolation.
3.4 Simulated ischaemia (SI) and reperfusion
Neonatal ventricular cardiac myocytes were exposed to a balanced salt solution, 
(composition in mM: NaCI 115, KCI 5, KH2PO4 1, MgS04 1.2, CaCl2 2 and 
HEPES 25) containing 5 mM potassium cyanide (KCN) and 20 mM 2-deoxy-D- 
glucose, for 60 minutes in a 5% C 02 incubator (37°C). Cyanide treatment was 
terminated by rinsing twice with phosphate buffered saline (PBS) [composition in 
g/l: NaCI 8 , KCI 0.2, Na2HP04 1.15, KH2P04 0.2]. The medium was then 
replaced by maintenance medium (Dulbecco’s modified Eagles medium with 100 
U/ml penicillin and 100 |^ g/ml streptomycin) for 30 minutes during the reperfusion 
period.
3.5 Evaluation of myocyte loss during simulated ischaemia (SI) and 
reperfusion (R)
To determine whether a gradual loss of myocytes into the supernatant occurred 
during the SI and reperfusion periods, the incubation medium was collected after 
60 minutes of SI as well as after 30 minutes reperfusion and centrifuged. The 
cells in the respective pellets were suspended in a small volume of buffer, 
stained by trypan blue (4% in PBS) and counted in a haemocytometer.
70
Stellenbosch University http://scholar.sun.ac.za/
71
3.6 High energy phosphate (HEP) measurement
HEP (adenosine triphosphate, ATP and creatine phosphate, CrP) were 
measured at indicated time points. Cardiac myocytes (-0.85 x 106 cells/mm2) 
were treated with 6% ice-cold perchloric acid and centrifuged at 8000 g for 5 min 
at 4°C. The supernatant was neutralized with KOH and filtrated through a 0.45|im 
(Millipore) filter. Analysis of HEP was done by a reversed phase high-pressure 
liquid chromatography (HPLC) technique developed by Victor and co-workers 
(1987). The protein content of the samples was determined in the acid precipitate 
by the method of Lowry (1951), using bovine serum albumin (BSA) as a 
standard.
3.7 Preparation of BSA/fatty acid complexes
Fatty acids were prepared according to the method of de Vries and co-workers 
(1997). Briefly, arachidonic acid or eicosapentaenoic acid was dissolved in 4 ml 
ethanol to yield a final concentration of 18.75 mM. An equal volume of 10 mM 
Na2C 03 was added. Ethanol was evaporated at 50-60°C under continuous N2- 
flow and the fatty acid containing mixture was added dropwise to 10  ml of 1 0 % 
bovine serum albumin (BSA) in PBS at 40°C. The BSA/fatty acid complexes were 
subsequently dialyzed four times at 4°C for 4-6 h against 250 ml 0.1 M 
[NH4]HC0 3 , and lyophilized. BSA and BSA/fatty acid complexes were dissolved 
in DMEM with antibiotics (100U/ml penicillin and 100 |ig/ml streptomycin) to yield 
a final BSA concentration of 1%. After filter sterilization, the media were stored at 
4°C until use. The fatty acid/BSA ratio in the medium amounted to 3.3 to 1. For 
control experiments BSA was prepared similar to the procedure as described 
above, but in the absence of added fatty acids.
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3.8 Experimental protocol for cells treated with fatty acids
DMEM containing either 1% BSA (in control cardiomyocytes) or fatty acids (final 
concentrations of 20 ^M) complexed to BSA was added to the cells 30 minutes 
before the onset of SI. Following treatment, the medium was removed and 
replaced with a KCN containing balanced salt solution (composition in mM: NaCI 
115, KCI 5, KH2PO4 1, MgS04 1.2, CaCfe 2 and H EPES 25) containing 5 mM 
potassium cyanide (KCN) and 20 mM 2-deoxy-D-glucose, for 60 minutes in a 5% 
C02 incubator (37°C). Cyanide treatment was terminated by rinsing twice with 
phosphate buffered saline (PBS). During reperfusion, the medium was replaced 
by maintenance medium (DMEM with 100 U/ml penicillin and 100 ng/ml 
streptomycin), containing either 1% BSA or fatty acids complexed to BSA, for 30 
minutes. (Preliminary studies showed that optimal protection of the myocytes 
was achieved when fatty acids were present before SI as well as during 
reperfusion).
3.9 Treatment of cells with SB203580, PD98059, SP600125 and 
wortmannin
PD98059 (10 pM), a selective inhibitor of MEK1/MEK2, the upstream activator of 
ERK1/ERK2 (Dudley et al., 1995) or SB203580 (1 pM), an inhibitor of p38-MAPK 
(Clerk & Sugden, 1998), or SP600125 (10 |iM), a JNK inhibitor (Vaishnav et al., 
2003), or wortmannin (100 nM), a PI-3-kinase inhibitor (Versteeg et al., 2000) 
was added to the cells 30 minutes before the onset of SI. Following treatment, 
the medium was removed and replaced with the KCN containing balanced salt 
solution (as described above). Inhibitors were present for 30 minutes before SI 
as well as during the reperfusion period. For controls, cardiomyocytes were 
incubated with maintenance medium alone containing the appropriate inhibition 
solvent.
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3.10 Treatment of cells with indomethacin, chelerythrine and phosphatase 
inhibitors
Indomethacin (10 ^M), a cyciooxygenase inhibitor, chelerythrine (10 ^M), an 
inhibitor of PKC catalytic activity, okadaic acid (1 i^M), an inhibitor of types 1 and 
2A serine/threonine phosphatases or orthovanadate (100 ^M), a specific inhibitor 
of tyrosine phosphatases was added to the cells 30 minutes prior to and during 
fatty acid treatment. Inhibitors were also present during the 30 minutes of 
reperfusion.
3.11 Analysis of membrane fatty acid composition
To examine the incorporation of supplemented fatty acids into the myocardial 
phospholipid fraction after a 60 minute incubation period, the cardiomyocytes 
were rinsed with cold buffer, scraped off and extracted with a 2:1  (vol/vol) mixture 
of chloroform and methanol which contained 0 .0 1 % butylated hydroxytoluene to 
prevent auto-oxidation of unsaturated fatty acids. The lipid extracts were washed 
with 0.15 M KCI according to the method of Folch et al (1957), and the remaining 
organic solvents vaporized under nitrogen. Phospholipids were isolated from 
other lipid classes by thin layer chromatography (Silica gel G plates, 10 x 20 cm; 
Analtech Inc., Mewark, DE) in hexane:diethyl-ether:acetic acid (80:20:1, v:v:v) 
(Zail & Pickering, 1979). The band containing phospholipids was removed 
completely from the plate and transmethylated with boron trifluoride-methanol to 
yield fatty acid methyl esters (Morrison & Smith, 1964). Individual fatty acid 
methyl esters were separated on a Varian 3300 gas chromatograph with an SP- 
2560 capillary column (100 m Supleco Inc., Belfonte, PA). The instrument was 
programmed for column, injector, and detector temperatures of 175, 225 and 
275°C, respectively. Helium was used as a carrier gas at a flow rate of 21 cm per 
second. Individual peaks were integrated with a programmable Varian 4290
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recorder/integrator. The peaks were identified by comparison with authentic 
standards.
3.12 Determination of cardiomyocyte viability
For the assessment of cell viability a modification of the 3-[4,5-dimethylthiazol-2- 
yl]-2,5-diphenyl tetrazolium bromide (MTT) assay described by Gomez and co­
workers was used (1997). The assay is based upon the principle of reduction of 
MTT into blue formazan pigments by viable mitochondria in healthy cells. At the 
end of the experiment, the medium was removed from the petri dishes and the 
cells washed twice with PBS. MTT (0.01 g/ml) was dissolved in PBS, and 500 p.l 
was added to each petri dish. Cells were subsequently incubated for 2 h at 37°C 
in an atmosphere of 5% CO2. This time period was found to be optimal for color 
development associated with formazan product formation. After the incubation 
period, cells were washed twice with PBS and one ml of HCI-isopropanol-Triton 
(1% HCI in isopropanol; 0.1% Triton X-100; 50:1) was added to each petri and 
gently agitated for 5 minutes. This caused the cell membranes to lyse and 
liberate the formazan pigments. The suspension was then centrifuged at 14 000 
rpm for 2 minutes. The optical density (OD) was determined 
spectrophotometrically at a wavelength of 540 nm and the values expressed as 
percentages of control values.
3.13 Western-blot analysis
Cardiomyocyte MAPKs, caspase-3 and poly-ADP-ribose-polymerase (PARP) 
protein were extracted with a lysis buffer containing (in mM): Tris 20, p- 
nitrophenylphosphate 20, EGTA 1, sodium fluoride (NaF) 50, sodium 
orthovanadate 0.1, phenylmethyl sulphonyl fluoride (PMSF) 1, dithiothreitol (DTT) 
1, aprotinin 10 |jg/ml, leupeptin 10 |jg/ml. Mitogen-activated protein kinase 
phosphatase-1 (MKP-1) protein was extracted with a lysis buffer containing (in 
mM): Hepes 50, EDTA 10, EGTA 10, PMSF 1, Aprotinin (1 ug/ml), Leupeptin (1
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ug/ml) and Triton (0.5%). The tissue lysates were diluted in Laemmli sample 
buffer, boiled for 5 minutes and 10 pg (MAPKs) or 50 pg protein (caspase-3, 
PARP and MKP-1) were separated by 10% SDS-PAGE. The lysate protein 
content was determined using the Bradford technique (1976). The separated 
proteins were transferred to a PVDF membrane (Immobilon™ P, Millipore), which 
were routinely stained with Ponceau Red for visualization of proteins. Non­
specific binding sites on the membranes were blocked with 5% fat-free milk in 
Tris-buffered saline-0.1 % Tween 20 (TBST) and then incubated with the primary 
antibodies that recognize phosphospecific ERK p42/p44 (Thr^/Tyr204) and total 
ERK, p38-MAPK (Thr180/Tyr182) and total p38-MAPK, JNK p54/p46 (Thr183/Tyr185) 
and total JNK, PKB/Akt (Ser473and Thr308) and total PKB/Akt, caspase-3 (p17 
fragment pAb) and PARP (p85 fragment pAb). Membranes were subsequently 
washed with large volumes of TBST (5X5 min) and the immobilized antibody 
conjugated with a diluted horseradish peroxidase-labelled secondary antibody 
(Amersham LIFE SCIENCE). After thorough washing with TBST, membranes 
were covered with ECL™ detection reagents and quickly exposed to an 
autoradiography film (Hyperfilm ECL, RPN 2103) to detect light emission through 
a non-radioactive method (ECL™ Western blotting). Films were densitometrically 
analysed (UN-SCAN-IT, Silkscience) and phosphorylated protein values were 
corrected for minor differences in protein loading, if required. Experiments were 
also performed to ensure that all signals were within the linear range of detection 
on the autoradiographs under our assay and gel loading conditions (fig 3.1).
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Figure 3.1 Experiments to ensure that signals are within the linear range 
of detection under our assay- and loading conditions.
5ng 110|ig| 15|ig 20\ig 25|ig 50jig protein loaded
1 1.5 1.6 1.8 2.1 2.2 fold activation
P-JNK 
fold activation
1 4.2 4.5 5.0 5.9 6.1 fold activation
1 1.1 1.7 1.9 1.92 1.98
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3.14 Morphological assessment and quantification of apoptotic myocytes
Hoechst 33342, a fluorescent nuclear binding dye, which allows clear distinction 
between apoptotic and normal cells on the basis of nuclear morphology 
(chromatin condensation and fragmentation), was used for quantification of 
apoptotic myocytes. Hoechst 33342 (prepared in PBS) was added to the culture 
medium at a final concentration of 50 (ig/ml. Cells were evaluated by 
fluorescence microscopy according to the following grading system: normal 
nuclei (blue chromatin with organized structure) and apoptotic cells (bright 
fluorescent chromatin which is highly condensed or fragmented). For each 
experimental condition, three separate myocyte populations were prepared. At 
least 400 cells from three randomly selected fields were counted in each petri 
and quantified for each experimental condition (total: 1200 cells/petri; >3600 
cells/experiment). The apoptotic index [percentage of apoptotic cells] was 
calculated as number of apoptotic cells/total cells counted X 100. Scoring was 
done blindly.
3.15 In vitro dephosphorylation assay
Myocytes were either incubated with fatty acids (FA) (20 ^M) or exposed to 60 
minutes SI and 30 minutes reperfusion as described previously. Cells were 
scraped from the culture dish, transferred to an eppendorf and sonicated for 10 
seconds. Phosphatases were extracted with a buffer containing (in mM): Hepes 
50, EDTA 10, EGTA 10, PMSF 1, Aprotinin (1 ug/ml), Leupeptin (1 ug/ml) and 
Triton (0.5%). The samples were centrifuged and the protein content of the 
supernatant was determined using the Bradford technique (1976). To determine 
whether the phosphatases were responsible for the inhibition of the kinases, the 
kinase and phosphatase containing lysates, obtained from myocytes after 
simulated ischaemia/reperfusion, were mixed (50 g^ protein each). Samples not 
incubated served as controls, while the rest were incubated at 30°C for 45 
minutes, with and without the tyrosine phosphatase inhibitor, vanadate (10mM).
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The reactions were stopped by addition of sample buffer containing: 250 mM 
Tris-HCI, 500mM DTT, 10% SDS, 0.5% Bromophenol Blue and 50% Glycerol. 
Proteins were separated by electrophoresis followed by Western blotting for p38 
as described before.
3.16 Perfusion technique of isolated rat heart
The well-characterized retrogradely (Langendorff model) perfused heart was 
used as experimental model. The hearts were rapidly excised and arrested in 
ice-cold Krebs-Henseleit bicarbonate buffer, pH 7.4, containing (in mM): NaCI 
119, NaHC03 24.9, KCI 4.74, KH2P04 1.19, MgS04 0 .6 , Na2S 0 4 0.59, CaCI2 
1.25, glucose 10. The buffer was oxygenated and kept at pH 7.4 by gassing with 
95% 0 2 / 5% C 02. Hearts were perfused retrogradely at a constant pressure (100 
cm H20). A water-filled latex balloon, connected to a pressure transducer was 
inserted into the left ventricle via the left atrium. Left ventricular end-diastolic 
pressure was set between 4 and 8 mmHg as baseline. Heart rate and the left 
ventricular developed pressure (LVDP) were monitored continuously on the 
computer, and function assessed before and after ischaemia.
3.17 Experimental protocol: functional studies (fig 3.2)
Hearts were perfused retrogradely for 40 minutes (stabilisation) followed by 25 
minutes global sustained ischaemia and reperfusion for 30 minutes (control, 
n=12). In the second protocol, hearts were perfused with albumin as indicated in 
figure 2. Albumin treated hearts (n=6 ) were stabilized for 10 minutes without 
albumin and for 30 minutes in the presence of albumin. This was followed by 25 
minutes sustained global ischaemia and 30 minutes reperfusion (10 minutes in 
the presence of albumin and 30 minutes in the absence of albumin). In the third 
protocol, EPA (n=7) or ARA (n=6 ) was added before and after sustained 
ischaemia as follows: hearts were stabilized for 10  minutes without the fatty acid 
and 30 minutes in the presence of the fatty acid/albumin. This was followed by 25
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minutes of global, sustained ischaemia followed by 30 minutes reperfusion (10 
minutes in the presence of the fatty acid/albumin and 20 minutes in the absence 
of the fatty acid/albumin. In the fourth protocol, the hearts were treated with EPA 
(n=6 ) or ARA (n=6 ) after global, sustained ischaemia only as follows: hearts were 
stabilized for 40 minutes followed by 25 minutes of global sustained ischaemia 
and 30 minutes of reperfusion, which included 10 minutes in the presence the 
fatty acid/albumin and 20 minutes in the absence of the fatty acid/albumin.
3.18 Statistical analysis
All results are expressed as means ± SEM. One-way ANOVA was performed for 
each group of treatments, using Bonferroni’s post-hoc test and p values < 0.05 
were regarded as significant. The number of experiments is indicated in the 
figure legends.
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Figure 3.2_______Experimental protocol:functional studies
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CHAPTER 4 RESULTS AND DISCUSSION: The regulatory roles of 
MAPKs and PKB/Akt on the development of apoptosis 
during simulated ischaemia and reperfusion (Sl/R) in 
neonatal cardiomyocytes
4.1 Introduction
During the past few years it has become clear that, in addition to necrosis, 
apoptosis plays a significant role in myocardial ischaemia/reperfusion injury 
(Kajstura et al., 1996; Gottlieb & Engler 1999). Anversa and Kajstura (1998) have 
demonstrated that apoptosis precedes cell necrosis and is in fact the major 
determinant of infarct size, but this statement has been questioned by others 
(Schaper et al., 1999 a & b), e.g. Kostin and co-workers recently published 
results where they concluded that apoptosis, oncosis and autophagy act in 
parallel to varying degrees in the failing human heart (2003). Shiraishi and co­
workers (2 0 0 1 ) have underlined the importance of the energy status in neonatal 
cardiac myocytes, where the presence of intracellular ATP favours a shift from 
necrosis to apoptosis via caspase activation. However, the precise mechanisms 
involved in stimulus recognition and progression to apoptosis in response to 
ischaemic injury or ATP depletion remains largely uncertain. Many studies have 
suggested that the mitogen activated protein kinases (MAPKs) as well as 
PKB/Akt may be important regulators of apoptosis in response to myocardial 
ischaemia/reperfusion, but reports on their precise roles are still conflicting.
Three major MAPKs, namely extracellular signal-regulated protein kinase (ERK), 
p38 and c-Jun NH2-terminal protein kinase (JNK) play a pivotal role in the 
transmission of signals from cell surface receptors to the nucleus (Bogoyevitch et 
al., 1996; Mansour et al., 1994). In many cell types the ERK cascade appears to 
mediate specifically cell growth and survival signals. For instance, it has been 
shown that inhibition of ERK enhances ischaemia-reperfusion induced apoptosis 
and that sustained activation of this kinase during simulated ischaemia mediates
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adaptive cytoprotection in cultured neonatal cardiomyocytes (Yue et al., 2000). 
On the other hand, the p38 and JNK families appear to be pro-apoptotic in many 
cell types (Obata et al., 2000; Park et al., 2000), however, their exact roles in 
regulating cell death are unclear. For example, Hreniuk and co-workers (2001) 
found that inhibition of JNK46 but not JNK54, significantly reduced 
reoxygenation-induced apoptosis while Wang et al (1998b) reported that 
activation of JNK by transfection of cultured rat neonatal cardiomyocytes with 
mitogen activated protein kinase kinase 7 (MKK7), an upstream activator of JNK, 
induced hypertrophy rather than apoptosis. Despite reports to the contrary 
(Weinbrenner et al., 1997; Zechner et al., 1998), several investigators support 
the concept that p38 activation is harmful to the ischaemic heart (Bogoyevitch et 
al., 1996; Mackay & Mochly-Rosen, 2000). These conflicting results regarding 
the role of p38 can possibly be attributed to the different isoforms (a and p) 
expressed in the heart (Saurin et al., 2000), which appear to mediate opposing 
functions. The p38a-isoform is implicated in apoptosis, whereas p38p is anti- 
apoptotic in neonatal rat cardiomyocytes (Michel et al., 2001). Further evidence, 
which links JNK and p38 to apoptosis, is the finding that their signalling pathways 
are associated with activation of effector caspases, including caspase 3 
(Chaudhary etal., 1999).
It has been suggested in several studies that PKB/Akt might be a critical 
regulator of cell survival. The transfection of a variety of cell types with 
constitutively active PKB/Akt alleles blocks apoptosis induced by a wide range of 
apoptotic stimuli, including growth factor withdrawal, ultraviolet irradiation, matrix 
detatchment, DNA damage and treatment of cells with anti-Fas antibody or 
transforming growth factor-beta (TGF-p) (Songyang et al., 1997; Dudek et al., 
1997; Kauffmann-Zeh etal., 1997; Kennedy etal., 1997; Chen etal., 1998; Rohn 
et al., 1998). Studies of PKB/Akt activation pathways have also shown that PI3- 
kinase is a mediator of an activator signal for PKB/Akt (Franke et al., 1995; 
Burgering et al., 1995; Kulik et al., 1997). PI3-kinase is considered one of the 
intracellular signals responsible for the transmission of anti-apoptotic signals for
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controlling cell survival. Overexpression of PI3-kinase in cells has been shown to 
cause a significant increase in survival of cells exposed to ionising radiation 
(Krasilnikov et al., 1999; Cataldi et al., 2001). Furthermore, it was also shown by 
Fujio and co-workers that PKB/Akt promotes survival of cardiomyocytes in vitro 
and protects against ischemia/reperfusion injury in the mouse heart (2000 ).
In the current study, an in vitro model of simulated ischaemia/reperfusion (Sl/R), 
induced by KCN and 2-deoxy-D-glucose, was used to achieve graded ATP 
depletion in cultured neonatal cardiomyocytes and to analyse the regulation of 
cardiomyocyte apoptosis. In addition, the phosphorylation pattern of the MAPKs 
and PKB/Akt during Sl/R was characterized and the significance of their 
phosphorylation in apoptosis was determined.
4.2 Results 
4.2.1 Myocyte loss during Sl/R
Myocyte loss during the experimental procedures, should it occur, could severely 
affect the outcome of the experiments. To establish whether any of the cellular 
manipulations resulted in a significant detachment of myocytes during the 
incubation periods, the number of cells in the supernatant (media) was counted 
after each insult. The number of detached cells was found to be less than 0.01% 
of the number of cells plated (data not shown). This was further corroborated by 
the fact that no protein loss [assessed by the Bradford technique (1976)] was 
detected during SI and reperfusion. Therefore, changes in viability or apoptotic 
index could not be ascribed to a decrease in cell number.
4.2.2 Cultured rat neonatal cardiomyocytes undergo time-dependent 
depletion of intracellular ATP and CrP during SI (Figure 4.1 A)
Confluent cardiomyocytes subjected to inhibition of glycolysis (with 2-deoxy-D- 
glucose) and oxidative phosphorylation (with KCN) displayed a rapid and
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Figure 4.1 A: Intracellular ATP- and CrP levels at various time points during simulated 
ischaemia (SI) and reperfusion. Myocytes were exposed to simulated ischaemia (KCN and 2- 
deoxy-D-glucose) followed by reperfusion for the indicated time periods. Results are 
expressed as means ± S.E.M. for four independent experiments (n=4). *p<0.001 vs control; 
'pO.OI vs control; *p<0.01 vs 60’SI. [Control values before onset of simulated ischaemia: 25 
± 5 nmol ATP/mg protein and 23.1 ± 3.5 nmol CrP/mg protein]
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Figure 4.1 B: Cell viability was measured during SI and reperfusion, using the MTT cell 
viability assay. Myocytes were exposed to simulated ischaemia (KCN and 2-deoxy-D- 
glucose) followed by reperfusion for the indicated time periods. Results are expressed as 
means ± S.E.M. for five independent experiments (n=5). *p<0.001 vs control; #p<0.001 vs 
60’SI.
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profound decrease in intracellular ATP levels to 18 ± 1.4% (p<0.001) of controls 
within 30 minutes of SI. The decrease in CrP was even more rapid compared to 
ATP: after only 15 minutes SI the intracellular CrP levels were decreased to 21.4 
± 1.4% (p<0.001) of controls. A plateaux for both ATP and CrP was reached after 
30 minutes SI. After 30 minutes reperfusion, ATP levels increased to 35 ± 1% 
and CrP to 70 ± 1.2% of their corresponding controls (p<0.01, 60 min SI vs 
60’SI/30’R for CrP).
4.2.3 Cardiomyocytes undergo time-dependent loss of viability during SI 
(Figure 4.1 B)
The MTT assay showed that a gradual loss of mitochondrial viability in 
cardiomyocytes occurred during SI reaching 41 ± 1.6% of control after 60 
minutes. However, there was a gradual but significant increase in mitochondrial 
viability during reperfusion, reaching 64 ± 2.8% after 30 minutes. This suggests 
that in at least 20% of cells the mitochondrial injury was reversible, while the cell 
membranes were intact.
4.2.4 Caspase-3 activation and PARP cleavage during SI and Sl/R (Figure 
4.1C)
Caspase-3 activation and PARP cleavage followed more or less the same 
pattern; both were maximal after 15 minutes SI [2.47 ± 0.23 fold (p<0.05) and 
2.55 ± 0.29 fold (p<0.05) fold increase for caspase-3 and PARP respectively]. 
Caspase-3 activation appears to be biphasic, reaching a second peak after 60 
minutes, while PARP cleavage remained high throughout SI. After 5 minutes of 
reperfusion, both caspase-3 and PARP returned to almost basal levels with 
significant increases in activation and cleavage after 15- and 30 minutes 
reperfusion [Caspase-3: 2.70 ± 0.4 fold (p<0.05) and 2.67 ± 0.38 fold (p<0.05) for
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Figure 4.1 C: Time course of PARP cleavage and caspase-3 activation during SI and 
reperfusion. Myocytes were exposed to simulated ischaemia (KCN and 2-deoxy-D-glucose) 
followed by reperfusion for the indicated time periods. Samples were analysed by Western 
blotting with antibodies recognizing cleaved PARP and caspase-3. Results were expressed 
as means ± S.E.M. for three independent experiments (n=3). *p<0.05 vs control.
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15- and 30 minutes reperfusion respectively; PARP: 2.4 ± 0.32 fold (p<0.05) and
2.4 ± 0.31 fold (p<0.05) for 15- and 30 minutes reperfusion].
4.2.5 Apoptotic Index during SI and Sl/R (Figures 4.1 D & E)
Cardiac myocytes, stained with Hoechst 33342 and assessed by fluorescence 
microscopy, showed condensed chromatin and fragmented nuclei after exposure 
to SI and reperfusion. During normoxia, 4.6 ± 1.1% cells showed spontaneous 
cell death (basal), which was maintained during SI. A significant increase in 
apoptotic cells [22.8 ± 6.58% (p<0.01)] was only observed after 60 minutes SI 
followed by 30 minutes reperfusion.
4.2.6 Phosphorylation of ERK, p38, JNK and PKB/Akt in cardiomyocytes 
subjected to SI and Sl/R (Figures 4.2 and 4.3)
To investigate whether the MAPKs as well as PKB/Akt were phosphorylated 
during the Sl/R protocol, cells were harvested at different times during SI and 
reperfusion. As shown in figure 4.2A, rapid and transient phosphorylation of p38 
occurred after 5 minutes of SI [5.9 ± 0.23 fold (p<0.001)], with a gradual 
decrease in phosphorylation up to 30 minutes where after it slowly increased 
again. A second peak of phosphorylation was observed at 60 minutes of SI [6.11 
± 0.26 fold (p<0.001)]. Five minutes of reperfusion did not induce a further 
significant increase in phosphorylation [6.83 ± 0.1 fold (p>0.05)], compared with 
60 minutes SI. p38 phosporylation declined afterwards. No significant changes in 
phosphorylation of ERK occurred during SI, but upon reperfusion, both the ERK- 
isoforms were phosphorylated with a peak increase at 5 minutes [6.09 ± 0.37 fold 
(p<0.001) and 1.75 ± 0.06 fold (p<0.01) for p44 and p42 respectively]. ERK-p42 
remained elevated up to 30 minutes of reperfusion [1.78 ± 0.12 fold (p< 0.01)], 
while p44 phosphorylation gradually decreased from 6.09 ± 0.37 to 3.50 ± 0.22 
fold (p<0.001). Phosphorylation of both isoforms of JNK (p54/p46) occurred
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Figure 4.1 D: Sl/reperfusion-induced apoptosis in cardiac myocytes. Myocytes were 
exposed to simulated ischaemia (KCN and 2-deoxy-D-glucose) followed by reperfusion for 
the indicated time periods. To quantify apoptotic myocytes, cell monolayers were fixed and 
stained with Hoechst 33342. The morphological features of apoptosis (cell shrinkage, 
chromatin condensation) were monitored by fluorescence microscopy. At least 400 cells from 
three randomly selected fields per dish were counted and each treatment was performed in 
triplicate. Results were expressed as means ± S.E.M. for three independent experiments 
(n=3). *p<0.001 vs control.
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Figure 4.1 E: Simulated Ischaemia / Reperfusion-induced apoptosis in cardiomyocytes 
(Fluoresence photomicrographs): 1. control; 2. 60’SI; 3. 60’SI/30’R. Arrows indicate apoptotic 
bodies.
Stellenbosch University http://scholar.sun.ac.za/
Total p38 
P-p38
^  time (minutes)
Figure 4.2
Stellenbosch University http://scholar.sun.ac.za/
P-JNK 54 
P-JNK 46
18
16
14
SI Reperfusion
*
f
o 12
4
2
0 =- I I T - }  f -
—  JNK 54 
M -  JNK 46
C
contr 5' 151 30* 4C 5ff 60' 5’ 15’ 30‘ 
tlm# (minutes)
Figure 4.2: Time course of p38, ERK and JNK phosphorylation in cardiomyocytes subjected 
to simulated ischaemia and reperfusion. Myocytes were exposed to SI (KCN and 2-deoxy-D- 
glucose) followed by reperfusion for the indicated time period. Samples were analysed by 
Western blotting with antibodies recognizing dual-phosphorylated MAPKs. Results were 
expressed as means ± S.E.M. for four to seven independent experiments (n=4-7). *p<0.001 
vs control; #p<0.01 vs control.
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Figure 4.3: Time course of PKB/Akt phosphorylation in cardiomyocytes subjected to 
simulated ischaemia and reperfusion. Myocytes were exposed to SI (KCN and 2-deoxy-D- 
glucose) followed by reperfusion for the indicated time period. Samples were analysed by 
Western blotting with antibodies recognizing phosphorylated Ser473 and Thr308 of PKB/Akt. 
Results were expressed as means ± S.E.M. for four to seven independent experiments (n=4- 
7). *p<0.001 vs control; #p<0.01 vs control.
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during reperfusion only, with maximal phosphorylation at 5 minutes (fig 4.2C) 
[16.2 ± 0.52 fold (p<0.001), declining gradually during further reperfusion.
PKB phosphorylation was determined using antibodies recognizing phospho- 
Ser473 and Thr308. As shown in figure 4.3A, Ser473 phosphorylation occurred after
5 minutes SI [2.75 ± 0.23 fold (p<0.01)] and returned to basal levels within 15 
minutes SI. However, there was no significant increase in Thr308 phosphorylation 
at this specific time-point. Ser473 was maximally phosphorylated after 5 minutes 
of reperfusion [5.63 ± 0.42 fold (p<0.001)], returning to basal levels after 30 
minutes. Similarly, Thr308 phosphorylation also peaked at 5 minutes reperfusion 
[3.2 ± 0.2 fold (p<0.001)] returning to basal levels after 15 minutes.
Please note that the total -p38, -ERK (p44 and p42), -JNK (p54 and p46) as well 
as -PKB remained unaltered throughout the experimental procedure.
4.2.7 The effects of SB203580, PD98059 and SP600125 on the MAPKs 
(Figures 4.4 A, B and C)
To evaluate the significance of p38, ERK and JNK activation during Sl/R, three 
specific inhibitors, SB203580, PD98059 and SP600125 respectively were used. 
Preliminary experiments indicated that, inhibition of the MAPKs was only 
achieved during reperfusion when the drugs were administered for 30 minutes 
before the onset of SI as well as during the reperfusion period. Therefore, in all 
studies, the inhibitors were present before and after SI. Samples were taken at 
the end of the 60 minutes SI and 30 minutes reperfusion period. In the presence 
of 1 jiM SB203580, p38 phosphorylation was significantly reduced from 3.07 ± 
0.59 to 1.03 ± 0.08 fold (p<0.05) after Sl/R. The MEK1/MEK2 inhibitor, PD98059, 
at 10 nM, caused a significant decrease in ERK 44 [3.84 ± 0.15 to 2.15 ± 0.26 
fold (p<0.001)] and ERK 42 phosphorylation [3.62 ±0.07 to 2.7 ± 0.3 fold 
(p<0.05)] during Sl/R. SP600125, a specific JNK inhibitor, at 10 ^M, caused a 
significant decrease in JNK 54 [2.16 ± 0.09 to 0.92 ± 0.10 fold (p<0.001)] and
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Figures 4.4 A, B and C: Effect of SB203580 (1 nM), PD98059 (10 nM) and SP600125 (10 
|iM) on MAPK phosphorylation during SI and reperfusion. SI and Sl/reperfusion were carried 
out either alone or following treatment with PD98059, SB203580 or SP600125. The drugs 
were administered 30 minutes before the onset of SI as well as during reperfusion to achieve 
optimal inhibition. (A) p38: *p<0.01: 60’SI/30’reperfusion vs 60’SI/30’reperfusion + SB. (B) 
ERK 44: *p<0.001: 60’SI/30’reperfusion vs 60’SI/30’reperfusion + PD; ERK 42: *p<0.05: 
60'SI/30’reperfusion vs 60’SI/30’reperfusion + PD. (C) JNK54 and JNK46 (*p<0.001): 
60’SI/30’reperfusion vs 60'SI/30’reperfusion + SP. Results were expressed as means ± 
S.E.M. for three independent experiments (n=3).
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JNK 46 [2.3 ± 0.04 to 1.03 ± 0.08 fold (p<0.001)] phosphorylation during Sl/R. 
The inhibitors had no effects on the total kinases.
4.2.8 The effect of wortmannin on PKB/Akt phosphorylation during Sl/R 
(Figures 4.5 A and B).
The significance of PKB/Akt phosphorylation during Sl/R in our cell model was 
evaluated with a PI-3-kinase inhibitor, wortmannin. The inhibitor was 
administered for 30 minutes before the SI period only. In this study, samples 
were taken after 5 minutes SI as well as at 5 minutes of reperfusion where 
phosphorylation has been to the maximum. After five minutes of SI, wortmannin 
induced a significant inhibition of PKB/Akt Ser473 [1.82 ± 0.12 to 1.07 ± 0.05 fold 
(p<0.05)] as well as Thr308 [0.85 ± 0.01 to 0.09 ± 0.12 fold (p<0.001)] 
phosphorylation. Wortmannin also caused a significant decrease in PKB/Akt 
Thr308 during reperfusion [1.71 ± 0.12 to 0.96 ± 0.09 fold (p<0.001)]. The total 
PKB/Akt remained unchanged throughout the experiment.
4.2.9 The effect of SB203580, PD98059, SP600125 and wortmannin on cell 
viability during Sl/R (Figure 4.6)
SB203580 (1 |xM) significantly increased cell viability during Sl/R [63.67 ± 1.85% 
to 84.33 ± 4.8% (p<0.05)]. Although PD98059 (10 ^M) and SP600125 (10 nM) 
reduced cell viability during Sl/R this was not significant. Wortmannin (100 nM) 
caused a small but significant reduction in cell viability during Sl/R [69.75 ± 
0.48% to 57.25 ± 3.42% (p<0.05)]. SB203580, PD98059 and SP600125 were 
added to the cells 30 minutes before the onset of SI as well as during 
reperfusion, while wortmannin was added only 30 minutes before the onset of SI.
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Figures 4.5 A and B: Effect of wortmannin (100 nM) on PKB/Akt phosphorylation (Ser473 and 
Thr308) during SI and reperfusion. SI and Sl/reperfusion were carried out either alone or 
following treatment with wortmannin. The drug was administered 30 minutes before the onset 
of the SI period. (A) PKB/Akt Ser473: control vs 5’SI (#p<0.01); control vs 60’SI/5’reperfusion 
(*p<0.001); 5’SI vs 5’SI + wortmannin ($p<0 .05 ). (B) PKB/Akt Thr308: control vs 
60’SI/5’reperfusion (*p<0.001); 5’SI vs 5’SI + wortmannin (**p<0.001); 60’SI/5’reperfusion vs 
60’SI/5’reperfusion + wortmannin (***p<0.001). Results are expressed as means ± S .E  M. for 
three independent experiments (n=3).
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Figure 4.6: Effect of SB203580 (1 ^M), PD98059 (10 nM), SP600125 (10 ^M) and 
wortmannin (100 nM) on cell viability using the MTT assay during SI and reperfusion. Results 
are expressed as means ± S.E.M. for five independent experiments (n=5). (A): control vs 
60’SI/30’reperfusion (*p<0.001); 60’SI/30’reperfusion vs 60’SI/30’reperfusion + SB ($p<0.05) 
(B): control vs 60’SI and control vs 60’SI/30’reperfusion (*p<0.001); 60’SI/30’reperfusion vs 
60’SI/30’reperfusion + wortmannin ($p<0.05). Results are expressed as means ± S.E.M. for 
three independent experiments (n=3).
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4.2.10 The effect of SB203580, PD98059, SP600125 and wortmannin on 
caspase-3 activation and PARP cleavage during Sl/R (Figures 4.7 A 
and B)
1 (jM SB203580 significantly inhibited caspase-3 activation and PARP cleavage 
during Sl/R [1.66 ± 0.03 fold to 1.06 ±0.07 fold (p<0.001) for caspase-3 and 2.17 
± 0.08 fold to 0.80 ± 0.09 fold (p<0.001) for PARP], However, SP600125, 
significantly increased caspase-3 activation during Sl/R [1.66 ± 0.03 fold to 2.56 
± 0.27 fold (p<0.001)]. Although 100 nM wortmannin caused a significant 
increase in PARP cleavage during Sl/R [2.26 ±0.12 fold to 3.43 ±0.15 fold 
(p<0.01)], caspase-3 remained unaltered during this period.
4.2.11 The effect of SB203580, PD98059, SP600125 and wortmannin on the 
apoptotic index during Sl/R (Figures 4.8 A & B)
As observed before, during normoxia (with and without the inhibitors), 4.6 ± 1.1% 
cells showed spontaneous cell death (as indicated by the apoptotic index), which 
was maintained during SI. A significant increase in apoptotic cells [22.8 ± 6.58% 
(p<0.01)] was observed after 60 minutes SI followed by 30 minutes reperfusion 
when compared to their corresponding controls. Treatment of the cells with 
SB203580 induced a significant decrease in the number of apoptotic cells during 
reperfusion [22.6 ± 2.94 % vs 9 ± 0.43% (p<0.001)], while SP600125 significantly 
increased [22.6 ± 2.94% vs 32.75 ± 4.13% (p<0.05)] the apoptotic index. 
Inhibition of ERK with PD98059 and PI3-kinase with wortmannin was without 
effect on the apoptotic index.
4.3 Discussion
4.3.1 Model
The model used in this study combines the following properties of ischaemia: 
Inhibition of mitochondrial respiration by cyanide which prevents the oxidation of
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Figure 4.7: Effect of SB203580, PD98059, SP600125 and wortmannin on caspase-3 
activation and PARP cleavage during SI and reperfusion. Sl/reperfusion was carried out 
either alone or following pretreatment with PD98059, SB203580 or SP600125. Results were 
expressed as means ± S.E.M. for three independent experiments (n=3). (A): 
60’SI/30'reperfusion vs 60’SI/30'reperfusion + SP (*p<0.001); 60’SI/30’reperfusion vs 
60’SI/30’reperfusion + SB (#p<0.05) (B): 60’SI/30’reperfusion vs 60'SI/30’reperfusion + 
wortmannin (#p<0.01).
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Figure 4.8: The effect of SB203580 (1 jiM), PD98059 (10 \iM), SP600125 (10 jiM) and 
wortmannin (100 nM) on the apoptotic index during SI and Sl/reperfusion. Myocytes were 
exposed to simulated ischaemia (KCN and 2-deoxy-D-glucose) followed by 30 minutes 
reperfusion. To quantify apoptotic myocytes, cell monolayers were fixed and stained with 
Hoechst 33342. The morphological features of apoptosis (cell shrinkage, chromatin 
condensation) were monitored by fluorescence microscopy. At least 400 cells from each of 
three randomly selected fields per dish were counted, and each treatment was performed in 
triplicate (-3600 cells/treatment). Results are expressed as means ± S.E.M. for three 
independent experiments (n=3). (A): 60’SI/30’reperfusion vs 60’SI/30’reperfusion + 
SB203580 (*p<0.001); 60’SI/30’reperfusion vs control (#p<0.01); 60'SI/30’reperfusion vs 
60’SI/30’reperfusion + SP600125 ($p<0.05) (B): 60’SI/30’reperfusion vs control (#p<0.01).
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cytochrome a3, thereby obstructing the electron transport chain and oxidative 
phosphorylation, while 2-deoxy-D-glucose inhibits glycolysis. A major difference 
from either in vivo ischaemia or other models of ischaemia entails a significant 
decrease in intracellular pH. However, in our model the pH was kept constant at
7.4 due to the use of a buffer. This metabolic inhibition resulted in an immediate 
time-dependent depletion of intracellular CrP and ATP, reaching a maximum 
after 30 minutes SI. Although thirty minutes reperfusion caused a significant 
elevation in CrP, the cells failed to significantly increase ATP levels. Failure of 
ATP levels to increase significantly during reperfusion has been observed by 
several other workers; Edoute and co-workers (1983) attributed this failure to 
depletion of adenine nucleotides and delayed resynthesis in the isolated 
perfused rat heart model. Despite this severe ischaemic insult induced in the 
present study, there was no significant loss of detached cells in the medium 
(supernatant).
The use of isolated cardiac myocytes subjected to simulated ischaemia and 
reperfusion has some obvious advantages, but also some disadvantages 
compared to in vivo ischaemia. For example, the use of 2-deoxy-D-glucose 
during simulated ischaemia will inhibit glycolysis by trapping phosphate as 2- 
c/eoxy-D-glucose-phosphate, which is an inhibitor of glycolysis. The 2-deoxy-D- 
glucose-phosphate is retained within the cell during the simulated reperfusion 
phase of the protocol, and will continue to inhibit glycolysis for a period of time, 
until the 2-deoxy-D-glucose-phosphate is broken down. There is also some 
evidence that glycolytically-derived ATP may be preferentially used as a 
substrate for energy-requiring membrane ion transporters, which would impair 
the myocytes treated with 2-deoxy-D-glucose more than myocytes in the isolated 
heart model. It is also possible that inhibition of glycolysis during the reperfusion 
phase hampers recovery in this particular model, but this remains to be 
established.
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Furthermore, it must be noted that heterogeneity of cell injury has an impact in 
models of ischaemia/reperfusion. It could be that a decrease in MTT reduction is 
due to a generalized decrease in mitochondrial function or it could be due to a 
small percentage of myocytes with no mitochondrial function, and others with 
normal or only slightly reduced function. Similarly, an increase in caspase 
activation could be due to a small amount of caspase activation in all myocytes, 
or to a large amount of caspase activation in a few myocytes. The problem of 
heterogeneity of cell injury is inherent to cell models and should be borne in mind 
in the interpretation of results.
4.3.2 Apoptosis
The stepwise depletion in high-energy phosphates observed in this model of SI 
prompted us to sequentially evaluate apoptosis and cell viability and to analyse 
the activation patterns of the MAPKs and the anti-apoptotic kinase, PKB/Akt. 
Hypoxic injury and intracellular ATP depletion have been shown to induce 
apoptosis in cultured cardiac myocytes (Shiraishi et al., 2001). Indeed, in our 
model, ischaemic injury and partial ATP depletion also resulted in the cleavage of 
PARP to its proteolyzed products, a phenomenon well known to result from 
caspase-3 activation. Interestingly, both caspase-3 activation and PARP 
cleavage, albeit low, are evident throughout the SI period. We have 
demonstrated a significant and specific increase in caspase-3 activation as well 
as PARP cleavage after 15 minutes of SI in the presence of a 53% reduction in 
ATP (fig 4.1a & c). Apparently, there is enough residual ATP to maintain ongoing 
apoptosis which is in accordance with results obtained by Shiraishi and co­
workers (2001) who reported that intracellular energy production is required to 
fuel the apoptotic machinery in ischaemically injured myocytes. The significant 
increase in DNA fragmentation and chromatin condensation after 30 minutes 
reperfusion also coincides with a significant rise in CrP (fig.1A), an indicator of 
resumption of mitochondrial function.
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It is of specific interest that in our model, Sl-induced caspase-3 activation and 
PARP cleavage, although associated with decreased mitochondrial viability (as 
indicated by the MTT assay), preceded any of the visible morphological changes 
that signify the final stage of apoptosis (see fig. 1C & D). It is only in response to 
30 minutes reperfusion that the nuclear condensation and fragmentation 
characteristic of apoptosis can be seen. These results suggest that although the 
apoptotic cascade was activated early during SI (5-15 minutes), the final 
execution phase (as indicated by Hoechst staining) was initiated only after 
reperfusion. The fact that the decrease in viability during SI was not 
accompanied by an increase in nuclear condensation raises an important point, 
namely that the MTT assay indicates cells with intact membranes but with 
compromised mitochondria. However, at this point the mitochondria may possibly 
still “recover” upon reperfusion, whereas nuclear condensation is irreversible. 
This may also be an explanation for the fact that there is an increase in cell 
viability during reperfusion (fig. 1B) -  the “recovery of dead cells” reflects 
mitochondria, which are still able to recover after SI.
4.3.3 MAPKs
We characterized the phosphorylation pattern of the three major MAPK subfamily 
members during Sl/R and found that in response to SI, p38 is activated in a 
biphasic pattern. Of interest is the observation that p38 was the only MAPK 
activated significantly during SI, during which time both caspase-3 and PARP 
cleavage were significantly increased, suggesting a possible causal relationship 
during this phase of the protocol. The biphasic pattern of p38 activation during 
simulated ischaemia is in agreement with observations made by Mackay and 
Mochly-Rosen in cultured neonatal cardiac myocytes (2000).
On the other hand, JNK was phosphorylated in response to 5 minutes 
reperfusion only and not during SI alone (fig. 2C). This is in contrast with the 
results obtained by Yue and co-workers (2000) who reported that
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cardiomyocytes, exposed to 1% 0 2, showed a transient activation of JNK within 5 
minutes of hypoxia. These discrepancies may be due to differences in the model 
of ischaemia used. The ERK pathway, suggested to be required for survival 
signalling in response to hypoxia/reoxygenation in cardiomyocytes (Abe et al., 
2000), was also significantly activated during reperfusion only (fig. 2 C).
The significance of activation of the MAPKs in SI and SI/R-induced apoptosis 
was further dissected by the use of appropriate inhibitors. PD98059 (an ERK 
pathway inhibitor) significantly reduced ERK44/ERK42 activation during Sl/R, 
while not affecting p38 and JNK phosphorylation significantly. However, 
treatment with PD98059 had no significant effect on cell viability or apoptosis (fig.
6 A, 7A & 8A). These observations were contrary to expectations since ERK 
activation is known to be anti-apoptotic. Among the substrates of ERK, p90 
ribosomal S6 kinase (p90RSK) is a ubiquitous and versatile mediator of ERK 
signal transduction (Frodin & Gammeltoft, 1999) and one of its functions include 
the phosphorylation of the pro-apoptotic protein BAD at serine 112, which 
specifically suppresses BAD-mediated apoptosis (Bonni et al., 1999). Yue and 
co-workers (2000) reported that PD98059 (50 |iM) significantly enhanced the 
activities of both p38 and JNK during hypoxia/reoxygenation, along with an 
increase in the number of apoptotic myocytes. These discrepancies mftjht be 
attributed to the hypoxic model used or to the differences in inhibitor 
concentration (10 |^ M vs 50 (a.M) used. Although not significant, PD98059 also 
caused an inhibition of p38 in our study during Sl/R, which might indicate a 
possible interplay between the MAPK signalling pathways.
SB203580 (an inhibitor of p38) at 1 nM inhibited activation of this kinase during 
Sl/R and reduced caspase-3 and PARP to almost control levels. This inhibition 
of p38 activation was also associated with a significant improvement in cell 
viability (fig. 6A) and reduction in the percentage of apoptotic cells (as indicated 
by Hoechst staining) during Sl/R (fig. 8A). These results are consistent with those 
obtained by Yue and co-workers (2000) who showed that SB203580 rescued
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63% myocytes from apoptosis. Despite some results to the contrary 
(Weinbrenner et al., 1997; Schulz et al., 2002), there is compelling evidence that 
inhibition of p38 during ischaemia is protective: SB203580 administered before 
sustained ischaemia decreased infarct size in rat hearts (Minamino et al., 1999, 
Nakano et al., 2000), while it improves morphology and viability in isolated adult 
cardiomyocytes (Marais et al., 2001). Furthermore, Schneider and co-workers 
(2001) also showed by that the inhibition of p38 during sustained ischaemia is 
protective in the isolated rat heart model. The association between a decrease in 
p38 activation and a reduction in apoptosis has also been demonstrated in a 
fibroblast cell line (Han et al., 2001).
SP600125 at a concentration of 10 nM inhibited JNK (both isoforms) 
phosphorylation (fig. 4A) and significantly increased caspase-3 activation (fig. 
7A) as well as the apoptotic index during reperfusion (fig. 8A). These results 
suggest that activation of JNK phosphorylation promotes survival of neonatal 
cardiomyocytes during reperfusion. Although several other groups correlated 
increased JNK activity with apoptosis (He et al., 1999; Hreniuk et al., 2001; 
Vaishnav et al., 2003) our results are in agreement with the recent study 
published by Dougherty and co-workers (2002) who reported for the first time 
that JNK activation in neonatal cardiac myocytes subjected to chronic hypoxia 
correlated with myocyte survival. These observations were also substantiated by 
a study on embryonic stem cell derived cardiac myocytes lacking MEKK1, and 
with significant suppressed JNK activity, which showed sensitization to H2O2 
treatment (Minamino et al., 1999). Interestingly, Dougherty and co-workers also 
reported that the activation of JNK during reperfusion is largely independent of 
p38 (2002).
The targets that determine the effects of JNK and p38 on cell survival or 
apoptosis are still not clear in cardiomyocytes. It has been shown that p38 can 
translocate to the mitochondria and phosphorylate Bcl-2 on Ser-87 and Thr-56 
which causes cytochrome c release, subsequent activation of downstream
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caspases and enhanced apoptosis in B lymphocytes (Torcia et al., 2001). 
Fiordaliso and co-workers also showed that hyperglycemia can lead to the 
phosphorylation of p53 at Ser 390 via p38 and this was paralleled by an increase 
in Bax-mediated myocyte cell death (2001). However, it is not yet known whether 
p38 targets mitochondria in cardiac myocytes subjected to ischaemia and 
reperfusion.
4.3.4 PKB/Akt
Several events occur simultaneously during the first 5 minutes of reperfusion, 
including a decrease in caspase-3 activation and PARP cleavage (fig. 1C), 
significant stimulation of all the MAPKs as well as PKB/Akt (fig. 2A-C and 3A,B). 
However, after 15 minutes of reperfusion, caspase-3 activation and PARP 
cleavage were significantly elevated which coincided with a marked reduction in 
PKB/Akt phosphorylation (fig 4.1c & 4.3). These observations are in agreement 
with the suggested pivotal role of PKB/Akt activation in cell survival. Although 
transient, PKB/Akt phosphorylation appears to be important in preserving cell 
viability in our model, since inhibition of this phenomenon with wortmannin led to 
a significant depression in the percentage viable cells and increased PARP 
cleavage. PKB/Akt phosphorylation also appears to be more important than ERK 
phosphorylation during reperfusion since inhibition of the latter with PD98059 
showed no effect on cell viability or apoptosis.
Full activation of PKB/Akt requires phosphorylation on two regulatory sites, Thr308 
in the activation loop and Ser473 in the hydrophobic domain. However, the 
contribution of each site towards PKB/Akt activation is not equal, while 
phosphorylation on Thr308 alone is able to increase PKB/Akt activity, 
phosphorylation on Ser473 alone does not significantly stimulate the kinase 
(Alessi et al., 1996). Furthermore, Hill and co-workers also demonstrated that 
pretreatment with 1 jiM staurosporine abolished insulin-stimulated PKB activation 
without affecting Ser473 phosphorylation (Hill et al., 2001). Therefore, we
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examined both phosphorylation sites on PKB in our cell model. Interestingly, 
wortmannin (PI3-kinase inhibitor) significantly inhibited Thr308 but not Ser473 
phosphorylation during reperfusion, indicating that part of PKB/Akt activation is 
independent of PI3-kinase in our cell model. PKB is activated downstream of PI3- 
kinase by the phosphoinositide-dependent protein kinases PDK-1 and PDK-2 
(Anderson et al., 1998). PKB in turn phosphorylates a number of downstream 
targets relevant to cell survival functions, including the pro-apoptotic Bcl-2 family 
member BAD (del Peso et al., 1997). Phosphorylation of BAD on Ser136 by PKB 
inhibits its pro-apoptotic function, thus promoting cell survival (Datta et al., 1997). 
Interestingly, BAD is not only a substrate for PKB, but is also phosphorylated by 
the MAPK kinase MEK (Punn et al., 2000), linking the classical Ras-MAPK 
pathway to cell survival. Another interesting observation is that PKB inhibition by 
wortmannin caused a significant increase in PARP cleavage and reduction in cell 
viability, without a significant effect on either caspase activation or the apoptotic 
index at 30 minutes reperfusion. This suggests that reperfusion-induced 
apoptosis occurs partially independent of PI3-kinase. However, it is possible that 
an increase in the apoptotic index may be seen if the reperfusion period is 
extended.
4.4 Summary
We have demonstrated that SI and reperfusion in neonatal cardiomyocytes is 
characterized by apoptosis, particularly during reperfusion. Apoptosis is most 
likely regulated by interplay between the concomitant changes in the activation 
pattern of p38, JNK, ERK and PKB. This is substantiated by p38 inhibition, which 
is associated with a significant improvement of cell viability and attenuation of 
apoptosis. On the other hand, JNK inhibition caused an increase in caspase-3 
activation and apoptosis during Sl/R, while PKB inhibition significantly increased 
PARP cleavage and reduced cell viability. However, ERK inhibition failed to 
affect apoptosis during Sl/R in this particular model. These results indicate that 
p38 is pro-apoptotic during and following SI/R-induced injury, whereas JNK
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activation limits SI/R-induced damage through the inhibition of caspase-3 
activation. We have also demonstrated that two distinct apoptotic-regulatory 
proteins are activated during Sl/R. Whereas the monophasic activation of JNK 
(within 5 minutes of reperfusion) seems to induce protection against subsequent 
apoptotic events, the biphasic and sustained activation of p38 observed from the 
onset of SI and throughout reperfusion, strongly induced apoptotic events, 
thereby overriding the beneficial anti-apoptotic properties of concomitant JNK 
activation.
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CHAPTER 5 RESULTS AND DISCUSSION: Long-chain polyunsaturated
fatty acids (PUFAs) attenuate ischaemia/reperfusion- 
induced apoptosis in neonatal cardiomyocytes via a 
mitogen activated protein kinase (MAPK) dependent 
pathway.
5.1 Introduction
Coronary heart disease (CHD) remains one of the leading causes of death in all 
Western industrialised countries. Although epidemiology and human intervention 
trials consistently show an inverse relationship between dietary omega-3 fatty 
acid consumption and mortality from heart disease (Burr et al., 1989; Siscovick et 
al., 1995; Daviglus et al., 1997; Pepe & McLennan, 2002), the mechanism of the 
beneficial actions of these fatty acids remains to be elucidated.
Long-chain polyunsaturated fatty acids (PUFAs), taken up by the cell from the 
extracellular environment or released from cellular triglycerides or membrane 
phospholipids play an important role in various biological processes in cardiac 
muscle cells. Not only do they serve as fuel or constituents of membrane 
phospholipids, but they are also involved in cellular signal transduction. In this 
regard, fatty acids can act either as second messengers or reversible modulators 
to amplify, attenuate or deviate a signal at a precise intracellular location (Sumida 
et al., 1993).
As stated previously, the mitogen-activated protein kinases (MAPKs) are a family 
of serine-threonine kinases that are activated in response to a variety of 
extracellular stimuli, (Robinson & Cobb, 1997; Ip & Davis 1998) including during 
ischaemia and reperfusion of the heart (Bogoyevitch et al., 1996; Knight & 
Buxton, 1996). The results presented in chapter 4, suggested that activation of 
the MAPKs, particularly p38, during simulated ischaemia and reperfusion of
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neonatal cardiomyocytes, plays a pivotal role in the development of apoptosis in 
this particular model. Manipulation of the activation state of these kinases by 
phosphatases may present a possible site of action for the beneficial effects of 
PUFAs. It is known that a family of dual-specificity phosphatases becomes 
transcriptionally induced, leading to dephosphorylation and inactivation of 
specific MAPKs within 30-60 minutes (Haneda et al., 1999). Currently «9 dual­
specificity phosphatase family members have been described, each of which has 
a slightly different substrate specificity, tissue distribution, subcellular localization, 
or inducible expression profile (Haneda et al., 1999). MKP-1 (mitogen-activated 
protein kinase phosphatase-1) is an important member of this family, which 
regulates inactivation of p38, JNK and ERK (Chu et al., 1996; Franklin & Kraft, 
1997; Li et al., 1999). However, very little or any information is available 
regarding the effects of long-chain PUFAs on phosphatases in the heart.
Another potential target of long-chain PUFAs might be the serine/threonine 
kinase PKB/Akt. PKB/Akt contains a pleckstrin homology (PH) domain that is part 
of a slightly larger portion in the NH2 terminus, called the Akt homology domain. 
The phosphoinositide 3-kinase (PI3-K) product phosphatidylinositol-3,4- 
bisphosphate binds in vitro directly to the PH domain and increases enzyme 
activity (Downward, 1998). PKB/Akt has been shown to be activated by factors 
that stimulate PI3-K, including thrombin, platelet-derived growth factor, and 
insulin (Downward, 1998). There is also increasing evidence that the PKB/Akt 
pathway participates in tissue salvage during ischaemia/reperfusion-induced 
injury (Brar et al., 2002; Andreucci et al., 2003).
Only a few culture-based studies have investigated the effect of EPA or ARA on 
cardiac myocytes. Chen and co-workers (2003) have recently showed that EPA 
inhibits hypoxia/reoxygenation-induced injury by attenuating upregulation of 
MMP-1 in adult rat cardiac myocytes, while Mackay and Mochly-Rosen (2001) 
demonstrated that ARA protects neonatal rat cardiac myocytes from ischaemic 
injury through activation of PKCs. As far as we know, no evidence exists for an
Stellenbosch University http://scholar.sun.ac.za/
99
interaction between EPA or ARA and the activation/inhibition of the MAPKs and 
PKB/Akt in neonatal rat cardiomyocytes during simulated ischaemia (SI) and 
reperfusion. Therefore, in order to assess the mechanisms of protection of long- 
chain polyunsaturated fatty acids (PUFAs) in injured/apoptotic heart cells, we 
treated neonatal cardiomyocytes with EPA and ARA prior to and after simulated 
ischaemia and determined their effects on cell viability, apoptosis and the 
activation of the MAPKs and PKB/Akt.
5.2 Results
5.2.1 Fatty acid composition (Table 5.1)
To assess whether in our particular model, fatty acids are incorporated into 
membrane phospholipids (PL), the fatty acid composition of the phospholipids of 
the myocytes were determined after a 60 minute incubation period. Results are 
presented in table 5.1. The cardiomyocytes grown in n-3 culture medium 
incorporated n-3 fatty acids in their PL which resulted in a phospholipid 
composition displaying high levels in EPA (p<0.001) and C22:5n-3 (p<0.01). 
Conversely, the cardiomyocytes grown in n-6 enriched culture medium were 
characterised by high levels of ARA (p<0.001) and C22:4n-6 (p<0.01) in their PL. 
Interestingly, there was a significant decrease in oleic acid (C18:1n-9) when 
myocytes were incubated with either ARA or EPA (p<0.001).
5.2.2 The effect of EPA, ARA and indomethacin on cell viability during 
simulated ischaemia (SI) and reperfusion (Figures 5.1 A & B)
To establish whether EPA and ARA induced protection in our particular cell 
model, the MTT cell viability assay was used. In this study, fatty acids were 
bound to albumin at a ratio of 3.3:1 [albumin has three high-affinity binding sites 
for fatty acids and another three or four lower affinity binding sites (Cistola et al., 
1987)].
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Table 5.1. Fatty acid composition of the total phospholipids of control 
cells, ARA-treated cells and EPA-treated cells
Fattv acid Control ARA cells EPA cells ANOVA
C16:00 13.10±0.57 12.11+0.73 14.2711.63 ns
C18:00 14.0±0.31 13.6810.36 11.78+0.87 ns
C18:1n-9 19.75±1.62 *12.7411.84 *7.62+0.53 p<0.001
C18:2n-6 3.29±0.22 2.7910.16 2.34+0.20 ns
C20:4n-6 10.58±0.43 *18.8611.18 7.9210.91 p<0.001
C20:5n-3 0.8510.14 0.5810.10 *8.1210.72 p<0.001
C22:4n-6 1.83±0.15 *3.39+0.40 1.19+0.17 p<0.01
C22:5n-3 2.28±0.24 2.3610.39 *5.9110.76 p<0.01
C22:6n-3 3.28+0.19 2.89+0.53 0.8110.28 ns
Table 5.1: Fatty acid composition of the phospholipids of rat cardiomyocytes incubated under 
normoxic conditions for 1 hour in ARA- and EPA (20 nM for both fatty acids) enriched media 
respectively, in comparison with the phospholipids of cardiomyocytes incubated in standard 
DMEM medium. Data are expressed as percentage of total fatty acids. Results are 
expressed as means ± S.E.M. for six independent experiments (n=6). *p<0.001 vs control.
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Figures 5.1 A & B: The effect of EP A  (20 nM), ARA (20 nM) and Indomethacin (10 ^M) 
on cell viability during SI and reperfusion. Cell viability was measured during SI 
(simulated ischaemia) and reperfusion, using the MTT cell viability assay. Myocytes 
were exposed to simulated ischaemia (KCN and 2-deoxy-D-glucose) for 60 minutes 
followed by 30 minutes reperfusion. Fatty acids were added to the cells for 60 minutes 
before the onset of SI as well as during reperfusion. Indomethacin was added to the 
cells for 30 minutes prior to the addition of the fatty acids as well as during fatty acid 
incubation. Fig 5.1 A: control SI vs control normoxia (#p<0.001); control Sl/R vs control 
nomnoxia ($p<0.001); Sl/R + EP A  and Sl/R + ARA vs control Sl/R (*p<0.001). Fig 5.1 B: 
Indomethacin, EPA+lndomethacin and ARA+lndomethacin vs control normoxia 
(**p<0.001); Indomethacin, EP A  and ARA vs control Sl/R. Results are expressed as  
means ± S.E .M . for six independent experiments (n=6).
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Neither EPA nor ARA had an effect on cell viability during SI in our cell model. 
However, both fatty acids significantly improved cell viability during Sl/R [64.13 ± 
1.66% to 85.09 ± 3.07% (p<0.001) for EPA and to 93.7 ± 0.33% (p<0.001) for 
ARA]. To ensure that eicosanoid biosynthesis was not involved in the fatty acid 
induced-protection during Sl/R, we pre-treated the cells with a specific 
cyclooxygenase-inhibitor, indomethacin (10 (iM). Indomethacin was added to the 
cells for 30 minutes prior to the fatty acids incubation period as well as during 
reoxygenation. Interestingly, indomethacin alone significantly reduced cell 
viability under normoxic conditions, both in the presence and absence of the fatty 
acids, while having no significant effect on fatty acid-induced protection during 
Sl/R.
5.2.3 The effect of EPA and ARA on caspase-3 activation, PARP cleavage 
and the apoptotic index during simulated ischaemia and reperfusion 
(Figures 5.2 A, B and C)
As was also shown in chapter 4, exposure of neonatal cardiomyocytes to 60’SI 
followed by 30’reperfusion, caused a significant increase in caspase-3 activation 
and PARP cleavage during Sl/R (p<0.001 for both). EPA and ARA significantly 
attenuated caspase-3 activation during Sl/R (p<0.01 for both). Both fatty acids 
also significantly inhibited PARP-cleavage during SI [11.97 ± 0.40 fold to 4.66 ± 
1.68 fold (p<0.001) for EPA and to 4.76 ± 0.34 fold (p<0.001) for ARA]. Cardiac 
myocytes, stained with Hoechst 33342 and assessed by fluorescence 
microscopy, showed condensed chromatin and fragmented nuclei after exposure 
to SI and reperfusion. During normoxia (with and without the fatty acids), 4.6% ± 
0.50% cells showed spontaneous cell death (basal). The fatty acids had no effect 
on the percentage of apoptotic cells during exposure to SI. However, the 
significant increase in apoptotic cells (p<0.001) observed after 60 minutes SI 
followed by 30 minutes reperfusion was markedly reduced by EPA and ARA 
(p<0.001 for both EPA and ARA vs Sl/R). Thus, EPA and ARA were equally 
effective in protecting the neonatal cardiomyocytes from apoptosis.
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Figure 5.2 A, B: The effect of EP A  and ARA on caspase-3 activation and PA RP cleavage 
during SI/Reperfusion. Myocytes were exposed to simulated ischaemia (KCN and 2-deoxy- 
D-glucose) for 60 minutes followed by 30 minutes reperfusion. Sam ples were analysed by 
Western blotting with antibodies recognizing cleaved PARP and caspase-3. Results are 
expressed as means ± S.E.M . for three independent experiments (n=3). Caspase 3: SI vs 
control normoxia (*p<0.05); Sl/R vs control normoxia (#p<0.001); Sl/R + EP A  and Sl/R +ARA 
vs control Sl/R ($p<0.01). PARP: SI vs control normoxia (*p<0.05); Sl/R vs control normoxia 
(*p<0.001); Sl/R + EP A  and Sl/R + ARA vs control Sl/R ($p<0.001).
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Figure 5.2 C: The effect of EP A  and ARA on SI/Reperfusion-induced apoptosis in 
cardiac myocytes. Myocytes were exposed to simulated ischaemia (KCN and 2- 
deoxy-D-glucose) for 60 minutes followed by 30 minutes reperfusion. To quantify 
apoptotic myocytes, cell monolayers were fixed and stained with Hoechst 33342. The 
morphological features of apoptosis (cell shrinkage, chromatin condensation) were 
monitored by fluorescence microscopy. At least 400 cells from three randomly 
selected fields per dish were counted and each treatment was performed in triplicate. 
Results are expressed as means ± S.E .M . for three independent experiments (n=3). 
Sl/R + EP A  and Sl/R + ARA vs control Sl/R (*p<0.001).
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5.2.4 The effect of EPA and ARA on the phosphorylation of ERK, p38 and 
JNK in cardiomyocytes subjected to simulated ischaemia and 
reperfusion (Figures 5.3 A, B and C)
After having established that both EPA and ARA increased cell viability and 
reduced apoptosis during exposure of cardiomyocytes to simulated ischaemia 
and reperfusion, the aim of the next series of experiments was to establish the 
role of the MAPKs in their protective action. Phosphorylation of ERK 1/2 
(p42/p44-MAPK), p38 and JNK (p46/p54-MAPK) was determined by Western 
blotting using phospho-specific antibodies. As shown before (chapter 4) SI and 
reperfusion significantly increased ERK and p38 phosphorylation, while JNK was 
significantly phosphorylated only during reperfusion. As shown in figure 5.3 A, 
EPA and ARA caused a significant increase in phosphorylation of ERK p42 
(p<0.01 and p<0.05 for EPA and ARA respectively) and ERK p44 (p<0.01 and 
p<0.05 for EPA and ARA respectively) during Sl/R. Both fatty acids attenuated 
p38 phosphorylation during both SI (p<0.001 and p<0.01 for EPA and ARA 
respectively) and reperfusion (p<0.05 for both EPA and ARA). JNK was 
phosphorylated only during reperfusion and phosphorylation of both JNK p46 and 
JNK p54 remained unaffected by EPA and ARA during this period. As observed 
previously, exposure of the cells to Sl/R, had no effect on the total amounts of 
the three kinases investigated.
5.2.5 PKC, an upstream mediator in ARA-induced MAPK phosphorylation 
(Figure 5.4 A, B)
To establish the possible contribution of PKC to the effects of polyunsaturated 
fatty acids on MAPK phosphorylation, chelerythrine, an inhibitor of PKC catalytic 
activity, was used. Chelerythrine (10 (xM) was added 30 minutes prior to and 
during EPA and ARA treatment, before and after SI. Interestingly, chelerythrine 
on its own, significantly decreased cell viability during Sl/R (p<0.01), but had no
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Figure 5.3 A, B and C: The effect of EP A  and ARA on p38, E R K  and JN K phosphorylation in 
cardiomyocytes subjected to simulated ischaemia and reperfusion. Myocytes were exposed 
to simulated ischaemia (KCN and 2-deoxy-D-glucose) for 60 minutes followed by 30 minutes 
reperfusion. Samples were analysed by Western blotting with phospho-specific antibodies 
recognizing dual-phosphorylated MAPKs. Results are expressed as means ± S.E.M . for four 
to six independent experiments (n=4-6). ERK 42: SI and Sl/R vs control normoxia (*p<0.001); 
Sl/R + EP A  vs control Sl/R (&p<0.01); Sl/R + ARA vs control Sl/R (3>p<0.05). ERK 44: 
*p<0.001 vs control normoxia; #p<0.001 vs control normoxia; $p<0.001 vs control Sl/R. p38: 
SI vs control normoxia (*p<0.001); Sl/R vs control normoxia (&p<0.05); SI + EP A  vs control SI 
(**p<0.001); SI + ARA vs control SI (*“ p<0.01); Sl/R + EP A  and Sl/R + ARA vs control Sl/R  
(#p<0.05). JNK 46: Sl/R vs control normoxia (&p<0.001). JNK 54: Sl/R vs control normoxia 
(&p<0.001).
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Figure 5.4 A: The effect of PK C inhibition on cell viability using the MTT assay during 
simulated ischaemia and reperfusion. Chelerythrine (10 |iM) was added to the cells for 30 
minutes prior to SI as well as during reperfusion. Results are expressed as means ± S.E.M . 
for three independent experiments (n=3). Sl/R + chelerythrine vs control Sl/R (#p<0.01); EPA  
+ chelerythrine and ARA + chelerythrine vs control normoxia (*p<0.001); Sl/R + EP A  and Sl/R  
+ ARA vs control Sl/R (**p<0.001); Sl/R + EP A  + chelerythrine and Sl/R +ARA + chelerythrine 
vs Sl/R + EP A  and Sl/R +ARA respectively ($p<0.001).
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Figure 5.4 B: Effect of PK C inhibition on MAPK phosphorylation during simulated ischaemia 
and reperfusion. Simulated ischaemia and reperfusion was carried out either alone or 
following treatment with chelerythrine (10 nM) or/and ARA (20 nM). Results are expressed as 
means ± S.E.M . for three independent experiments (n=3). Sl/R + chelerythrine + ARA vs Sl/R  
+ ARA (*p<0.001); Sl/R + ARA vs control Sl/R (**p<0.001).
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effect during normoxia. Chelerythrine significantly attenuated EPA- and ARA- 
induced increase in cell viability (p<0.001) during normoxia as well as during Sl/R 
as shown in figure 5.4 A. Although chelerythrine significantly inhibited ARA- 
induced ERK phosphorylation (p<0.001 for both ERK-p44 and ERK-p42) (fig 5.4
B), neither p38, nor JNK phosphorylation was affected by PKC inhibition. Similar 
results were also obtained with EPA (data not shown).
5.2.6 Phosphatases as mediators in ARA-induced MAPK inhibition (Figure
5.5 A, B, C and D)
To determine whether phosphatases were involved in EPA and ARA induced 
inhibition of p38, we made use of tyrosine- (orthovanadate) and serine-threonine 
phosphatase inhibitors (okadaic acid). Vanadate (100jxM) did not alter cell 
viability under normoxia, although it significantly improved viability when ARA 
was added (p<0.01). Vanadate significantly inhibited ARA-induced protection 
during Sl/R [84.67% ± 8.51 % to 57% ± 4.58% (p<0.01)] as shown in figure 5.5 A. 
Okadaic acid did not have any significant effects under normoxia or during Sl/R. 
As expected, vanadate significantly increased p38 (p<0.001) as well as JNK 
phosphorylation (data not shown) during normoxia. Vanadate also caused a 
significant increase in p38 phosphorylation when compared with ARA-induced 
inhibition of p38 (fig 5.5 B) during Sl/R [1.49 ± 0.15 fold to 2.72 ± 0.14 fold 
(p<0.05)], but had no significant effect on JNK phosphorylation (data not shown). 
Both EPA and ARA significantly increased MKP-1 induction during Sl/R (fig 5.5
C). Interestingly, vanadate significantly inhibited ARA-induced MKP-1 induction 
(fig 5.5 D) during Sl/R [3.75 ± 0.15 fold to 2.5 ± 0.2 fold (p<0.05)], but had no 
effect under normoxic conditions.
5.2.7 In vitro dephosphorylation of p38 (Figure 5.6)
To determine whether MKP-1 upregulation was responsible for attenuation of 
p38 phosphorylation, we co-incubated the samples where the kinase was
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Figure 5.5 A: Effect of okadaic acid and vanadate on cell viability using the MTT assay  
during SI/Reperfusion. Okadaic acid (1 |iM), an inhibitor of types 1 and 2A serine/threonine 
phosphatases or orthovanadate (100 jiM), a specific inhibitor of tyrosine phosphatases was 
added to the cells 30 minutes prior to and during fatty acid treatment. Inhibitors were also 
present during 30 minutes of reperfusion. Results are expressed as means ± S.E.M . for three 
independent experiments (n=3). ARA + vanadate vs control normoxia (*p<0.01); Sl/R + ARA  
vs control Sl/R (**p<0.01); Sl/R + ARA + vanadate vs Sl/R + ARA (#p<0.01).
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Figure 5.5 B: Effect of vanadate on p38 phosphorylation during Sl/R. Simulated ischaemia 
and reperfusion was carried out either alone or following treatment with vanadate and/or ARA. 
Orthovanadate (100 nM), a specific inhibitor of tyrosine phosphatases were added to the cells 
30 minutes prior to and during fatty acid treatment. Inhibitor was also present during 30 
minutes of reperfusion. Results are expressed as means ± S.E.M . for three independent 
experiments (n=3). vanadate vs control normoxia (*p<0.001); Sl/R + ARA vs control Sl/R  
(**p<0.001); Sl/R + ARA + vanadate vs Sl/R + ARA (#p<0.05).
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Figure 5.5 C  & D: Effect of ARA and vanadate on MKP-1 induction during Sl/R. Simulated 
ischaemia and reperfusion was carried out either alone or following treatment with vanadate 
and/or ARA or EPA . Orthovanadate (100 (xM), a specific inhibitor of tyrosine phosphatases 
were added to the cells 30 minutes prior to and during fatty acid treatment. Inhibitor was also 
present during 30 minutes of reperfusion. Results are expressed as m eans ± S.E.M . for three 
independent experiments (n=3). Sl/R + A RA and Sl/R + EP A  vs control Sl/R (*p<0.001); Sl/R  
+ ARA + vanadate vs Sl/R + ARA (#p<0.05); ARA vs control normoxia ($p<0.01).
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Figure 5.6: In vitro dephosphorylation of p38 during Sl/R. Myocytes were either treated with 
fatty acids (20 |iM) or exposed to 60 minutes SI followed by 30 minutes of reperfusion. A: 
Fatty acid controls without Sl/R. B : Fatty acid treated lysates were added to Sl/R lysates. C: 
Fatty acid lysates were incubated with Sl/R lysates for 45 minutes at 30°C without the 
phosphatase inhibitor, vanadate. D: Fatty acid lysates were incubated with Sl/R lysates for 45 
minutes at 30°C with the phosphatase inhibitor, vanadate. Results are expressed as m eans ± 
S.E.M . for three independent experiments (n=3). ARA + Sl/R and EP A  + Sl/R vs control 
(*p<0.01); ARA + Sl/R (inc.) + vanadate and EP A  + Sl/R (inc.) + vanadate vs ARA + Sl/R  
(inc.) and EP A  + Sl/R (inc.) (^ < 0 .01) respectively.
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maximally phosphorylated (Sl/R) with the sample where the phosphatase was 
maximally induced (ARA + Sl/R). There was a significant decrease in p38 
phosphorylation when the Sl/R + ARA sample (with 45 minutes incubation) was 
compared with the control sample (not incubated) [6.24 ± 0.41 fold to 1.9 ± 0.05 
fold (p<0.01). When vanadate was added during incubation, the effect of the 
phosphatase on p38 phosphorylation, was abrogated [1.9 ± 0.05 fold to 6.48 ±
1.1 fold (p<0.01)]. Similar results were obtained when EPA was used.
5.2.8 The effect of ARA and PI3-K inhibition on PKB/Akt phosphorylation 
(Figures 5.7 A & B)
To determine whether the PKB/Akt pathway participates in ARA induced 
protection, wortmannin, an inhibitor of PI 3-K, was used. Phosphorylation of 
PKB/Akt was determined by Western blotting using antibodies recognising either 
phospho- Ser473 or Thr308. Wortmannin (100nM) was added only for 30 minutes 
before fatty acid supplementation and not during reperfusion. Wortmannin 
significantly inhibited PKB/Akt Thr308 phosphorylation [0.16 ± 0.03 fold (p<0.01)] 
during normoxia, as well as during Sl/R. Interestingly, wortmannin was unable to 
inhibit PKB/Akt Ser473 phosphorylation significantly. ARA caused a significant 
decrease in PKB/Akt Ser473 phosphorylation [2.36 ± 0.22 fold to 0.96 ±0.12 fold 
(p<0.001)] during Sl/R, but Thr308 phosphorylation remained unaffected during 
this period. However, wortmannin significantly inhibited Thr308 phosphorylation in 
ARA-treated cells [1.74 ± 0.12 fold to 0.84 ± 0.06 fold (p<0.001)].
5.2.9 The effect of ARA and PI3-K inhibition on cell viability (Figure 5.7 C)
In view of the fact that ARA caused a significant inhibition of PKB/Akt Ser473 
phosphorylation during Sl/R, the effect of ARA and wortmannin was measured 
on cell viability. Wortmannin caused a significant decrease in cell viability in the 
Sl/R control group (p<0.05) as well as in the ARA-treated group [92 ± 2.04 % to 
71 ±2.34 % (p<0.001)].
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Figure 5.7 A & B: The effect of ARA on PKB/Akt phosphorylation in cardiomyocytes 
subjected to simulated ischaemia and reperfusion. Myocytes were exposed to simulated 
ischaemia (KCN and 2-deoxy-D-glucose) for 60 minutes followed by 30 minutes reperfusion. 
Wortmannin (100 nM) was added to the cells for 30 minutes prior to SI. Samples were 
analysed by Western blotting with phospho-specific antibodies recognizing phosphorylated 
Ser473 and Thr308 of PKB/Akt. Results are expressed as means ± S .E .M . for four to three 
independent experiments (n=3). Ser473: Sl/R vs control normoxia (#p<0.001); Sl/R + ARA vs 
Sl/R (*p<0.001). Thr308: wortmannin vs control normoxia ($p<0.01); Sl/R vs control normoxia 
(#p<0.05); Sl/R + wortmannin vs control Sl/R (&p<0.001); Sl/R + ARA + wortmannin vs Sl/R + 
ARA (*p<0.001).
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Figure 5.7 C : The effect of ARA and PI3-K inhibition on cell viability using the MTT assay  
during simulated ischaemia and reperfusion. Myocytes were exposed to simulated ischaemia 
(KCN and 2-deoxy-D-glucose) for 60 minutes followed by 30 minutes reperfusion. 
Wortmannin (100 nM) was added to the cells for 30 minutes prior to SI. Results are 
expressed as means ± S.E.M . for three independent experiments (n=3). Sl/R + wortmannin 
vs control Sl/R (#p<0.05); Sl/R vs control normoxia (*p<0.001); Sl/R + ARA vs control Sl/R  
($p O .001 ); Sl/R + ARA + wortmannin vs Sl/R + ARA (&p<0.001).
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5.2.10 The effect of ARA and PI3-K inhibition on caspase-3 activation and 
PARP cleavage during Sl/R (Figure 5.7 D)
As it was shown in the previous chapter, PI 3-K inhibition caused a significant 
increase in PARP cleavage during Sl/R [2.3 ± 0.1 fold to 2.8 ± 0.12 fold 
(p<0.05)]. ARA significantly inhibited caspase-3 activation as well as PARP 
cleavage during Sl/R [2.3 ± 0.1 fold to 0.73 ± 0.06 fold for PARP and 2.66 ± 0.38 
fold to 0.88 ± 0.04 fold for caspase (p<0.001 for both PARP and caspase-3)]. 
Interestingly, when added to the ARA-induced protected group, wortmannin 
caused a significant increase in caspase activation during Sl/R [0.88 ± 0.04 fold 
to 2.49 ±0.31 fold (p<0.01)].
5.2.11 The effect of ARA and PI3-K inhibition on the apoptotic index (Figure
5.7 E)
SI and reperfusion significantly increased the number of apoptotic cells (p<0.001) 
compared to control cells in the normoxia group. ARA significantly reduced the 
number of apoptotic cells during Sl/R [22.6 ± 2.94% to 5.2 ± 1.02% (p<0.001), 
while the addition of wortmannin to the latter group caused a significant increase 
in the number of apoptotic cells [5.2 ± 1.02% to 14.8 ± 1.1% (p<0.05)].
5.3 Discussion
As also shown in chapter 4, the results presented in this chapter confirmed that 
the model used is characterized by a reduction in cell viability during SI, 
increased apoptosis, particularly during reperfusion, activation of ERK, p38 and 
PKB during both SI and Sl/R, while JNK was activated during reperfusion only.
As expected, there was a significant increase in incorporation of the fatty acids in 
the phospholipids of the cardiomyocytes when they were added under normoxic 
conditions. There was a significant increase in ARA (C20:4n-6) which was further
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Figure 5.7 D: The effect of ARA and PI3-K inhibition on caspase-3 activation and PARP  
cleavage during Sl/Reperfusion. Myocytes were exposed to simulated ischaemia (KCN and 
2-deoxy-D-glucose) for 60 minutes followed by 30 minutes reperfusion. Wortmannin (100 nM) 
was added to the cells for 30 minutes prior to SI. Samples were analysed by Western blotting 
with antibodies recognizing cleaved PA RP and caspase-3. Results are expressed as means 
± S.E.M . for three independent experiments (n=3). C a sp ase  3: Sl/R vs control normoxia 
(*p<0.001); Sl/R + ARA vs control Sl/R (*p<0.01); Sl/R + ARA + wormannin vs Sl/R + ARA  
(&p<0.01). PA R P : Sl/R vs control normoxia (*p<0.001); Sl/R + wortmannin vs control Sl/R  
(#p<0.05); Sl/R + A RA vs control Sl/R (*p<0.001).
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Figure 5.7 E : The effect of ARA and PI3-K inhibition on SI/Reperfusion-induced apoptosis in 
cardiac myocytes. Myocytes were exposed to simulated ischaemia (KCN and 2-deoxy-D- 
glucose) for 60 minutes followed by 30 minutes reperfusion. To quantify apoptotic myocytes, 
cell monolayers were fixed and stained with Hoechst 33342. The morphological features of 
apoptosis (cell shrinkage, chromatin condensation) were monitored by fluorescence 
microscopy. At least 400 cells from three randomly selected fields per dish were counted and 
each treatment was performed in triplicate. Results are expressed as means ± S.E.M . for 
three independent experiments (n=3). Sl/R vs control normoxia (*p<0.001); Sl/R + ARA vs 
control Sl/R (#p<0.001); Sl/R + ARA + wortmannin vs Sl/R + ARA ($p<0.05).
Stellenbosch University http://scholar.sun.ac.za/
105
elongated to C22:4n-6. There was also a significant increase in EPA under these 
conditions and this fatty acid was further elongated to C22:5n-3. C22:5n-3 was 
further metabolised via another elongation step, delta-6-desaturation as well as 
p-oxidation to C22:6n-3. Interestingly, when EPA and ARA were added to the 
cells, a significant decrease in oleic acid (C18:1n-9) in the phospholipid fractions 
of the membrane was observed. This might be due to the fact that these fatty 
acids replaced oleic acid in the sn-2 position of the cell membrane phospholipids.
The results suggest that EPA and ARA, when present as free fatty acids rather 
than when incorporated into the phospholipid fraction of membranes, are 
responsible for protecting the neonatal cardiomyocytes from apoptosis. This was 
evidenced by the fact that although the PUFAs were incorporated into the cell 
membranes before SI, protection was seen only when the fatty acids were also 
present during reperfusion (fig 5.1 A). It is therefore possible that EPA and ARA 
exert their beneficial effect by directly stimulating or modulating a second 
messenger system, rather than by becoming constituents of membrane 
phospholipids: if it was acting via membrane phospholipids, it probably would 
have been beneficial during the SI periods when no free fatty acids were present 
in the incubation medium.
In this study, it was shown convincingly that the long-chain polyunsaturated fatty 
acids, EPA and ARA, protect neonatal cardiomyocytes from 
ischaemia/reperfusion-induced injury as demonstrated by the significant increase 
in percentage viable cells during Sl/R (fig 5.1 A). Although rat heart cells have no 
detectable lipoxygenase activity and only a very limited cyclooxygenase activity 
(Hohl & Rosen, 1987), we have shown through a specific cyclooxygenase- 
inhibitor, indomethacin, that eicosanoid biosynthesis was not involved in this 
process during reperfusion. However, it appears that cyclooxygenase activity is 
essential for maintenance of viability during normoxia (fig 5.1 B).
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It was also demonstrated that the increase in cell viability by EPA and ARA was 
associated with significant inhibition of apoptosis in this model, using different 
indicators (fig 5.2 A-C). Apoptosis has been consistently observed in cardiac 
myocytes after ischaemia/reperfusion injury and may represent a direct 
mechanism by which myocytes are damaged (Yue e t al., 2000; Hreniuk et al., 
2001). Indeed, SI/R-induced injury resulted in cleavage of PARP to its 
proteolysed products, a phenomenon that is well known to result from caspase-3 
activation. Inhibition of apoptosis may, therefore, offer a unique approach 
towards amelioration of ischaemic injury.
As discussed previously, the MAPKs are important regulators of apoptosis in 
response to myocardial ischaemia/reperfusion (Saraste et al., 1997; Yue et al., 
2000). Therefore, the effects of EPA and ARA were investigated on the 
phosphorylation status of the three major MAPK subfamily members that are 
activated during SI and reperfusion in the neonatal cardiomyocyte. In this study, 
EPA and ARA alone, failed to stimulate basal MAPK activity. These results partly 
corroborate the findings of Yang et al (Yang et al., 1998), who have also 
demonstrated that EPA alone failed to stimulated basal MAPK enzyme activity in 
bovine carotid artery cells. During Sl/R, the effects of these fatty acids on the 
three MAPKs studied, varied markedly: EPA and ARA significantly reduced p38 
phosphorylation during SI as well as during reperfusion, while JNK-p54 and JNK- 
p46 phosphorylation remained unchanged during reperfusion. In contrast, both 
fatty acids induced a significant increase in ERK-p44 and ERK-p42 
phosphorylation during reperfusion (fig 5.3). Although a number of studies have 
investigated the action of ARA on MAPKs in different cell types (Rao et al., 1994; 
Hii et al., 1995; Madamanchi et al., 1998), this is the first demonstration that ARA 
and EPA have profound effects on MAPK phosphorylation in neonatal 
cardiomyocytes during simulated ischaemia and reperfusion-induced injury.
As discussed above, the effects of these long-chain PUFAs on the activation 
pattern of the MAPKs differs. Interestingly, chelerythrine, a PKC inhibitor, did not
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affect p38 or JNK phosphorylation, but it significantly inhibited ARA-induced ERK 
phosphorylation demonstrating an upstream role for PKC in this regard (fig 5.4 
B). PKC inhibition did not affect viability under normoxic conditions (fig 5.4 A), but 
it increased susceptibility of the cells to SI/R-induced damage. We also achieved 
the same reversal of ARA-induced protection by down-regulation of PKC by pre­
treating cells with 100|o,M TPA for 24h (results not shown). These findings are in 
agreement with those obtained by Mackay and Mochly-Rosen who demonstrated 
that ARA protects neonatal rat cardiac myocytes from ischaemic injury via PKCs 
(2001). A number of other studies have also demonstrated the involvement of 
PKC in activation of the MAPK pathway in different cell types (Clark & Murray, 
1995; Chang etal., 1998).
To further investigate the mechanism of action of ARA and EPA on p38 and JNK 
inhibition during Sl/R, it was decided to evaluate the role of the phosphatases in 
this scenario. Okadaic acid, an inhibitor of type 1 and type 2A serine/threonine 
phosphatases (Taffs et al. 1991) as well as orthovanadate, which is a specific 
inhibitor of tyrosine phosphatases (including MKP-1) were used (Gordon, 1991; 
Charles et al., 1993). Although both okadaic acid (results not shown) and 
vanadate (fig 5.5 B) significantly increased basal levels of p38 phosphorylation, 
only vanadate could significantly attenuate ARA-induced inhibition of p38 during 
Sl/R. As far as we know, this is the first evidence for a role for a tyrosine 
phosphatase in ARA-induced inhibition of p38. Although 50 or more tyrosine- 
specific protein phosphatases (PTPs) have been characterized, little is known 
about their general importance in terminating MAPK signalling. One subclass of 
the PTPs, the dual-specificity phosphatases (DSPs), is capable of 
dephosphorylating both phosphotyrosine and phosphothreonine residues. In this 
study MKP-1 was targeted, which has been shown to be activated by oxidative 
stress (Keyse & Emslie, 1992). The results obtained showed that both EPA and 
ARA (fig 5.5 C) caused a significant increase in MKP-1 induction during Sl/R, 
which suggests that these fatty acids exert their beneficial effects partly through 
the induction of the DSPs (specifically MKP-1), which in turn can deactivate p38
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(Lim et al., 2001; Franklin & Kraft, 1997). This hypothesis was confirmed using 
an in vitro dehosphorylation assay showing that MKP-1 might indeed be 
responsible for the dephosphorylation of p38 (fig 5.6). Our results are in 
agreement with those of Metzler and co-workers who reported that ARA induces 
MKP-1 expression in vascular smooth muscle cells via the activation of tyrosine 
kinases. In addition, Communal et al reported that MKP-associated 
dephosphorylation of both phosphotyrosine and phosphothreonine residues on 
JNK1/2 and p38 correlated with their inactivation in the failing human 
myocardium (Franklin etal, 1998).
The involvement of the anti-apoptotic kinase, PKB/Akt, in the cellular response to 
ARA was also evaluated. It is of great interest that ARA inhibited PKB/Akt Ser473 
phosphorylation during Sl/R, while Thr308 remained phosphorylated (fig 5.7 A & 
B). The results indicated that the continued phosphorylation of PKB/Akt Thr308 
and the inhibition of the other phosphorylation site (Ser473) of PKB/Akt is 
associated with ARA-induced protection of neonatal cardiomyocytes, viz an 
increase in cell viability (fig 5.7 C) as well as a decrease in caspase-3 activation, 
PARP cleavage and the apoptotic index during Sl/R (fig 5.7 D & E). Since we 
only measured the phosphorylation of PKB/Akt and not its activity, we can only 
speculate that the sustained phosphorylation of Thr308, while Ser473 is inhibited, is 
adequate for PKB/Akt activation and subsequent inhibition of apoptosis in ARA- 
induced protected cells. This is substantiated by the findings that 
phosphorylation on Thr308 alone is able to increase PKB activity, while 
phosphorylation on Ser473 alone does not significantly stimulate the kinase 
(Alessi etal., 1996; Bellacosa etal., 1998)
Studies of PKB/Akt activation pathways have shown that PI3-K is a mediator of 
an activation signal for PKB/Akt (Kauffmann-Zeh et al., 1997; Kennedy et al., 
1997; Franke et al., 1995; Burgering & Coffer, 1995; Kulik et al., 1997). PI3-K is 
considered one of the intracellular signals responsible for the transmission of 
anti-apoptotic signals for controlling cell survival and over-expression of PI3-K in
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cells has been shown to cause a significant increase in survival of cells exposed 
to ionising radiation (Kraslinikov et al., 1999; Cataldi et al., 2001). On the other 
hand, specific inhibitors of PI3-K cause an increase in apoptosis and a decrease 
in cell survival (Scheid et al., 1995; Kennedy et al., 1997). PKB/Akt may also be 
activated by a PI3-K independent mechanism, for example, in response to heat 
shock or increases in intracellular calcium or cyclic adenosine monophosphate 
(cAMP) (Moule et al., 1997; Konishi et al., 1996; Sable et al., 1997; Filippa et al., 
1999). The results obtained in the present study have demonstrated that the 
protective actions of ARA are PI3-K dependent, since wortmannin significantly 
increased caspase-3 activation as well as the apoptotic index during Sl/R (fig 5.7 
D & E). There was also a decrease in cell viability when wortmannin was added 
to the ARA-treated cells. However, there was no significant increase in PARP 
cleavage during this period. It is possible that an increase in PARP cleavage 
might occur if the reperfusion period is extended.
In summary, our results have shown that: i) the increased phosphorylation of 
ERK by EPA and ARA is beneficial and PKC-dependent, and ii) the reduced 
phosphorylation of p38 correlates with increased MKP-1 protein levels. Both 
increased ERK phosphorylation and the inhibition of p38 may contribute to the 
increased cell viability and decrease in apoptosis induced by either EPA or ARA. 
Results presented in other studies (Metzler et al., 1998; Communal et al., 2002), 
as well as our own, indicate that the MAPKs are central regulators of reactive 
signalling in cardiac myocytes. The ability to directly manipulate MAPK signalling 
has been shown to protect cardiomyocytes from ischaemia/reperfusion-induced 
apoptosis/injury. This notion suggests that members of the MAPK signalling 
cascade would be ideal targets for pharmacological intervention to treat 
ischaemia/reperfusion injury. Indeed, several investigators have demonstrated 
that inhibition of p38 with SB203580 protects cardiomyocytes from 
ischaemia/reperfusion injury and that sustained ERK activation is necessary for 
this protection (Bogoyevitch et al., 1996; Punn et al., 2000). Thus the results 
obtained in the present study suggest that these long-chain PUFAs might offer
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an alternative, non-pharmacological strategy to protect the heart against 
ischaemia/reperfusion-induced injury.
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CHAPTER 6 RESU LTS AND DISCUSSION: The effects of EPA and 
ARA on functional recovery after global sustained 
ischaemia in the isolated perfused rat heart.
6.1 Introduction
It is clear form our previous results that ARA and EPA protect neonatal 
cardiac myocytes from simulated ischaemic and reperfusion injury. Although it 
is well documented that omega-3 fatty acids are anti-arrhythmic and protect 
the heart from reperfusion injury (McLennan eta l. , 1985; 1988; 1992; Kang & 
Leaf, 2003), there is no data available on the direct effect of these fatty acids 
on the isolated perfused rat heart model. In addition, in previous studies the 
omega-3 fatty acids were given as supplements in the diets of rats or in vitro 
to neonatal cardiac myocytes. As far as we know, this is the first study, which 
describes the effects of EPA as well as ARA when added before and after 
sustained global ischaemia on functional recovery during reperfusion of the 
isolated retrogradely perfused rat heart model.
6.2 Results
In order to compare the functional recovery of the hearts in the different 
groups, the heart rate (beats/min), coronary flow (ml/min) and left ventricular 
developed pressure (mmHg) were monitored at 10 minute intervals during a 
40 minute stabilization phase and again during reperfusion after global 
sustained ischaemia.
With the exception of EPA, when added before and after ischaemia, all hearts 
showed a significant (p<0.05) reduction in coronary flow, heart rate (HR), left 
ventricular developed pressure (LVDP) and rate pressure product (RPP = HR 
x LVDP) during reperfusion after 25 minutes of global ischaemia, when 
compared to values obtained during the stabilization period.
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6.2.1 Coronary flow
Pre-ischaemic coronary flow (CF) averaged 12.6 ± 0.7 ml/min for the control 
group at the end of the stabilization phase and 8.3 ± 0.6 ml/min at the end of 
the reperfusion period. When EPA was added before and after ischaemia 
(EPA b & a), there was a significant increase in CF compared to the control 
group at the end of the stabilization phase (17.4 ± 0.6 ml/min, p<0.05) as well 
as at the end of the reperfusion period (11.7 ± 0.4 ml/min, p<0.05). There 
were no significant differences in the CF, before as well as during the 
reperfusion phase, when EPA was added only after sustained ischaemia or 
when ARA and albumin were compared to the control group.
6.2.2 Left ventricular developed pressure
During the pre-ischaemic phase, the LVDP was similar in all groups (control 
value: 94 ± 4 mmHg). However, there was a significant increase in LVDP 
during reperfusion in the groups when ARA or EPA was added before and 
after global ischaemia [51 ± 5 mmHg for ARA (p<0.05) and 80 ± 11.7 mmHg 
for EPA (p<0.001)], when compared with the control untreated hearts or 
hearts treated with albumin only. Interestingly, there was an almost 80% 
recovery after global ischaemia in the EPA group (before & after) when 
compared to pre-ischaemic values. In fact, the significant reduction during 
reperfusion seen in all the other groups was absent in these hearts. LVDP of 
hearts having received ARA after global ischaemia only, was significant lower 
(p<0.05) than that of hearts having received the fatty acids before and after 
global ischaemia and similar to those of untreated controls and albumin- 
treated hearts.
6.2.3 Rate pressure product (RPP)
The pre-ischaemic values for all groups were similar after 40 minutes of 
stabilization. However, there was a significant increase in RPP after global 
ischaemia when ARA (before & after) was compared to the albumin-treated
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(5245 ± 1875 to 15200 ± 2275, p<0.05) as well as when both EPA groups 
were compared to the control group [5382 ± 857 to 26580 ± 3330, p<0.001 for 
EPA (before & after) and 14530 ± 2448, p<0.05 for EPA (a)]. As was 
observed for LVDP, RPP of hearts perfused with ARA after global ischaemia 
only, was significantly reduced and similar to those of untreated controls and 
albumin-perfused hearts.
6.3 Discussion
The aim of this study was to determine whether the beneficial effects 
observed upon addition of the long-chain PUFAs to neonatal cardiomyocytes, 
were also evident in the perfused heart model. It is clear from our results that 
both EPA and ARA significantly improved functional recovery after global 
sustained ischaemia, with optimum protection when the fatty acids were 
present both before and after sustained ischaemia.
The results obtained with EPA are not surprising, since many studies in 
humans as well as in animal models and cultured myocytes support these 
findings. For example, mortality by coronary heart disease is reduced as a 
consequence of dietary long-chain omega-3 PUFA administration (De Lorgeril 
et al., 1994; Siscovick et al., 1995; Albert et al., 1998; Marchioli et al., 1999). 
Long-chain PUFAs prevent or retard arrhythmias induced by ischaemia, for 
example, intravenous infusion of docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) into canine myocardium prevented ventricular 
fibrillation after ischaemia (McLennan eta!., 1988; Billman eta l. , 1994; Leaf et 
al., 1998; 1999). These anti-arrhythmic effects have been described in a 
variety of animal species (McLennan et al., 1985; 1992; Hock et al., 1990; 
Billman et al., 1994) and are thought to function in a similar manner in 
humans (Burr, 1989; Burr et al., 1989; De Lorgeril et al., 1994; Siscovick et 
al., 1995). In addition to their anti-arrhythymic effects, these long-chain 
omega-3 PUFAs also reduce reperfusion injury in the heart. Oskarsson and 
co-workers (1993) showed that dietary fish oil supplementation significantly
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reduced myocardial infarct size in a dog model where the left circumflex artery 
was occluded for 90 minutes, followed by 6 hours of reperfusion.
The results obtained in this study confirmed the cardioprotective effects of 
PUFAs observed in nutritional studies and further demonstrated that relatively 
short term administration of EPA is also effective in the isolated perfused rat 
heart. However, apart from one study by Mackay and Mochly-Rosen (1999) 
on isolated neonatal cardiac myocytes, this is the first study to show the 
protective effect of an omega-6 long-chain PUFA in the isolated rat heart 
model. We have demonstrated that ARA significantly improved functional 
recovery when added before and after sustained global ischaemia. 
Interestingly, although EPA also induced protection when added after global 
ischaemia only, ARA was without effect when added during this period.
These results are in striking contrast to the well-known harmful effects of long- 
chain fatty acid oxidation on the ischaemic/reperfused heart, e.g. palmitate in 
the perfusate greatly increased membrane damage and is toxic to the 
ischaemic myocardium (De Leiris et al., 1975; Liedtke et al., 1978). It is also 
well established that the lipid composition of heart membranes is altered 
during ischaemia, whereas accumulation of nonesterified fatty acids may 
follow activation of the phospholipases and increased hydrolysis of 
glycerolipids (Prinzen eta l., 1984; Van derVusse eta l., 1997). Disturbed lipid 
metabolism (Van Bilsen et al., 1991), associated with a defective deacylation- 
reacylation cycle of phospholipid fatty acids leading to free arachidonic acid 
accumulation (Das et al., 1986), has been described during the reperfusion 
phase. Indeed, Das and co-workers (1986) demonstrated a rapid release of 
free arachidonic acid from the isolated ventricular myocardium within the initial 
10 minutes of reperfusion, which was also associated with increased activity 
of phospholipase A2. However, it seems that it is not the ARA p e r  s e  which is 
harmful to the cardiac myocyte, but rather its oxidation products. For example 
He and co-workers (2001) showed that inhibition of cytochrome P450 
monooxygenases which catalyse ARA oxidation to a variety of biologically 
active eicosanoids, reduced infarct size in a model of Langendorff-perfused 
rat and rabbit hearts.
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The results presented in chapter 5, showed that both ARA and EPA are avidly 
incorporated into membrane phospholipids of neonatal cardiomyocytes in 
culture. It is to be expected that this also occurs in the perfused rat heart (de 
Jonge et al., 1996) and that the membrane phospholipid fatty acid 
composition is considerably changed during sustained ischaemia and 
reperfusion (Picard et al., 1998). It is thus possible that the fatty acids (EPA 
and ARA) presented to the myocytes upon reperfusion will then be available 
to induce MKP-1 induction and subsequent p38 dephosphorylation. The latter 
could lead to inhibition of PLA2 (Degausee et al., 2001) and prevention of 
reperfusion-induced phospholipid degradation. However, it is clear from the 
above that the metabolism of long-chain PUFAs by the isolated rat heart 
needs to be further investigated.
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Table 6.1 The effect of albumin, ARA and EPA on functional recovery of hearts subjected to global 
sustained ischaemia and reperfusion.
Control
(n=12)
Albumin
(n=8)
ARA (before & 
after) (n=6)
ARA (after) 
(n=6)
EPA  (before & after) 
(n=8)
EPA (after) 
(n=6)
Coronary flow
• before
• after 
(ml/min)
12.6±0.7
8.3±0.6°
13.2±0.78
8.8±0.6°
12.3±1.7 
7.6±0.8°
14.1 ±1.2 
6.9±0.4°
17.4±0.6*Ye 
11 .7±0.4°*Te
15.2±0.8
8.6±0.6°
Heart rate
• before
• after 
(beats/min)
324112
266±12°
326±11
243±19
309±24
284±23
332±16
276±12°
o
O 
CO 
CM 
CM
+l 
+
l
"fr 
r- 
n 
cn
351 ±9 
319±15°
LVDP
• before
• after 
(mm Hg)
94±4
20±3°
98±7
19.8±5.6oS
97±9 
51 ±5°*
104±7
14.3±2.8oS
101 ±4 
80±11 ,7**Te
113±5 
44.7±5.7°
* p<0.05 vs control; ** p<0.001 vs control; Tp<0.001 vs albumin; 8p<0.05 vs ARA (before and after); ep<0.05
vs EPA  after; °p<0.05 vs “before vs after”
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Figure 6.1 A and B: RPP of hearts perfused with standard KH solution 
containing either albumin, EPA or ARA before and after global ischaemia (b & 
a) and EPA or ARA just after global ischaemia (a). 20 |aM of fatty acid bound 
to albumin (ratio:3.3:1) was added to the perfusion solution. The rate pressure 
product was calculated by multiplying the heart rate and the LVDP, (n=6-12); * 
ARA (b&a) and EPA (a) vs control (after ischaemia) (p<0.05); EPA (b&a) vs 
control (after ischaemia) (** p<0.001); EPA (b&a) vs albumin (after ischaemia) 
($p < 0 .0 0 1 ).
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CHAPTER 7 FINAL CONCLUSIONS AND FUTURE DIRECTIONS
An in vitro model of simulated ischaemia/reperfusion (Sl/R), induced by KCN and
2-deoxy-D-glucose, was used to achieve graded ATP depletion in cultured 
neonatal cardiomyocytes. It was demonstrated that activation of p38 is 
associated with development of apoptosis. Myocyte ATP depletion during SI 
induced p38 activation as well as an upregulation of two molecules that are 
implicated in the late transduction phases of apoptosis, viz caspase-3 and 
poly(ADP-ribose) polymerase (PARP) cleavage. Reperfusion induced JNK 
activation and stimulated chromatin condensation and fragmentation, implicating 
involvement of this MAPK in the final stage of apoptosis. However, our 
subsequent inhibitor studies clearly indicate that, whereas p38 promotes 
apoptosis in neonatal cardiomyocytes in response to SI, JNK promotes survival 
in response to reperfusion. This suggests that p38 and JNK have distinct but 
different functions during SI/R-induced apoptosis in our cell model.
In order to assess the mechanisms of protection of long-chain polyunsaturated 
fatty acids (PUFAs) in injured/apoptotic heart cells, we treated neonatal 
cardiomyocytes with EPA and ARA prior to and after simulated ischaemia. Using 
this model, we demonstrated for the first time that EPA and ARA protect neonatal 
cardiomycytes from ischaemia/reperfusion-induced apoptosis through a MAPK- 
dependent pathway and that these beneficial effects might be exerted through 
increased induction of a dual-specific phosphatase, MKP-1, which can 
dephosphorylate p38. We have also shown that ARA inhibits one 
phosphorylation-site of PKB/Akt (Ser473), while it does not affect Thr308. Also, 
chelerythrine, a PKC inhibitor, did not affect p38 or JNK phosphorylation, but 
significantly inhibited ARA-induced ERK phosphorylation, suggesting an 
upstream role for PKC in this regard during Sl/R (fig 7.1).
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The beneficial effects of EPA and ARA could also be elicited in the perfused rat 
heart model subjected to ischaemia/reperfusion. Both fatty acids significantly 
improved functional recovery when added before and after sustained ischaemia, 
with EPA being the more effective fatty acid.
The prevention of CHD in the community remains a challenge and only a few 
drug therapies have demonstrated to reduce the risk of sudden cardiac death. 
Dietary intake of modest amounts or low-dose n-3 PUFA supplementation in 
patients with a prior myocardial infarction is low-cost, low-risk interventions. It is 
time for clinicians, researchers and policymakers to give increased attention to 
the beneficial effects of these fatty acids and to translate this considerable body 
of experimental, epidemiological, and clinical evidence into clinical practice.
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Figure 7.1 Proposed mechanism for the protective actions 
of EPA and ARA in the heart
I
t  apoptosis
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